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1.1 Discovering disease genes 
There are about 6000 human genetic diseases, almost 4000 of which do not have a known 
molecular basis in 2009 (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM)[1]. These 
diseases have a wide spectrum of phenotypic manifestations which are triggered by underlying 
genetic perturbations. While disease phenotypes are readily observable, the underlying 
mutations are far more problematic to characterize. Different techniques are suited to the 
elucidation of disease genetics, depending on the underlying genetic architecture of the 
disease. They fall into two general categories, genetic mapping[2] and functional candidate 
gene approaches. Genetic mapping uses correlation of disease phenotypes with genetic 
markers to localize the disease mutation to a particular genomic region in a hypothesis-free 
manner. It does not make use of disease phenotype information, other than for th-e delineation 
of diseases. On the other hand, functional candidate gene approaches use molecular biological 
knowledge to hypothesize the involvement of particular genes in the disease under 
investigation, which are subsequently tested for mutations in patients. These approaches utilize 
more information about disease phenotype and known disease biology. 
An important advantage of functional approaches is that they facilitate not only disease gene 
identification but also disease biology elucidation. Nevertheless, data and knowledge limitations 
have negated these advantages, and genetic mapping has historically been the most productive 
approach to disease gene identification[2]. However, with the advent of the post-genomic era 
and its associated flood of molecular data, functional approaches have been reinvigorated and 
this trend is set continue into the future. Somewhat surprisingly however, disease phenotype 
data—one of the most readily available sources of information about diseases—have received 
much less attention than molecular genetic data in this recent surge in interest in functional 
approaches. 
Below we first take a brief look at genetic mapping, after which we look at current 
Bioinformatics-driven functional approaches to large-scale candidate gene prioritization—which 
thus far have generally been applied to the results of genetic mapping. Finally we introduce the 
main topic of this thesis, namely the importance of disease phenotype information and its 
potential utility in functional candidate disease gene approaches. Further introduction into this 
topic is provided in chapter 2. However, before proceeding we first need to take a look at what 
disease phenotypes actually are. 
1.2 Disease phenotypes 
Disease phenotypes are the ultimate consequences of the mutations in disease genes. They 
are also the most immediate source of information about what the underlying disease mutations 
might be, provided they are comprehensively observed and recorded. Herein lies an important 
and difficult to overcome problem, however, as the phenotypic effects of disease-related 
mutations can vary extensively. Such effects could be prominent and obvious physical 
malformations or functional impairments, or they could be very subtle and easily overlooked 
ones[3]. They need not even be externally observable physical features; instead they could be 
changes in molecular phenomena such as mRNA transcript levels, protein modification statuses 
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or metabolite concentrations[4,5], as well as behavioral changes[6]. Additionally, anatomical and 
physiological changes can occur over the course of a patient’s lifetime, so the phenotypic state 
of a patient at a given point in time does not necessarily reflect the full disease phenotype. In 
fact, disease phenotypes can even span generations—such as in diseases with genetic 
anticipation which leads to progressively more severe phenotypes in successive 
generations[7,8]. This phenotypic complexity makes it more difficult to identify and record 
disease phenotypes fully and accurately. 
Some diseases have very specific and limited phenotypic effects, while others have extensive 
effects on patient phenotypes. For instance, cleft lip can occur as an isolated symptom while 
other diseases such as those associated with the TP63 gene[9,10] and Hutchinson-Gilford 
progeria (MIM: 176670) affect multiple systems and have wide-ranging phenotypic effects. 
While some diseases (such as skeletal malformations) manifest themselves during the 
developmental process, others only appear postnatally or at later life stages (e.g. 
neurodegenerative diseases). Some have constant effects on phenotype, while others (such as 
the previously mentioned neurodegenerative diseases) have progressive effects. Disease 
phenotypes can differ from each other quantitatively as well as qualitatively. Finally, many 
diseases have phenotypes that can vary substantially between patients.Despite these 
complexities, disease phenotypes are the most readily observable effects of genetic mutations 
and form a valuable source of information for disease research. 
The use of such phenotypic information in genetic disease investigation will be discussed later, 
after a brief look at current genetic and bioinformatic methods for finding disease genes. 
1.3 Genetic mapping 
There are two primary approaches to the genetic mapping of human disease genes, namely 
linkage analysis[11] and association studies[12]. These two approaches are complementary. 
Linkage analysis is best suited to the identification of rare mutations with large effects on the 
phenotype, such as those underlying Mendelian diseases. Association studies on the other 
hand are better suited to identifying common mutations with modest effects on the phenotype, 
such as those involved in complex diseases. Both approaches result in the delineation of a 
genomic region suspected to contain the disease mutation, which can subsequently be 
sequenced in both patients and controls in order to identify the causative mutation – an 
approach termed “positional cloning”[2]. 
Linkage analysis is responsible for the vast majority of disease genes identified to date[2]. In 
linkage analysis, genomic markers are sought that co-segregate with the disease phenotype in 
affected families. This indicates that the disease mutation is on the same chromosome as the 
marker, and that they are in close enough proximity to result in a lack of chromosomal 
crossovers between them. The use of restriction fragment length polymorphisms in the 
1980s[13] and short tandem repeats in the 1990s[14] led to the generation of a sufficient density 
of markers across the whole genome to make linkage analysis feasible as a tool for the 
systematic localization of human disease genes on the genome[15]. Nevertheless, the resulting 
linkage regions are still quite large, generally ranging from about 2 to 10 million DNA basepairs 
and containing tens to hundreds of genes (http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM). 
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Therefore, it is still expensive and time-consuming to identify the disease gene within the 
linkage regions by positional cloning. 
Association studies are a complementary approach to linkage analysis. They are conceptually 
simple, involving the identification of genetic variants that occur significantly more frequently in 
affected individuals than in unaffected individuals. As they rely on statistical overrepresentation, 
they are better suited to identifying common genetic variants than rare variants. Such genetic 
variants need not have very strong associations with the disease phenotype as long as they are 
statistically significant, and this detection power can be improved by increasing the size of the 
study population. As a result, association studies are particularly suited to investigating complex 
polygenic diseases in which several different genetic variants contribute only modestly to the 
final disease phenotype. In contrast, linkage analysis is better suited to identifying rare genetic 
variants that have a strong association with the disease phenotype, which makes it more suited 
to the analysis of Mendelian diseases where single mutations of large effect cause the disease 
phenotype.  
In the past, most association studies investigated the associations between specific candidate 
genes and the disease in question[15]. This was necessitated by the inability to conduct such 
studies on a genome-wide scale, due to technical limitations. However, these targeted studies 
generally struggled with limited and poorly reproducible results[2]. Only with the recent 
development of techniques for high throughput genotyping has it finally become feasible to 
conduct association studies at a genome-wide scale using large sample sizes[2]. These 
genome-wide association studies (GWASs), first proposed in the mid 1990s[16-18] have driven 
a recent explosion in the number of disease variants found[2]. Nevertheless, these studies 
generally result in the identification of genomic regions which could contain several genes – or 
sometimes no genes at all – complicating the identification of the relevant disease genes and 
necessitating further analysis[19]. 
In addition to these systematic genome-wide searches for disease genes using genetic mapping 
techniques, prior biological knowledge about genes can also be exploited to identify candidate 
disease genes based on their apparent functional links to disease processes. Such functional 
candidate gene approaches have met with limited success in the past[2], but they have been 
given a new lease of life by the various genome-scale functional analyses[17] that are now 
possible in the post-genomic era. The rapid expansion in large-scale functional data along with 
the concurrent expansion of the field of bioinformatics has finally made such large-scale 
functional analyses tractable. 
1.4 Functional candidate disease gene approaches using bioinformatics 
Despite the deluge of biological data that have been generated over the past decade, they are 
still too limited to enable pragmatic genome-scale functional candidate disease-gene 
prioritization. Therefore, bioinformatic approaches to functional candidate gene prioritization 
have so far generally been combined with genetic mapping (Chapter 2). This is a powerful 
combination as the two approaches complement each other nicely. Genetic mapping restricts 
the number of genes that need to be prioritized, but is frequently not sufficient by itself to identify 
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the causative disease gene. Functional approaches on the other hand benefit greatly from the 
restriction of the search space to tens or hundreds of genes instead of thousands. 
As previously mentioned, linkage mapping, which is the most commonly used genetic mapping 
technique, frequently results in the delineation of a disease-associated genomic region (locus) 
containing tens to hundreds of genes. Up until the present day it is still laborious and expensive 
to sequence many genes, so it is necessary to prioritize the candidate genes in the disease 
locus in order to minimize the amount of sequencing required to identify the causative disease 
gene. This situation is changing however, as the advent of the genomics era, our increased 
knowledge of molecular biology, and the identification of more and more disease genes which 
can be used as starting points have resulted in this candidate gene approach gaining more 
traction[20]. To assist in this process, several bioinformatic tools and approaches have been 
developed in the past years (Chapter 2 and ref.[21]). 
Such candidate gene approaches are made possible by the close relationship between genes 
and phenotypes. The fundamental premise behind all such approaches is namely that 
functionally related genes result in similar disease phenotypes when mutated. In other words, 
common molecular processes are assumed to underlie similar diseases, leading to the search 
for genes associated with particular disease processes or biological processes associated with 
particular disease genes (Figure 1). This results in candidate genes being sought based on 
functional relationships with other genes known to cause the same or similar phenotypes (such 
as ENDEAVOUR[22]). A second approach based on the same premise is to look for sets of 
functionally related genes in combinations of loci associated with the same or similar diseases 
(such as POCUS[23] and Prioritizer[24]). Finally, disease candidate genes can be identified 
through their direct association with biological processes known to be involved in the disease in 
question (such as Genes2Diseases[25] and GeneSeeker[26]). These approaches are discussed 
further in chapter 2 and will not be elaborated upon here. 
Functional candidate gene approaches also readily permit, and can even benefit from, the 
concurrent investigation of several different diseases. The existence of genetically 
heterogeneous diseases, as well as genes which can lead to different disease phenotypes 
when mutated, indicate that the relationship between disease genes and phenotypes is not 
insular. Rather, it is clear that there are common biological processes linking different 
diseases[27-29]. Therefore, functional approaches to disease gene prioritization should enable 
knowledge of the pathobiology of certain diseases to be transferred to other distinct but related 
diseases. This is dependent on the identification of phenotypic relationships between diseases, 
which in turn requires appropriate disease phenotype descriptions. However, disease 
phenotype analysis has historically not received as much attention as disease genetics analysis, 
and the most suitable ways to describe and encode disease phenotypes are yet to be identified. 
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Figure 1: Bioinformatic approaches to positional candidate disease gene prioritization. (A) Functional links 
can be sought between candidate disease genes and known disease genes. This approach is used by 
ENDEAVOUR. (B) If there are several different disease-associated genomic loci, common functional 
modules can be sought that link genes in the different loci together. Given that these loci are all 
associated with the same disease, such overrepresented functional modules are likely to be involved in 
the disease etiology. This approach is used by POCUS and Prioritizer. (C) Functional links between 
candidate genes and disrupted disease processes or phenotypic features can be sought directly. This 
approach is used by Genes2Diseases and GeneSeeker. 
 
1.5 The importance of the phenotype 
In contrast to disease genes, disease phenotypes are easier to observe. This makes them one 
of the most useful resources currently available to the disease researcher, provided that this 
information is properly collected and recorded. As mentioned earlier, this can be challenging to 
do properly, but it is essential in order to investigate the full extent of the relationships between 
disease genes and phenotypes. 
Disease phenotypes can be viewed as collections of individual phenotypic features, which occur 
in different combinations in different diseases. Diseases that consist of a combination of co-
occurring phenotypic features are called syndromes. These syndromes do not consist of 
independent sets of features; rather there is significant feature overlap between different 
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syndromes. The nature of this overlap is not random; rather syndromes can be grouped into 
collections of similar phenotypes known as syndrome families[30]. For instance, mutations in 
the TP63 gene can give rise to several phenotypically overlapping syndromes[9,10]. There are 
several classes of similar neurodegenerative diseases such as the spinocerebellar ataxias[31] 
and Charcot-Marie-Tooth syndrome subtypes[32]. There are also several families of related 
syndromes with grouped according to their etiology into various “opathies”, such as muscle[33] 
and neuronal[34] channelopathies, neurocristopathies[35] and ciliopathies[36]. These are just a 
few of the many examples of phenotypically related syndromes that can be grouped into 
families (http://www.ncbi.nlm.nih.gov/omim/). Such shared features between syndromes 
suggest that genes involved in the different syndromes interact with each other at some point in 
the path from gene to phenotype. 
The fact that diseases have such phenotypic structure can be exploited to guide functional 
analyses. The most obvious case is that phenotypic features can indicate the location and 
timing of the disease process (Figure 1C). These phenotypic features, if seen in diseases of 
unknown etiology, can give a clue as to the nature of the underlying molecular dysfunction. 
Neurodegenerative diseases are probably caused by molecular processes that affect neuronal 
homeostasis, while congenital skeletal dysmorphologies must be caused by defects in pre-natal 
skeletal development. This knowledge can be used to narrow the list of candidate genes. 
Though these examples may seem trivial, this is a general principle that also extends to less 
obvious cases. For instance, though ciliopathies are phenotypically diverse, there are specific 
features that tend to occur frequently in them, such as retinal degeneration, cystic kidney and 
liver disease and situs inversus[36]. The presence of these phenotypic features in diseases of 
unknown etiology can be used to hypothesize ciliary dysfunction as a potential disease 
mechanism[36]. Indeed, such an approach has already been successfully used to predict novel 
ciliopathies[37,38]. 
As well as providing direct insight into the nature of underlying disease processes, disease 
phenotypes can be used to identify which groups of diseases are more likely to share underlying 
disease processes and which are less likely to have any relationship with each other, through 
the determination of phenotypic similarity between diseases. This can inform functional 
candidate prioritization approaches that look for functional relationships between known disease 
genes and novel candidates, such as ENEAVOUR (Figure 1A), by suggesting which diseases 
can be used to generate the pool of known disease genes. It is equally applicable to 
approaches that look for functional relationships between candidates from disparate genomic 
loci (Figure 1B), to inform the selection of loci to use. 
Due to the importance of disease phenotypes in such functional approaches to candidate 
disease gene prioritization, and given the increasing importance of large-scale functional 
analyses in candidate gene prioritization, we decided to systematically investigate the degree to 
which disease phenotype similarity reflects common underlying disease processes. 
1.6 Outline of the thesis 
In this thesis we investigate the degree to which similar disease phenotypes are caused by 
functionally related genes. We begin by determining whether genes causing identical disease 
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phenotypes do indeed tend to be functionally related, using two objective measures of gene 
functional relatedness. We then investigate whether such functional relatedness extends 
beyond those disease genes that lead to identical disease phenotypes, to those causing 
phenotypically similar but nevertheless distinct diseases. 
However, we start in chapter 2 with an overview of the relationships between disease genes 
and disease phenotypes. This chapter expands on the discussion in sections 1.3 and 1.4 above. 
We emphasize the modular nature of genetic diseases, showing based on empirical knowledge 
that they are modular at both the genetic and the phenotypic level. Such modularity enhances 
the degree to which phenotypic similarity can be used to infer genetic similarity by highlighting 
functional genetic modules. Additionally, we give an overview of bioinformatic approaches to 
candidate disease gene prioritization, which exploit the relationships between functional 
genetics and phenotypes. 
We proceed in chapter 3 to investigate the degree to which protein-protein interactions, the 
strongest indicator of functional relatedness between two proteins,  can be used to prioritize 
candidate disease genes for genetically heterogeneous diseases. Given that they result in very 
similar or identical disease phenotypes, these genetically heterogeneous diseases represent the 
strongest degree of phenotypic similarity between disease genes. We show that genes causing 
the same disease have a much stronger tendency to interact with each other at the protein level 
than other genes. In this analysis we also use protein-protein interaction data from other 
species, and show that such functional relationships between disease genes are conserved 
through evolution, as protein-protein interactions from other species are equally good at 
predicting disease genes as human protein-protein interactions. Importantly for candidate 
disease gene prioritization, we find that literature-derived human protein-protein interactions are 
strongly biased toward known disease genes and may therefore not be representative for novel 
candidate disease gene prediction. 
In chapter 4 we investigate whether another type of objective functional relationship between 
genes, namely coordinated expression or co-expression, is stronger for genes underlying the 
same disease. In contrast to the previously investigated protein-protein interaction data, co-
expression data are more abundant and less biased in their ascertainment. However, they are 
also less powerful at identifying functional relationships between genes than protein-protein 
interactions. We compensate for this by utilizing evolutionary conservation of co-expression to 
strengthen the correspondence between co-expression and functional relatedness. The 
rationale is that genes whose expression patterns are coordinately regulated in multiple 
evolutionarily distant species are more likely to be functionally related, as there has been a 
selective pressure to maintain this pattern through evolution. We show that the expression of 
genes causing the same disease is generally more closely coordinated than that of other genes, 
and that this effect can be strengthened by exploiting evolutionary conservation of co-
expression. We further show that such evolutionarily conserved gene co-expression can be 
used to improve candidate disease gene prioritization. 
In chapter 5 we turn our attention from disease genes to disease phenotypes, investigating the 
genetic coherence of the human phenome – the sum total of all human (disease) phenotypes 
Chapter 1: General Introduction 
19 
 
and their relationships to each other. Having shown that genes causing virtually identical 
disease phenotypes tend to be functionally related, we seek to confirm that this phenomenon 
extends beyond identical phenotypes to overlapping but non-identical phenotypes. In order to 
do this, disease phenotypes need to be described in a systematic manner that can enable 
quantitative phenotypic overlap estimation. This has historically been done using text mining of 
free text phenotype descriptions, but this approach does not result in systematic phenotype 
descriptions due to the limitations of text mining. There are several databases that 
systematically annotate disease phenotypes with phenotypic features, but is not clear how 
useful they will be for such disease phenome analyses. In this chapter we confirm that the 
relationship between similar phenotypes and similar molecular genetics does indeed extend to 
separate but overlapping disease phenotypes. We additionally identify several database 
properties that influence the genetic coherence of systematically determined phenotype 
clusters. 
We conclude in chapter 6 with a look into the future of the field, and the importance of 
phenotype-guided bioinformatic analyses therein. Due to the advent of new sequencing 
technologies, this field is going to change rapidly over the coming years. Positional candidate 
gene prioritization is becoming less relevant due to the ability to sequence entire candidate loci 
or even whole genomes relatively cheaply and quickly. However, there will be new challenges, 
such as making sense of the large number of mutations and genetic variants such high 
throughput approaches uncover, and identifying what their contributions are to the disease 
process. 
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Abstract 
Evidence from many sources suggests that similar phenotypes are begotten by functionally 
related genes. This is most obvious in the case of genetically heterogeneous diseases such as 
Fanconi anemia, Bardet-Biedl or Usher syndrome, where the various genes work together in a 
single biological module. Such modules can be a multiprotein complex, a pathway, or a single 
cellular or subcellular organelle. This observation suggests a number of hypotheses about the 
human phenome that are now beginning to be explored. 
First, there is now good evidence from bioinformatics analyses that human genetic diseases can 
be clustered on the basis of their phenotypic similarities and that such a clustering represents 
true biological relationships of the genes involved. 
Second, one may use such phenotypic similarity to predict and then test for the contribution of 
apparently unrelated genes to the same functional module. This concept is now being 
systematically tested for several diseases. Most recently, a systematic yeast two-hybrid screen 
of all known genes for inherited ataxias indicated that they all form part of a single extended 
protein-protein interaction network. 
Third, one can use bioinformatics to make predictions about new genes for diseases that form 
part of the same phenotype cluster. This is done by starting from the known disease genes and 
then searching for genes that share one or more functional attributes such as gene expression 
pattern, co-evolution, or gene ontology.  Ultimately, one may expect that a modular view of 
disease genes should help the rapid identification of additional disease genes for multifactorial 
diseases once the first few contributing genes (or environmental factors) have been reliably 
identified. 
 
Introduction 
With the arrival of the post-genomic era, the use of the candidate gene approach – in which 
gene candidacy is estimated based on knowledge about gene function – to augment or even 
supplant positional cloning has become more prevalent, and this trend will probably continue 
into the future[1,2]. Disease phenotypes provide a valuable window into the function of genes 
which can be exploited in the candidate gene approach. Here we discuss the relationship 
between genes and phenotypes and the application of this knowledge to the elucidation of 
genetic diseases, with an emphasis on malformation syndromes. 
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Relationship between genes and phenotypes 
The functional genetics of syndrome families 
Human malformation syndromes do not fall into neatly separated categories. Instead there is 
much overlap between syndromes, leading to the clustering of similar syndromes into syndrome 
families[3]. In addition, even within a particular syndrome there is often substantial phenotypic 
variation. This overlap in phenotype between different syndromes leads to ambiguity in their 
classification, with a tendency to lump similar syndromes together on the one hand and a 
tendency to split them into different entities on the other[4]. This situation is further complicated 
by the fact that there is not a one-to-one relationship between syndromes and genes. Typically, 
multiple syndromes can be caused by mutations in the same gene and a single disorder can be 
caused by mutations in different genes[5]. The existence of phenotypic variability is not 
surprising given that genes work in concert to form and maintain the human body. Different 
alleles of different genes in different individuals integrate differently with each other to create 
different final phenotypes. This is the basis of human phenotypic diversity and an important 
factor contributing to the fact that no two individuals are identical.  
However, not all genes are equally functionally related. Functionally distant genes may have 
little or no impact on each other, while strongly related genes – for instance genes in the same 
protein complex or biochemical pathway – together perform a single biological function. Such 
strongly related genes may thus lead to the same or similar phenotypes when mutated, 
potentially resulting in the phenomenon of syndrome families[6] (see Figure 1). If the 
relationship is strong enough the resulting phenotypes may be clinically inseparable, leading to 
a genetically heterogeneous syndrome rather than a syndrome family. 
There are numerous examples of diseases or groups of diseases with similar phenotypes that 
are caused by functionally related genes (see table 1 for a few examples).  
While there is a tendency for similar disease phenotypes to be caused by functionally related 
genes, the converse does not hold true in all cases. Mutations that affect different functions of a 
pleiotropic gene can result in different phenotypic manifestations. A well-known example is the 
XPD gene, which is involved in both basal transcription and DNA repair[7]. Mutations in this 
gene can lead to different disease phenotypes depending on which of these two functions is 
compromised[8]. An even better known example is the lamin A/C gene (LMNA), which can lead 
to a host of different disease phenotypes collectively called laminopathies (see e.g.[9,10] for 
reviews) depending on where the mutation is located[11].  Also, nonsense and frameshift 
mutations of different regions of the GLI3 gene cause Greig cephalopolysyndactyly, and 
Pallister-Hall syndrome, respectively, because this gene again contains at least two separate 
biological functions[12]. Moonlighting enzymes form an interesting subset of pleiotropic genes 
that have regulatory or structural functions that are unrelated to their enzymatic function[13]. 
Mutations in these genes may lead to disease phenotypes that do not correlate with the known 
enzymatic function of the causative gene[14]. 
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Figure 1. Possible relationships between genes and phenotypes. The similar phenotypes of Stickler, 
Marshall and OSMED syndromes are caused by mutations in the functionally closely related genes 
COL2A1, COL11A1 and COL11A2. The phenotypically distinct Pallister-Hall syndrome is caused by 
mutations in the functionally unrelated or only weakly related GLI3 gene. Several genes can underlie one 
phenotype, as in the case of Stickler syndrome which can be caused by mutations in each of the three 
collagen genes. Conversely, one gene can lead to different phenotypes as in the case of COL11A1 
(Stickler and Marshall phenotypes) and COL11A2 (Stickler and OSMED phenotypes). Thickness of black 
lines linking genes indicates (hypothetical) degree of functional relatedness between them. 
 
Also, epistasis can mask the phenotypic effect of a gene[15], obscuring the link between gene 
and phenotype. The phenotypic effect of a mutation in a disease gene could be buffered or 
aggravated by alleles of other genes, leading to greater variablility in disease phenotype. In a 
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large scale epistasis study of metabolic enzymes in baker’s yeast (Saccharomyces 
cerevisiae)[16], it was found that mutations in genes in certain metabolic modules could 
influence the effect of mutations in genes in other modules – for instance mutations in 
respiratory genes aggravated the effects of mutations in genes involved in glycolysis. 
The question may therefore be asked whether pleiotropy, epistasis, and diversity of gene 
function together obscure the modular view of genetic disease, or whether the relationship 
between functional genetic modules and phenotype is actually the rule in human disease. 
The modular nature of the phenome 
A first test for the hypothesis that similar phenotypes are caused by mutations in functionally 
related genes is provided by large scale phenotyping studies in Saccharomyces cerevisiae, or 
baker’s yeast[38,39]. Dudley and colleagues[38] analyzed the growth phenotypes of 4710 yeast 
mutants under 21 environmental conditions and found that phenotype correlated with the 
cellular function of the mutated gene. They also found significant pleiotropy in gene function. 
Similarly, Ohya and colleagues[39] used high-throughput image processing to automatically 
quantify yeast morphological phenotypes. Using 4718 deletion strains, they found that similar 
phenotypes were caused by deletions of functionally related genes. 
In humans, similar analyses have also been done. In a first attempt, Jimenez-Sanchez and 
colleagues[40] investigated the relationship between the functional classes of disease genes 
and certain disease properties such as age at onset, mode of inheritance and reduction of life 
expectancy. They found associations between various functional categories and disease 
features; for instance transcription factors are overrepresented in diseases that manifest 
themselves in utero, while enzymatic insufficiencies tend to manifest themselves in the neonatal 
period. Freudenberg & Propping[41] clustered 878 diseases of known genetic origin from the 
OMIM database[42] according to phenotypic similarity, and found that genes leading to 
phenotypically similar diseases tend to have more similar functional annotation than other 
genes.  
We have recently used an automated text mining approach to perform a similar analysis on over 
5000 OMIM phenotypes, defined by higher resolution phenotypic descriptions[43]. Using 
standardized phenotypic feature terms from the Medical Subject headings (MeSH) controlled 
vocabulary, we mined OMIM records for disease-associated phenotypic features. These feature 
terms were further weighted according to specificity, rarity in the OMIM database and relative 
frequency of occurrence in the given syndrome record. This resulted in standardized and 
quantified descriptions of syndromes using feature vectors instead of plain text. This allowed for 
phenotypic similarity scores to be systematically generated for all 25 million syndrome pairs. We 
then sought to associate phenotype similarity with various measures of shared gene function. 
We found that phenotypic similarity between syndromes did indeed correlate with the sequence 
similarity of their disease genes. Significant correlations were also present between phenotype 
similarity and shared protein motifs, shared functional annotation of their underlying genes, and 
protein-protein interactions. 
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Table 1. Examples of functionally related genes that lead to similar disease phenotypes when mutated. 
The different types of genetic relationships listed here are not mutually exclusive and genes could be 
related in several of these ways. These are not the only ways genes can be related. 
Genetic relationship Examples Comments 
Similar gene structure/function 
(homologs) 
Stickler, Marshall and OSMED syndromes all 
caused by mutations in collagens[17-20]. 
Collagens also interact with each 
other. 
Fanconi Anemia caused by mutations in 
several genes involved in the functioning of a 
DNA repair complex[21,22]. 
Usher syndrome type I caused by mutations in 
genes forming a protein complex involved in 
both inner ear hair cell differentiation and 
retinal photoreceptor synapses[23,24]. 
Hermansky-Pudlak syndrome caused by 
mutations in subunits of three protein 
complexes involved in lysosomal vesicle 
trafficking[25,26]. 
Protein-protein interactions, 
especially protein complexes 
Inherited ataxias caused by mutations in 
proteins that form an extended functional 
network[27]. 
Protein-protein interactions are a 
broad category that overlaps 
with the others mentioned here; 
proteins in the same pathway or 
developmental process may 
interact with each other, and 
homologous proteins often 
interact through di- or 
multimerization as is the case 
with the collagens mentioned 
above. 
Pallister-Hall and Smith-Lemli-Opitz (SLOS) 
syndromes caused by mutations in GLI3 and 
DHCR7 genes respectively[28-30]; both are 
involved in the hedgehog signaling 
pathway[31,32]. 
Same pathway 
Muscle-Eye-Brain Disease, Walker-Warburg 
Syndrome and Fukuyama Congenital Muscular 
Dystrophy caused by genes involved in the 
glycosylation of α-dystroglycan [33]. 
There are several different kinds 
of pathways, such as metabolic 
pathways, signal transduction 
pathways, or even protein 
modification pathways like the α-
dystroglycan glycosylation 
pathway mentioned here. 
Neurocristopathies, caused by defective neural 
crest development[34,35]: Hirschsprung 
Disease, Waardenburg, Waardenburg-Shah, 
DiGeorge, and Congenital Central 
Hypoventilation (CCHS, or Ondine’s curse) 
syndromes. Same developmental or 
organogenesis process 
Cilia-related disorders, caused by defective 
cilia biogenesis[36,37]: Bardet-Biedl, 
Kartagener and Meckel syndromes, Primary 
Ciliary Dyskinesia, Polycystic Kidney Disease. 
Overall phenotypic similarity is 
not always high for these 
diseases but they can often be 
linked though shared traits. For 
instance, aganglionic megacolon 
occurs in various 
neurocristopathies and situs 
inversus occurs in several cilia-
related diseases. 
 
Chapter 2: The modular nature of genetic diseases 
27 
 
Predicting disease genes 
Different bioinformatics strategies have been developed to predict and prioritize potential 
disease genes, and several web tools and bioinformatic approaches are now available (Table 
2). They can be classified into three broad, not mutually exclusive categories: those based on 
intrinsic disease gene properties, those that use expression patterns and phenotypic information 
directly, and those that look at functional relatedness between candidate genes. These three 
categories differ in the extent to which they utilize disease phenotype information varying from 
simply distinguishing between disease and non-disease phenotypes on the one hand to the 
systematic comparison of disease phenotypes at the individual trait level on the other. 
Are disease genes different? 
A number of recent analyses have shown that there are systematic differences between disease 
genes and non-disease genes. While the biological basis for such systematic differences might 
not be immediately apparent, they could theoretically be used to evaluate the likelihood that a 
given candidate gene is disease-causing. However, their discriminatory power is still poor at the 
level of individual diseases, because up to half of all genes are classified as potentially disease-
causing. 
For instance, disease genes tend to be highly expressed and have tissue-specific expression 
patterns, as shown by Bortoluzzi and colleagues[44] and Smith & Eyre-Walker[45]. The latter 
study also found that disease genes have higher mutation rates over evolutionary time, a result 
confirmed by Huang and colleagues[46]. However, these higher disease gene mutation rates 
are challenged by results from Lopez-Bigas & Ouzounis[47] and Adie and colleagues[48], who 
found – both using decision tree computer learning algorithms – that disease genes tend to be 
more highly conserved with a broader phylogenetic extent. These apparently conflicting results 
were reconciled by Tu and colleagues[62], who separated the non-disease genes into two 
categories: housekeeping genes and non-housekeeping genes. They showed that the higher 
disease gene mutation rates found by the first two studies were due primarily to the low 
mutation rates of the housekeeping genes, while the higher conservation level of disease genes 
found by the latter two studies were due to the faster evolution of the non-housekeeping genes 
in the non-disease gene set. 
Other findings from the two decision tree-based approaches were that disease genes tend to 
have fewer close paralogues (homologues resulting from gene duplication) – suggesting that 
their loss of function in disease cannot be adequately compensated for by a closely related 
counterpart – and that they tend to differ in some potentially regulation-related features such as 
having longer mRNA 3’ UTRs (Untranslated Terminal Regions), a higher proportion of genes 
with signal peptides, a higher proportion with CpG islands at their promoters (usually associated 
with housekeeping genes) and longer intergenic distances. These algorithms are available on 
the web for use by researchers (see Table 2). 
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Table 2. Existing approaches and web tools for the prediction or prioritization of disease candidate genes. 
Approach Online availability Data types used 
Approaches based on disease gene properties 
Bortoluzzi et al. 
[44] 
Article supplementary material at 
http://physiolgenomics.physiology.org/cgi/content/full/00095.2003/DC1/ Expression 
Smith & Eyre-
Walker [45] - Sequence, expression 
Huang et al. [46] Additional data files available from journal website at http://genomebiology.com/2004/5/7/R47 Sequence, expression 
DGP [47] http://cgg.ebi.ac.uk/services/dgp/ Sequence 
PROSPECTR [48] http://www.genetics.med.ed.ac.uk/prospectr/ Sequence 
Approaches using links between genes and phenotypes 
Genes2Diseases 
[49,50] http://www.ogic.ca/projects/g2d_2/ 
Sequence, functional 
annotation, literature 
mining 
BITOLA [51] http://www.mf.uni-lj.si/bitola/ Literature mining 
Tiffin et al. [52] Article supplementary data available at http://www.sanbi.ac.za/tiffin_et_al/ Expression, literature 
mining 
GeneSeeker 
[53,54] http://www.cmbi.ru.nl/GeneSeeker/ 
Expression, phenotype, 
literature mining 
GFINDer [55,56] http://www.bioinformatics.polimi.it/GFINDer/ Expression, phenotype 
TOM [57] http://www-micrel.deis.unibo.it/~tom/  Expression, functional 
annotation 
Approaches using functional relatedness between candidate genes 
Freudenberg & 
Propping [41] - 
Phenotype, functional 
annotation 
OMIM phenome 
map [43] http://www.cmbi.ru.nl/MimMiner/ 
Phenotype, sequence, 
functional annotation, 
protein interactions 
Protein-protein 
interactions [58] 
Article supplementary material on journal website at 
http://www.jmedgenet.com/supplemental/ Protein interactions 
POCUS [59] Additional data files available from journal website at http://genomebiology.com/2003/4/11/R75 Functional annotation 
SUSPECTS [60] http://www.genetics.med.ed.ac.uk/suspects/ Sequence, expression, functional annotation 
Prioritizer [61] http://www.prioritizer.nl/ 
Expression, functional 
annotation, protein 
interactions 
Endeavour [62] http://www.esat.kuleuven.be/endeavour/ 
Sequence, expression, 
functional annotation, 
pathways, literature 
mining 
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Recently, Lopez-Bigas and colleagues conducted a more comprehensive analysis of the 
general properties of disease genes[63]. They found extensive correlations between various 
gene properties and disease characteristics. For instance, they confirmed an earlier 
identified[40] relationship between gene functional class and disease mode of inheritance; 
enzymes and transporters are mostly involved in recessive diseases, while transcription 
regulators and structural molecules are usually associated with a dominant mode of inheritance. 
Importantly for phenotype- and functional genetics-based approaches to disease gene 
discovery, they also confirm that disease gene functional classification and expression patterns 
correlate with the type of disease they cause when mutated. 
While these studies show that there are quantitative differences between disease genes and 
non-disease genes, these approaches are much too broad to be practically useful in the search 
for causative genes for specific diseases. In fact, the two methods that can be used for this – 
the decision trees of Lopez-Bigas and Adie and colleagues – classify respectively ~31% and 
~44% of the entire genome as probable disease genes. Even so, they do not always detect the 
correct disease genes in benchmark tests. For practical purposes, the use of specific disease 
phenotypes, as in the approaches described below, is more productive. 
Candidate genes based on phenotype 
A number of bioinformatic approaches directly prioritize genes according to disease phenotypes 
or disease-associated phenotypic traits.  These tools use gene expression patterns, gene 
ontology functional annotation, text mining of MEDLINE abstracts or data from mouse mutants 
to arrive at a list of most likely candidates. Typically, such approaches enrich candidate genes 
by 5- to 10-fold over random. While this is encouraging, benchmark tests only test for known 
disease genes, which means that the performance of these systems may be overestimated. 
Here we describe several disease candidate gene identification web tools and approaches that 
are based on directly linking candidate genes to disease phenotypes. 
Two web tools, Genes2Diseases[49,50] and BITOLA[51] (see Table 2 for web locations), 
primarily use text mining of MEDLINE abstracts to associate genes from a candidate region to 
diseases. They essentially automate literature searches for associations between candidate 
genes and diseases, relieving the researcher of much manual searching. Being automated, they 
naturally do not interpret the literature as intelligently as a researcher would; however they can 
assist the researcher in prioritizing or narrowing down the list of candidate genes. The 
Genes2Diseases web tool, which is also based on gene functional annotation in databases in 
addition to text mining, performed reasonably well in benchmark tests. Using 100 artificial 30Mb 
disease loci, the target disease gene was recovered in 87 cases, and was among the top 8 
genes in 47/100 cases. 
A third literature mining-based approach was taken by Tiffin and colleagues[52], though they did 
not create a web interface for it. In this approach, candidate genes are ranked according to their 
expression overlap with disease-related anatomical regions. The associations between 
diseases and anatomical regions are retrieved from MEDLINE abstracts by text mining. The 
strength of this approach is the use of a controlled vocabulary of standardized anatomical terms 
(eVOC) to describe the gene expression patterns, and it was able to successfully select the 
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correct disease gene in 15 out of 17 test cases whilst reducing the candidate gene set to ~63% 
of its original size on average. 
Other web tools that place the emphasis on disease gene expression patterns are 
GeneSeeker[53,54], GFINDer[55,56] and TOM[57]. These tools can also be used to help 
identify interesting candidate disease genes. Similar to the approach used by Tiffin and 
colleagues, our GeneSeeker interactive web tool also matches postional candidate genes to 
diseases using anatomical expression patterns. However, it uses terms entered by human 
experts rather than terms associated with the disease through automated literature mining, and 
it does not use a controlled vocabulary. This interactive nature increases its utility to 
researchers, as they can use their own choice of terms rather than depending on the tool to 
automatically generate appropriate terms for them. In addition, GeneSeeker also incorporates 
mouse expression data, expanding the amount of data it can exploit for disease association. Its 
performance is naturally dependent on the chosen search terms, but in a test using 10 
syndromes with known genesis, the causative gene was retrieved while the list of candidates 
was reduced from 165 to 22 on average. To our knowledge, GeneSeeker is also the only web 
tool that has thus far been successfully applied in clinical research, as it was used to identify the 
gene for an inherited skeletal dysplasia[65]. 
The GFINDer web tool contains a module that uses tissue mRNA expression patterns to 
analyze candidate disease genes. This tool works in the reverse direction relative to the others 
in that it identifies disease phenotypes from the OMIM database that are most likely to be 
associated with a given set of genes, rather than starting out with a given disease phenotype 
and identifying candidate genes. In other words, it identifies candidate diseases for a given set 
of genes rather than candidate genes for a given disease. Despite this, it can still be used to find 
potentially interesting disease genes in a candidate gene set as it may detect genes known to 
cause similar diseases. TOM uses microarray gene expression data and optionally also 
functional annotation to find positional candidate genes that are related to known disease 
genes, or to find related genes in multiple candidate disease loci. 
While these direct candidate gene approaches typically enrich 5- to10-fold over random, there 
are a number of weaknesses, notably that they rely on the relatively poor annotation of many 
human genes, and the small number of genes that have a known knock-out phenotype in mice. 
Using functional genetic modules to identify candidate genes 
If we assume that genes which lead to the same phenotype are functionally related, as has 
been shown for several diseases (e.g. [66-71]), then we may define candidate genes as those 
that are functionally related to the known causative genes for the same or similar diseases. As 
mentioned earlier, the OMIM database has been systematically analyzed to identify 
relationships between gene functional relatedness and phenotypic similarity[41,43]. The results 
indicate that there is indeed a strong correlation between phenotype similarity and a number of 
relations at the gene and protein levels. This approach may therefore also be used for candidate 
disease gene prediction, as it can highlight functional genetic modules containing known 
disease genes that cause similar disease phenotypes.  
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More directly, Lim and colleagues[27] have systematically tested this approach for inherited 
ataxias. They found by using yeast two-hybrid approaches that most if not all genes for human 
inherited ataxias form part of a single expanded protein network of 54 genes. This result is 
interesting as previously none of the known ataxia-causing proteins were known to interact with 
each other. It is also a concrete illustration of the relationship between genetic modules and 
syndrome families, and suggests that other syndrome families might also be caused by proteins 
that form functional genetic modules. 
Recently, we have also used protein-protein interactions to predict novel candidate disease 
genes for genetically heterogeneous diseases[58]. We collected a total of 72940 protein-protein 
interactions between 10984 human proteins, mostly from human datasets, but some of which 
were mapped from other species. We then used this protein-protein interaction network to look 
for positional candidate disease genes for 383 genetically heterogeneous diseases, based on 
their interactions with known disease proteins. We made almost 300 predictions for 48 
diseases, of which about 10% are expected to be correct based on benchmark tests with known 
disease genes. This represents a 10-fold enrichment over using positional data only. Though 
not available through a web tool, the predictions are available online as supplementary data 
accompanying the publication (Table 2). 
In addition to protein-protein interactions, functional annotation can also be used to link different 
genes into larger functional modules. Turner and colleagues[59] developed an approach 
(POCUS) which compares the functional annotation of genes in different candidate loci, looking 
for gene combinations in the different loci that share the most functional annotation terms. The 
idea is that if there are functionally related genes in different disease loci, they may be part of a 
genetic module underlying the disease phenotype. In tests this approach resulted in a 12-fold to 
42-fold enrichment in candidate genes depending on locus size. Unfortunately POCUS also 
does not have a web interface, though supplementary data accompany the publication (Table 
2). 
A recent trend in bioinformatic disease gene prediction tools is the combination and integration 
of several different types of functional genomic data in order to better predict or prioritize 
candidate disease genes. Adie and colleagues further expanded their decision tree-based 
system, described in the previous section, to accommodate the investigation of candidate 
disease regions for specific diseases[60] (SUSPECTS). To this end they augmented it with 
different types of functional genomic data – coexpression, shared protein domains and 
functional annotation – which are used to rank candidate genes based on their similarity to 
known disease genes associated with the query disease. This approach performs substantially 
better than their previous approach (PROSPECTR) which does not take disease-specific 
information into account, and is available through the web (Table 2). 
The most comprehensive approaches developed to date that attempt to prioritize positional 
candidate genes by integrating various types of genomic data are Prioritizer[61] and 
Endeavour[62]. Both tools are available as downloadable software (see Table 2), but cannot be 
used directly over the web. Prioritizer attempts to identify functional similarities between genes 
in different candidate regions by integrating coexpression, protein-protein interaction, and 
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functional annotation data using a Bayesian network. It performs relatively well, as the correct 
disease gene was amongst the top five candidates 54% of the time in a benchmark test using 
artificial loci with 100 genes each. Endeavour, on the other hand, uses a user-supplied training 
set of known disease genes to prioritize genes in candidate loci. It integrates more data types 
than Prioritizer, utilizing sequence similarity, expression data, protein-protein interactions, 
functional annotation, pathway data and regulatory information based on transcription factor 
binding sites, and it performs remarkably well with a good training set of known disease genes. 
Naturally, its success is dependent on the availability of a set of known disease genes for the 
disease in question or similar diseases. 
An example of the success of combining different types of genomic data is a recent study by 
Calvo and colleagues[72] which attempted to identify novel genes involved in mitochondrial 
dysfunction. They combined several types of genomic data including mitochondrial targeting 
sequences, cis-regulatory motifs, protein domains, (co)expression, protein homology and mass 
spectrometry data to identify nuclear-encoded genes associated with mitochondrial function. 
The resulting genes were checked against chromosomal loci to identify candidate genes for 
mitochondrial disorders, one of which was confirmed. Although this was an analysis of a specific 
disease category, it shows that combining functional genomics data can be successful in 
predicting disease genes. 
One limitation of many of these approaches is that they rely quite heavily on functional 
annotation of candidate genes, and are therefore inherently biased toward better characterized 
genes. This raises the question of how representative these benchmark tests with known 
disease genes are for novel disease gene prediction. Nonetheless, functional genetic modules 
containing known disease genes are clearly an important new route towards effective candidate 
disease gene prediction. 
 
Formalizing phenotype descriptions 
To be maximally effective, phenotypic trait-based methods require formalized, standardized and 
preferably also quantified disease phenotype descriptions. Phenotypic information is the most 
readily attainable information relating to genetic diseases. It does not require genetic studies as 
are required for positional cloning. Doctors are adept at identifying even the slightest phenotypic 
alterations in disease patients and given the worldwide nature of the medical community, vast 
amounts of detailed phenotypic information already exist in the medical literature awaiting full 
exploitation[73]. Furthermore, a few excellent disease databases such as the Online Mendelian 
Inheritance in Man (OMIM)[42] database collect and store large amounts of this information in 
one place.  
 Unfortunately, most phenotypic information is not currently stored in formats that are amenable 
to automated processing. Most phenotypic data are stored as prose, as in the OMIM database, 
and the use of phenotypic terms in disease description is not standardized in the literature. 
Furthermore, some phenotypes are described in more detail than others. These factors make 
automated processing of phenotypic information difficult. 
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In order to create an automated disease phenotype analysis tool, a standardized system of 
phenotypic description would be invaluable[74]. In addition to standardized description, more 
quantitative information such as frequency of occurrence is important for automated processing. 
To begin with this would permit related diseases to be systematically associated with each other 
even if they are classified separately in OMIM; it would enable a more rigorous classification of 
disease phenotypes. More importantly, it would allow more systematic association of disease 
phenotypes with underlying disease genes, allowing their impact on phenotype to be measured 
more precisely.  
The Orphanet database of rare human malformation disorders[75] already uses a systematic 
means of classifying disease phenotypes including trait lists annotated with frequency of 
occurrence. This approach illustrates the direction that needs to be taken for phenotype 
databases to be even more useful to automated processing tools than they currently are. 
Controlled vocabularies such as eVOC[76] or the National Library of Medicine’s Medical Subject 
Headings (MeSH) can be used to standardize terms used in phenotype description. For 
craniofacial malformation syndromes it remains difficult to find unequivocal terms that capture 
the complete phenotypic information. In this regard, a picture still tells more than a thousand 
words. Quantitative topological information acquired using computerized analysis techniques 
such as the  ‘Dense Surface Model’[77-79] (Figure 2) and Gabor wavelet[80] technologies could 
potentially lead to more rigorous phenotype comparisons than text-based descriptions. A human 
phenome project, as proposed by Freimer & Sabatti[81], is clearly needed in some shape or 
form. 
 
Future prospects 
Given a more structured phenotype description system, topological analyses of the human 
phenome landscape can be conducted with more precision. For instance, disease phenotypes 
could be clustered to create a phenotypic similarity network of inherited diseases, as already 
attempted by us and also by Cantor & Lussier with courser phenotype descriptions[43,82]. Such 
a phenotype network would be valuable for syndrome classification and could facilitate research 
into the underlying genetics[6].  
For instance, a similarity-based network of syndrome phenotypes could be overlaid over a 
functional relatedness-based network of genes such as that created by Franke and 
colleagues[61]. The hypothesis that similar phenotypes are caused by functionally related 
disease genes could then be tested on a genomic – and phenomic – scale. Additionally, known 
causative genes from syndromes that are phenotypically similar to a genetically uncharacterized 
syndrome can be used to query the gene network for functionally related candidate genes 
(Figure 3). 
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Figure 2. The use of Dense Surface Models (DSMs) for facial morphology quantification. (A) DSM-based 
images of children with Williams-Beuren syndrome (WBS) and control children. Patient HR has an 
atypical form of WBS. These 3D facial images were synthesized in Dense Surface Models (DSMs) that 
integrate large numbers of facial images. (B) Scatterplot display of the unseen classification of normal 
and WBS DSMs. The position of patient HR’s DSM is located between typical WBS and control DSMs. 
This illustrates the means by which DSMs can be used to quantify and distinguish a syndrome’s 
characteristic facial morphology from normal facial morphology, or that of a different syndrome. See 
reference [71] for further details. Reprinted with permission from Tassabehji et al., Science 310:1184-7 
(18 Nov 2005). Copyright 2005 AAAS.  Note: Modified from published article; photographs of patients’ 
faces removed. 
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Figure 3. Mapping phenotype networks to gene networks for candidate disease gene prediction. In this 
hypothetical example, diseases 1, 2 and 3 have known causative genes (genes A, C and E respectively), 
and are all phenotypically related to disease 4 which lacks an identified causative gene. If the known 
causative genes are functionally closely related, as in this case, then candidate genes (genes B and D) 
can be hypothesized for disease 4 due to their close functional relationships to the known genes of the 
phenotypically related diseases. This kind of analysis could potentially also identify higher level links 
between functional genetic modules and syndrome families. Green lines connect (green) known disease 
genes with their (green) diseases, while red lines indicate potential causative links between (red) 
candidate genes and the (red) disease of unknown etiology. Black lines of varying thickness indicate the 
degree of phenotypic and functional similarity between diseases and genes respectively. 
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The modular nature of disease genes is rapidly changing the way in which candidate genes are 
mostly defined. Ultimately, one may expect that this modular view of disease genes should be 
especially helpful for the rapid identification of additional disease genes for multifactiorial 
diseases, once the first few contributing genes (or environmental factors) have been reliably 
identified. 
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Abstract 
Background: For a large number of genetically mapped disease loci, the responsible genes 
have not yet been identified. Physically interacting proteins tend to be involved in the same 
cellular process and mutations in their genes may lead to similar disease phenotypes. It should 
thus be possible to use protein-protein interactions to predict genes for genetically 
heterogeneous diseases. 
Objective: To investigate how successful protein-protein interactions are in predicting genetic 
disease genes. 
Methods: A total of 72,940 protein-protein interactions between 10894 human proteins were 
used to search 432 loci for candidate disease genes representing 383 genetically 
heterogeneous hereditary diseases. For each disease, the protein interaction partners of its 
known causative genes were compared  with the disease-associated loci lacking identified 
causative genes. Interaction partners located within such loci were considered candidate 
disease gene predictions. Prediction accuracy was tested using a benchmark set of known 
disease genes. 
Results: Almost 300 candidate disease gene predictions were made. Some of these have since 
been confirmed. On average, 10% or more are expected to be genuine disease genes 
representing a 10-fold enrichment compared to positional information only. Examples of 
interesting candidates are AKAP6 for arrythmogenic right ventricular dysplasia 3 and SYN3 for 
familial partial epilepsy with variable foci. 
Conclusions: Exploiting protein-protein interactions can greatly increase the likelihood of 
finding positional candidate disease genes. When applied on a large scale they can lead to 
novel candidate gene predictions. 
 
Introduction 
Many human genetic diseases can be caused by multiple genes. Since they lead to the same or 
similar disease phenotypes, the underlying genes are likely to be functionally related. Such 
functional relatedness can be exploited to aid in the finding of novel disease genes[1]. Direct 
protein-protein interactions are one of the strongest manifestations of a functional relation 
between genes, so interacting proteins may lead to the same disease phenotype when mutated. 
Indeed, several genetically heterogeneous hereditary diseases are known to be caused by 
mutations in different interacting proteins, such as Hermansky-Pudlak syndrome and Fanconi 
anemia[2,3]. Also, a recent study showed that interacting proteins tend to lead to similar disease 
phenotypes when mutated[4]. Therefore protein-protein interactions might in principle be used 
to identify potentially interesting disease gene candidates. 
A large number of human protein-protein interactions have been described in the literature[5]. 
These literature-based interactions are reliable, but are naturally biased toward better studied 
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proteins and have already been exploited by the community for disease gene prediction. 
Protein-protein interactions from high throughput experiments do not have this bias, though they 
are also generally less reliable than literature-based interactions[6]. These high throughput sets 
are especially interesting for novel disease gene prediction since they can contain previously 
undescribed protein-protein interactions. There are two human high throughput protein-protein 
interaction sets available[7,8], but more are available from other species. These first have to be 
mapped to interactions between human proteins before they can be applied to disease gene 
prediction. 
We investigated how successful protein-protein interactions are in predicting candidate disease 
genes for genetically heterogeneous hereditary diseases using a systematic large scale 
bioinformatics approach. To be as comprehensive and unbiased as possible we used both 
literature-based and high throughput human protein-protein interactions, and human-mapped 
high throughput interactions from three other species – Drosophila melanogaster (fruit fly), 
Caenorhabditis elegans (nematode) and Saccharomyces cerevisiae (baker’s yeast). To identify 
potential new candidate disease genes, we examined whether disease proteins had interaction 
partners which were located within other loci associated with that same disease; such 
interaction partners were considered to be candidate disease genes. Several of these 
predictions have since been confirmed. 
 
Methods 
Genetic disease data 
Disease data were obtained from the Online Mendelian Inheritance in Man (OMIM, 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM) ”Morbid Map” list of diseases. This list 
contains disease loci and known disease genes from the OMIM database[9]. We selected 
genetically heterogeneous hereditary diseases with at least one known disease-causing gene 
and at least one disease locus lacking an identified causative gene. Disease subtypes were 
pooled into single diseases. A disease can have several loci, some of which may overlap each 
other. For instance, there are several X-linked mental retardation subtypes, many of which have 
been mapped to overlapping loci. Therefore, a single protein-protein interaction could result in 
multiple candidate gene predictions for different disease subtypes. 
The loci vary in length and gene count, with a median of 88 genes per locus, and a mean of 
123.6, the loci lengths are not normally distributed. Whole chromosome loci were excluded from 
the analyses. In total, there were 383 diseases in the data set. Together these diseases have 
1195 disease loci with identified disease genes and 432 disease loci lacking identified causative 
genes. 
The data set used in the benchmark tests contained all the genetically heterogeneous 
hereditary diseases from Morbid Map with at least two known disease genes (289 diseases, 
1114 disease loci with known disease genes, 1003 distinct genes). Only loci with known disease 
genes were used in the benchmark tests. 
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Protein-protein interaction sets 
Five protein-protein interaction data sets were used in this study, from four different species – 
human, Drosophila melanogaster (fruit fly), Caenorhabditis elegans (nematode worm) and 
Saccharomyces cerevisiae (baker’s yeast) (Table 1). One of the human interaction sets 
contained manually curated protein-protein interactions culled from the literature, while all the 
other protein interaction data were from high throughput protein-protein interaction experiments. 
 
Table 1: Protein-protein interaction sets used in the study. 
Interaction 
set 
Source of 
interaction data * 
Number of 
proteins in human-
mapped 
interactions † 
Number of 
human-
mapped 
interactions ‡ 
References Comments 
HPRD set Literature 6005 19728 [5] Downloaded october 21 2005. 
Human Y2H 
set 
High throughput 
experiments 
(Y2H) 
2686 5211 [7,8] Interactions from both 
experiments pooled. 
Fly set High throughput 
experiment (Y2H) 4706 16313 [10] 
All interactions were 
used, regardless of 
confidence level. 
Worm set High throughput 
experiment (Y2H) 1933 5771 [11] 
Downloaded from DIP 
database. 11 
Yeast set 
High throughput 
experiments 
(Y2H, PCP) 
2455 27098 Y2H:[13,14] PCP:[15,16] 
Interactions from all 
four experiments 
pooled. 
Combined 
high 
throughput 
set 
All high 
throughput sets 8162 54048 See above Excluding HPRD 
Total 
combined 
set 
All interaction sets 10894 72940 See above Including HPRD 
*
 Y2H: Yeast two-hybrid protein-protein interaction assay; PCP: Protein complex purification experiment 
(based on mass spectrometry) 
†
 These are the proteins that could be automatically mapped to human Ensembl gene IDs 
‡
 These are the interactions from the original interaction sets that could be automatically mapped to 
human Ensembl gene IDs 
 
The non-human protein-protein interactions were mapped to human proteins using orthology 
relationships. Orthology between the other species’ and human proteins was determined using 
the Inparanoid program[17], with default settings, on the whole (protein) genomes of the 
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species. Genomes were acquired from Ensembl[18] for the metazoan species and from the 
Saccharomyces Genome Database[19] for yeast. Where one non-human protein was 
orthologous to several human proteins, the interaction was assumed to be valid for all these 
proteins. 
Candidate gene prediction 
For all the diseases in the heterogenic diseases data set, the following actions were performed:  
1. The protein interaction partners were determined for each known disease protein. 
2. The chromosomal locations of the genes coding for these interacting proteins were 
determined using gene location data from the Ensembl database. The cytogentic loci 
were mapped to chromosomal base pair ranges using the Ensembl database, which 
specifies cytogenetic band boundaries as exact base pair positions, rounded off to the 
nearest 100kb.  
3. These chromosomal locations were checked to see if they fell within one or more 
disease loci (of the same disease) that lacked a known disease gene. 
4. Each interacting protein gene that was located within one of these loci was considered a 
candidate gene prediction. 
5. If a candidate gene lay within multiple (overlapping) loci of the same disease, each of 
them was counted as a separate prediction. 
This procedure was carried out using a custom written C++ program (available on request), as 
were the benchmark and randomization tests described below. 
Benchmark tests 
The benchmark test is introduced to examine how well a protein-protein interaction set performs 
in recovering known disease genes from different loci known to be involved in the same 
disease. These tests were therefore carried out analogously to the candidate gene prediction 
tests, with the exception that the protein interactor positions were examined against the disease 
loci with known disease genes (as opposed to the loci with unidentified disease genes). As with 
the prediction tests, these genes and their associated disease loci were taken from OMIM 
Morbid Map. 
If an interactor lay within a disease locus it was considered a candidate gene prediction (a 
positive). If this interactor was indeed the known disease gene in that locus, it was considered a 
correct prediction (true positive). If it was not the known disease gene for that locus, it was 
considered a wrong prediction (false positive). 
Randomization tests 
Due to the complex nature of the data – potentially overlapping loci with different gene counts 
and networked protein-protein interactions – protein interactor randomization tests were used to 
estimate the significance of the candidate gene prediction and benchmark results. In each case 
the genome was randomly shuffled and each protein in the interaction set was replaced with its 
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counterpart from the shuffled genome. This approach retains the original structure of the 
interaction network, it only randomizes the protein identities. 
1000 randomization tests were carried out for each of the ten analyses: five protein-protein 
interaction sets, each of which was used for both novel disease gene prediction and for 
benchmarking. In addition, separate randomization tests were carried out for the two combined 
data sets, the combined high throughput set and the total combined set. 
Two other types of randomization tests were carried out for each data set, namely the 
randomization of the gene positions on the genome and the shuffling of the protein interactors in 
the interactor sets. These lead to similar results as the interactor identity randomization (data 
not shown) and were left out of the results for brevity. 
 
Results 
Benchmark tests perform well above random expectation 
In order to examine how well protein-protein interaction sets predict disease genes in other loci 
of the same disease, we first carried out benchmark tests that  attempted to predict known 
disease genes. These tests were carried out using only diseases with multiple known causative 
genes and their disease-associated loci from OMIM Morbid Map, allowing the candidate gene 
predictions to be evaluated for accuracy and overrepresentation. With regard to the number of 
disease gene interaction partners that are located in another locus of the same disease, the 
HPRD interaction stands out as having over twice as many as would be expected by chance 
(Figure 1). The high throughput sets all score higher than the vast majority of their randomized 
controls, though the magnitude of this differs from the fly set scoring higher than all but two 
controls to the worm set scoring higher than 823 of the 1000 randomized controls. We thus 
show here an overrepresentation of disease gene interaction partners in other disease-
associated loci, suggesting that disease genes encode proteins that tend to interact with each 
other. 
The tendency for proteins associated with the same disease to interact with each other can be 
tested more directly by examining what percentage of these correctly localized interaction 
partners are indeed the known disease causing genes in those loci (Figure 2). Once again, the 
HPRD protein-protein interactions performed very well. Almost 60% of these interacting proteins 
corresponded to the known disease-causing genes in these loci. The high throughput protein 
interaction sets had a lower performance (9%-17%, with an average of 12%), but they all did 
much better than their randomized controls. Except for the two smallest sets, all interaction sets 
substantially outperformed every single run of their corresponding 1000 randomized controls. 
This implies that disease protein interaction partners, when located within other loci of the same 
disease, are at least 10-fold more likely to be involved in that disease than the other genes in 
these loci, given that randomly chosen locus genes have on average a 1% (1/88) chance of 
being correct. 
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Figure 1. Overrepresentation of physically interaction proteins from loci associated with the same 
disease. The different protein-protein interaction sets used are on the X-axis, while the Y-axis contains 
the number of disease protein interactors falling within another locus associated with the same disease 
(hits) in the benchmark locus set. Black stars and associated shaded boxes indicate the values based on 
the real interaction data sets, while the box plots indicate the values resulting from the 1000 randomized 
interactor controls per set (numbers in clear boxes are medians). The value for the combined interaction 
data set (indicated by the black arrow) is not included in the plot to keep the Y-axis scale manageable. 
The HPRD and total combined sets score much higher than all their randomized controls, the difference 
is smaller for the high throughput sets. HT = High Throughput. 
 
An interesting result is that the yeast interaction set is more accurate in predicting candidate 
genes than the other high throughput sets, including those using “native” human proteins. Most 
of the yeast interactions are based on protein complex purification rather than yeast two-hybrid 
assays. A likely explanation for the relatively good performances of the yeast interactions is the 
previously observed higher quality of protein-protein interaction data from protein complex 
purification experiments relative to yeast two-hybrid assays[6]. 
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Figure 2. Relatively high likelihood of.finding a disease gene from protein interaction data in a given 
locus. The different protein-protein interaction sets used are on the X-axis, while the Y-axis contains the 
percentage of disease protein interactors falling within other disease loci that correspond to the known 
disease genes in those loci. Black stars (and associated shaded boxes) indicate the values based on the 
real interaction data sets, while the box plots indicate the values resulting from the 1000 randomized 
interactor controls per set. Randomized controls have median accuracies of less than 1%. All interaction 
sets substantially outperform all their controls, with the HPRD scoring exceptionally high. HT = High 
Throughput. 
 
Candidate disease gene prediction results follow similar patterns 
Having established the validity of the approach for known disease genes we compared the 
likelihood of mapping an interactor to a disease locus to chance expectation for disease loci for 
which we do not know the disease gene. As shown in Figure 3, the three largest data sets and 
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the combined data all showed an increase relative to the medians of the randomization 
experiments. This result is consistent with that of the benchmark experiments for the high 
throughput data. It indicates an appreciable enrichment for true disease genes in the prediction 
results. Nevertheless the majority of the candidates are still probably false positives.  
 
 
Figure 3. Candidate disease gene prediction hit counts. The different protein-protein interaction sets used 
are on the X-axis, while the Y-axis contains the number of disease protein interactors falling within 
another locus associated with the same disease (hits) in the candidate gene prediction locus set. Black 
stars (and associated shaded boxes) indicate the values based on the real interaction data sets, while the 
box plots indicate the values resulting from the 1000 randomized interactor controls per set (numbers in 
clear boxes are medians). The fly and yeast sets score higher than the majority of their randomized 
controls, but the two smallest sets do not perform above random expectation. The HPRD scores relatively 
lower than the fly and worm sets, but still above the majority of its controls. HT = High Throughput. 
 
In contrast to the high throughput results from fly and yeast, the HPRD results do show a large 
discrepancy between the benchmark results and the novel gene prediction results. In the latter 
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the enrichment of interactors in disease loci is much smaller than in the former. This suggests 
that the majority of disease genes which could be found using HPRD protein-protein interactions 
have already been detected by the community, which is unsurprising given that all these 
interactions have previously been described in the literature. Some of the interactions in the 
HPRD are even based on research on disease genes in the first place. (e.g. [20-23]) Therefore, 
the HPRD benchmark results are not representative for its novel gene prediction results. 
The two smallest high throughput interaction sets, Human and Worm, show no signal for the 
prediction of novel disease genes. It should be noted that the candidate gene prediction disease 
data set contains fewer target loci (432) than the benchmark data set (1114). One explanation 
for this might be that the combination of a small number of interactions and a small number of 
target loci prevents the two smallest sets from showing any signal here. 
The full list of predicted candidate disease genes and their corresponding interactions are given 
in Supplementary Table 1. 
Confirmed and refuted predictions 
A few candidate disease gene predictions could be confirmed or refuted due to the fact that the 
disease-causing genes are known but absent from the list of known disease genes used in the 
study (Table 2). These disease loci were treated as having unidentified causative genes during 
the study, but manual inspection of the results led to their identification as disease loci with 
known causative genes. 
Promising leads 
In addition to these confirmed prediction the protein interaction sets also led to a number of 
plausible but unconfirmed candidate gene predictions. For instance, the AKAP6 (A-kinase 
(PRKA) anchor protein 6) gene is predicted as a candidate gene for arrythmogenic right 
ventricular dysplasia 3 (OMIM 602086) based on an HPRD interaction with RYR2 (ryanodine 
receptor 2). A-kinase anchor proteins are involved in cardiac myocyte contractility and may be 
involved in heart failure.[27,28] SYN3 (synapsin III) was predicted as a candidate gene for 
familial partial epilepsy with variable foci (OMIM 604364) based on an HPRD interaction with 
SYN1 (synapsin I), which is causative for epilepsy, X-linked, with variable learning disabilities 
and behavior disorders (OMIM 300491). There are several other interesting examples, which 
can be viewed in Supplementary Table 1. 
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Table 2: Confirmed and refuted candidate disease gene predictions. A prediction is considered confirmed 
if it is known in the literature to be causative for the relevant disease, and considered refuted if a different 
gene in the same locus is known to be causative for that disease. It is important to note that a “refuted” 
candidate gene may not have been screened and excluded in the literature, and may thus still be a valid 
candidate. 
Disease subtype Candidate genes Based on interaction with * 
Original disease 
subtype Status Comments 
Branchiootic 
syndrome 3 
[608389] 
SIX1 (sine oculis 
homeobox homolog 1) 
[601205] † 
EYA1 (eyes 
absent homolog 1) 
[601653] 
Branchiootic syndrome 
1 [602588] Confirmed 
Confirmed in 
literature[24], but not 
in Morbid Map version 
used. Interaction 
occurs in fly, worm 
and HPRD sets. 
LCK (lymphocyte-
specific protein-
tyrosine kinase) 
[153390] 
SCID due to LCK 
deficiency [153390] 
PTPRC  (protein-
tyrosine 
phosphatase, 
receptor type, C) 
[151460] 
SCID due to LCK 
deficiency [151460] 
SCID, autosomal 
recessive, T-
negative/B-
positive type 
[600802] 
JAK3 (Janus kinase 3) 
IL2RG (interleukin 
2 receptor, 
gamma) [308380] 
SCID, X-linked 
[300400] 
Confirmed 
Relevant Ensembl 
gene ID erroneously 
mapped to INSL3 
symbol instead of 
JAK3, thus JAK3 not 
mapped to an 
Ensembl gene ID. All 
interactions from 
HPRD. 
Nephronophthisis 
4 [606966] 
Nephronophthisis, 
juvenile [256100] 
Senior-Loken 
syndrome 4 
[606996] 
NPHP4 (nephrocystin 
4) [607215] 
NPHP1 
(nephrocystin 1) 
[607100] 
Senior-Loken 
syndrome 1 [266900] 
Confirmed 
NPHP4 gene symbol 
not mapped to 
corresponding 
Ensembl gene ID in 
Ensembl database 
version used. HPRD 
interaction. 
Charcot-Marie-
Tooth disease, 
type 2L [608673] 
HSPB8 (heat shock 
22kDa protein 8) 
[608014] 
HSPB1 (heat 
shock 22kDa 
protein 1) 
[602195] 
Charcot-Marie-Tooth 
disease, axonal,  type 
2F [606595] 
Confirmed 
HSPB8 identified as 
disease gene in 
OMIM database, but 
not in Morbid Map. 
HPRD interaction. 
DNCL1 (dynein light 
chain, LC8-type 1) 
[601562] 
DNM2 (dynamin 2) 
[602378] 
Charcot-Marie-Tooth 
disease, dominant 
intermediate B 
[606482] 
RNF10 (ring finger 
protein 10) [not in 
OMIM] 
GARS (glycyl-
tRNA synthetase) 
[600287] 
Charcot-Marie-Tooth 
disease, axonal,  type 
2D [601472] 
Charcot-Marie-
Tooth disease, 
type 2L [608673] 
MAPKAPK5 (mitogen 
activated protein 
kinase-activated 
protein kinase 5) 
[606723] 
HSPB1 (heat 
shock 22kDa 
protein 1) 
[602195] 
Charcot-Marie-Tooth 
disease, axonal,  type 
2F [606595] 
Refuted 
HSPB8 is causative 
(see above). HSPB8 
identified as disease 
gene in OMIM 
database, but not in 
Morbid Map. Two 
HPRD interactions, 
one yeast. 
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Table 2: Continued… 
Disease subtype Candidate genes Based on interaction with * 
Original disease 
subtype Status Comments 
Polycystic kidney 
disease, infantile 
severe, with 
tuberous sclerosis 
[600273] 
PKD1 (polycystin 1) 
[601313] 
PKD2 (polycystin 
2) [173910] 
Polycystic kidney 
disease, adult, type II 
[173910] 
Confirmed 
Disease caused by 
chromosomal deletion 
which affects two 
genes, PKD1 and 
TSC2[25]. Mentioned 
in OMIM, but not in 
Morbid Map. HPRD 
interaction. 
Pachyonychia 
congenita, 
Jadassohn-
Lewandowsky 
type [167200] 
KRT6A (keratin 6A) 
[148041] 
KRT17 
(keratin 17) 
[148069] 
Pachyonychia 
congenita, Jackson-
Lawler type [167210] 
Confirmed 
Ensembl ID maps to 
KRT6E, KRT6D, 
KRT6C and KRT6A. 
OMIM uses KRT6A 
name, whereas 
Ensembl uses KRT6E 
as primary name, thus 
mapping to 
corresponding 
Ensembl gene ID 
failed. From human 
high throughput set. 
Marfan-like 
connective tissue 
disorder [154705] 
FBLN2 (fibulin 2) 
[135821] 
FBN1 (fibrillin 1) 
[134797] 
Marfan syndrome 
[154700] Refuted 
Causative gene is 
TGFBR2 (TGF-beta 
receptor II) [190182]. 
FBLN2 was 
suspected but refuted 
in literature[26]. 
Mentioned in OMIM, 
but not in Morbid Map. 
HPRD interaction. 
PRPF3 (Pre-
MRNA processing 
factor 3 homolog) 
[607301] 
Retinitis pigmentosa 
18 [601414] 
PRPF8 (Pre-
MRNA processing 
factor 8 homolog) 
[607300] 
Retinitis pigmentosa 
13 [600059] 
ENSG00000163510 
[not in OMIM] 
PRPF31 (Pre-
MRNA processing 
factor 31 homolog) 
[606419] 
Retinitis pigmentosa 
11 [600138] 
Retinitis 
pigmentosa 26 
[608380] 
HECW2 (HECT, C2 
and WW  domain 
containing E3 ubiquitin 
protein ligase 2) [not in 
OMIM] 
PRPF3 (Pre-
MRNA processing 
factor 3 homolog) 
[607301] 
Retinitis pigmentosa 
18 [601414] 
Refuted 
Causative gene is 
CRKL (ceramide 
kinase-like) [608381]. 
Gene name not 
mapped to Ensembl 
gene ID in Ensembl. 
Three interactions 
from yeast set, one 
from fly set. 
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Table 2: Continued… 
Disease subtype Candidate genes Based on interaction with * 
Original disease 
subtype Status Comments 
PRPF3 (Pre-
MRNA processing 
factor 3 homolog) 
[607301] 
Retinitis pigmentosa 
18 [601414] 
LUC7L2 (LUC7-like 2) 
[not in OMIM] 
PRPF31 (Pre-
MRNA processing 
factor 31 homolog) 
[606419] 
Retinitis pigmentosa 
11 [600138] 
Retinitis 
pigmentosa 10 
[180105] 
METTL2 
(methyltransferase like 
2A) [607846] 
CRX (cone-rod 
homeobox) 
[602225] 
Retinitis pigmentosa, 
late onset dominant 
[268000] 
Refuted 
Causative gene is 
IMPDH1 (IMP 
dehydrogenase 1) 
[146690]. Morbid Map 
version used contains 
two entries for this 
subtype, one with and 
one without 
associated gene. Two 
from yeast set, one 
from fly set. 
SF3B2 (splicing factor 
3b, subunit 2) 
[605591] 
HSPD1 (heat 
shock 60kDa 
protein 1) 
[118190] 
Spastic paraplegia 13 
[605280] Spastic 
paraplegia 17 
[270685] 
KLC2 (kinesin light 
chain 2) [601334] 
KIF5A (kinesin 
family member 5A) 
[602821] 
Spastic paraplegia 10 
[604187] 
Refuted 
Known gene is 
BSCL2 (seipin) 
[606158]. Mentioned 
in OMIM, but not 
listed in Morbid Map. 
Both from HPRD set, 
KLC2 also from fly 
and worm sets. 
EIF4G1 (eukaryotic 
translation initiation 
factor 4-gamma 1) 
[600495] 
EIF4A2 (eukaryotic 
translation initiation 
factor 4A, isoform 2) 
[601102] 
KPNA1 (karyopherin 
alpha 1) [600686] 
Dyskeratosis 
congenita, 
autosomal 
dominant 
[127550] 
CPA3 
(carboxypeptidase A3, 
mast cell) [114851] 
DKC1 (dyskerin 1) 
[300126] 
Dyskeratosis 
congenital 1 [305000] Refuted 
Causative gene is 
TERC  (telomerase 
RNA component) 
[602322]. Gene 
symbol not mapped to 
Ensembl gene ID in 
Ensembl database 
version used. Three 
from fly set (EIF4G1, 
EIF4A2, KPNA1) one 
from yeast (CPA3). 
*
 These are the known disease genes, associated with other disease subtypes, which have physical 
protein-protein interactions with the candidate disease genes. 
†
 Square brackets contain OMIM numbers for both diseases and genes. 
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The HPRD interaction set is biased toward disease proteins 
As it is based on literature-described interactions, the HPRD interaction set is expected to be 
biased toward known disease genes. These proteins would be better studied, and known 
interactions with candidate disease proteins would have been investigated by the community 
already. This bias can already be seen in the HPRD benchmark results, but it can be quantified 
more directly by the proportion of the interacting proteins that are known disease proteins. Here 
once again the bias is clear – the proportion of interacting proteins that occur in the 
heterogeneous disease protein set is twice as high for the HPRD set as for the high throughput 
sets, and is well over twice the proportion of Ensembl proteins in the disease protein set (Table 
3). 
It is encouraging to see that such a large proportion of these predictions were confirmed, though 
these are generally from the HPRD interaction set (of which 10 were confirmed and 5 refuted). 
From the high throughput sets there were 2 confirmed and 13 refuted predictions, which is 
consistent with their benchmark results (Figure 2). This list may not be exhaustive due to the 
complexities of thoroughly investigating all these predictions by hand, but we do not expect 
these proportions to change substantially. In any case the benchmark results remain valid, since 
the known-gene disease loci are not susceptible to this misannotation problem. 
Interestingly, even the high throughput sets are enriched for disease genes. This suggests that 
genetically heterogeneous disease proteins are more likely to have protein-protein interactions, 
or that they have more easily detectable interactions. 
Protein-protein interactions add as much information as localization 
Hereditary diseases do not always have genetic loci associated with them. It is therefore 
interesting to see how much protein-protein interactions can at all predict the candidate disease 
gene pool in the absence of any genetic localization data. When disregarding localization 
information entirely in the benchmark disease gene set, the combined high throughput protein-
protein interaction set still has a prediction accuracy of 0.7%. This is two orders of magnitude 
higher than the chance of randomly picking the disease protein from the entire genome and is of 
the same order of enrichment as genetic localization, which generally reduces the candidate 
gene pool from ~20000 to ~100. Combining these two information sources enriches the 
candidate gene pool a further order of magnitude to a 1-in-10 chance (12%) of picking the right 
disease gene (Figure 2), which corresponds to a 1000-fold enrichment relative to the entire 
genome. 
Needless to say, the HPRD interaction set performs much better than the combined high 
throughput set, resulting in a prediction accuracy of 6.6% when localization data are 
disregarded. This corresponds to a 1000-fold enrichment even before localization is taken into 
account. Once again, combining this with localization information leads to a further 10-fold 
enrichment resulting in the 58% accuracy found in this study. 
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Table 3: Overrepresentation of heterogeneous disease genes in HPRD protein interaction set (Chi-
square test). The disease gene enrichment in HPRD is highly significantly higher than in the high 
throughput sets (P < 1e-13 after Bonferroni correction for every case). 
 
Number of 
proteins in 
interaction 
set 
Subset also in 
disease protein 
set 
Subset also in 
disease protein 
set (percentage) 
Chi-
square P-value  
HPRD set 
(literature based) 6005 678 11.29% 550.2098 < 2.2e-16 
Human Y2H set 
(high throughput) 2686 146 5.44% 4.845 0.03 
Fly set (high 
throughput) 4706 276 5.86% 18.109 2.1e-5 
Worm set (high 
throughput) 1933 101 5.23% 2.086 0.15 
Yeast set (high 
throughput) 2455 141 5.74% 7.838 0.005 
Reference set – all human protein-coding genes in Ensembl 
 Total In disease set Percentage 
  
Ensembl known 
genes 22242 1003 4.51%   
 
 
Discussion 
The hypothesis being investigated here is that interacting proteins would often lead to similar 
disease phenotypes when mutated, enabling the usage of protein-protein interactions to 
suggest candidate disease genes. Our results do suggest that this is indeed the case. Given the 
average locus size of close to a hundred genes and high throughput interaction benchmark 
accuracies of 9-17%, positional candidate genes that interact with known disease genes have a 
more than 10-fold higher likelihood of being disease-causing genes than random locus genes. 
These results are a minimal estimate 
There are several practical limitations to the degree to which protein-protein interactions can 
predict disease gene candidates. To begin with, high throughput protein-protein interaction sets 
– especially yeast two-hybrid sets – are inherently noisy and contain a lot of interactions with no 
biological relevance[10-14]. Therefore we might be predicting a disease gene based on an 
interaction that does not occur in vivo, but which did erroneously appear in a yeast two-hybrid 
assay. Indeed, only 5.8% of the human, fly and worm Y2H interactions were confirmed by the 
HPRD, even amongst proteins common to both sets. However, given the Y2H set prediction 
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accuracies of over 10% and the fact that the HPRD is not exhaustive, the proportion of Y2H 
interactions that are genuine is probably substantially higher than this figure suggests. 
Nevertheless, these high noise levels could reduce the accuracy of the Y2H based predictions 
relative to other techniques, as evidenced by the higher performance of the mainly protein 
complex purification-based yeast interaction set. 
Another practical limitation is the mapping of the high throughput interactions from other species 
to human proteins. In this study, when a protein in the other species had multiple human 
orthologues, the interaction was transferred to all of them. However, this need not be the case in 
reality. Encouragingly, we have previously shown that interactions between proteins are quite 
conserved across species and that conserved interactions tend to involve functionally related 
proteins[29]. Also, the yeast set outperforms the other sets despite its evolutionary distance to 
humans – though this may be due to the fact that most yeast interactions were from more 
reliable protein complex purification experiments rather than yeast two-hybrid assays. 
Apart from the protein interactions, the designation of the candidate disease loci can also be a 
source of noise. Some of the candidate disease loci were designated based on incorrect 
reasoning, or faulty linkage assignment. For instance, we have recently shown that a family with 
EEC syndrome linked to chromosome 19 (EEC2, OMIM 602077)[30] actually has a mutation in 
the P63 gene denoted EEC3 (OMIM 604292) which is localized on human chromosome 
3q27[31]. However, the EEC2 locus remains in OMIM as a separate EEC locus with unidentified 
causative gene. 
Furthermore, the use of cytogenetic bands to designate disease loci in OMIM Morbid Map can 
lead to problems in locating the genes in the Ensembl database.  
Though they do not have sharp boundaries in reality, the Ensembl database uses specific base 
pair positions (rounded off to the nearest 100 kb) as band boundaries. Thus, genes lying in the 
vicinity of a band boundary could easily be assigned to separate bands in the literature and the 
Ensembl database. Indeed over 20% of the known disease genes in OMIM Morbid Map are 
associated with loci that differ from their Ensembl annotation. Most of these genes lie between 1 
Mb and 10 Mb of their Morbid Map-annotated loci on the same chromosome. The use of 
markers instead of cytogenetic bands could improve this, however OMIM Morbid Map does not 
include marker information. 
Finally, phenotypically similar diseases can be functionally related, even though they are 
classified as different diseases. Since this study uses preexisting disease classifications rather 
than systematic phenotypic similarity analysis, potential links between disease genes causing 
similar but differently classified disease phenotypes would be overlooked. This would reduce the 
number of predictions made, without affecting the accuracy of those predictions that have been 
made. 
All these practical limitations reduce the accuracy of the predictions, meaning that the true 
degree to which proteins involved in the same genetic disease interact is likely to be much 
higher. With higher quality protein interaction sets and more precise locus demarcation and 
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more systematic disease phenotype descriptions the value of this approach to disease gene 
prediction should increase even further. 
Apart from the practical limitations, there are fundamental limits to the prediction capacity of 
protein-protein interactions. Two interacting proteins need not lead to similar disease 
phenotypes when mutated – for instance they may have different but overlapping functions or 
one may be more dispensable than the other. Also, disease proteins may lie at different points 
in a molecular pathway and need not interact with each other directly. Disease mutations need 
not even involve proteins, as is the case with TERC (telomerase RNA component) in autosomal 
dominant dyskeratosis congenita (see Table 2). Protein-protein interactions will thus not be 
capable of detecting every novel disease protein. Despite these fundamental limitations, the 
high proportion of disease proteins among correctly localized HPRD interaction partners is 
promising, although this interaction set is biased. And despite their practical limitations, even the 
high throughput data sets have prediction accuracies of up to 17%. Therefore, in the absence of 
practical limitations, these fundamental limitations should result in a prediction accuracy that lies 
between these two values. 
Outlook 
This study provides evidence that the systematic use of protein-protein interaction data may 
lead to an approximately 10-fold improvement of positional candidate gene prediction. At the 
same time, the quality and quantity of the data available can be much improved. Though almost 
73,000 interactions between almost 11,000 proteins were used in this study, the actual number 
of interactions between these proteins should be much higher since all interaction assaying 
techniques miss large numbers of interactions[6,7]. In addition, a more systematic phenotypic 
classification of diseases, such as our recently developed text-mining approach[32], may lead to 
more interactions between related disease genes being identified. With increasing quantity and 
quality of interaction and phenotypic data and more dense interaction networks, the 
performance and utility of this approach to disease gene prediction should improve even further. 
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Abstract 
Background: Genes that are co-expressed tend to be involved in the same biological process. 
However, co-expression is not a very reliable predictor of functional links between genes. The 
evolutionary conservation of co-expression between species can be used to predict protein 
function more reliably than co-expression in a single species. Here we examine whether co-
expression across multiple species is also a better prioritizer of disease genes than is co-
expression between human genes alone. 
Results: We use co-expression data from yeast (S. cerevisiae), nematode worm (C. elegans), 
fruit fly (D. melanogaster), mouse and human and find that the use of evolutionary conservation 
can indeed improve the predictive value of co-expression. The effect that genes causing the 
same disease have higher co-expression than do other genes from their associated disease 
loci, is significantly enhanced when co-expression data are combined across evolutionarily 
distant species. We also find that performance can vary significantly depending on the co-
expression datasets used, and just using more data does not necessarily lead to better 
prioritization. Instead, we find that dataset quality is more important than quantity, and using a 
consistent microarray platform per species leads to better performance than using more 
inclusive datasets pooled from various platforms. 
Conclusions: We find that evolutionarily conserved gene co-expression prioritizes disease 
candidate genes better than human gene co-expression alone, and provide the integrated data 
as a new resource for disease gene prioritization. 
 
Background 
In the past few years several bioinformatic tools and approaches have been developed to assist 
medical genetic researchers in positional candidate disease gene identification (reviewed in [1]; 
see also [2-5]). Several tools use functional genomics to prioritize candidate genes located 
within disease-associated genomic loci by evaluating functional relationships between known 
disease genes and positional candidate genes[6-8]. These tools are based on the premise that 
genes which are involved in the same disease phenotype are likely to be functionally 
related[1,9,10]. This has indeed been shown to be the case as evidenced by the fact that these 
tools all perform better than random expectation in the prediction or prioritization of candidate 
disease genes. Nevertheless, not all types of functional genomic data perform equally well in 
terms of sensitivity and specificity[2,7,8]. Microarray expression data have wider coverage than 
other high-throughput genomic data such as protein-protein interactions, as genome-scale 
expression analyses are readily and routinely performed with them. Additionally, they are less 
biased toward better studied genes than gene function annotation or literature mining, although 
the latter approaches fare better at prioritizing disease candidate genes[2,7,8]. Therefore, given 
the large coverage of co-expression data and their complementarity to functional annotation and 
literature mining, it is of importance to maximize the disease gene predictive value of this type of 
data. 
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Several bioinformatic candidate disease gene prioritization tools already incorporate microarray-
based co-expression data[2,6-8,11,12]. This approach is based on the assumption that if two 
genes are functionally related then their expression should vary concordantly across tissues and 
under different circumstances, and proposes that their expression profiles should therefore be 
correlated. For candidate disease gene prioritization, the use of co-expression analysis is 
preferable to the use of tissue-specific gene expression patterns, as it is a better predictor of 
functional relatedness between genes[13]. 
However, co-expression data can be applied more comprehensively than is currently 
implemented by these tools. One important and currently underexploited approach is to 
incorporate co-expression data from other species. One might expect that while human co-
expression data are the most relevant for disease gene prioritization, evolutionary conservation 
of co-expression can be used to enhance the reliability of identified co-expression relationships. 
The premise is that co-expression relationships that are maintained across phylogenetically 
distant organisms must be under selective pressure, and should therefore be functional – a 
premise that has indeed been confirmed in several previous studies[14-17]. Though one tool 
already includes multi-species co-expression data[11], the improvement in disease gene 
ranking performance due to the exploitation of evolutionary conservation has not yet been 
investigated. 
We therefore investigated the predictive value of conserved co-expression for candidate 
disease gene prioritization. To this end we analyzed how well co-expression between known 
and candidate disease genes could prioritize positional candidate disease genes. We restricted 
our analysis to known disease genes from genetic diseases containing at least two known 
causative genes. We constructed artificial loci of 100 candidate genes around the known 
disease-causing genes, and investigated the tendency of these causative genes to have higher 
co-expression with other known causative genes compared to the non-causative candidate 
genes from the same disease loci. Using co-expression data from five eukaryotic species – 
baker’s yeast (Saccharomyces cerevisiae), nematode worm (Caenorhabditis elegans), fruit fly 
(Drosophila melanogaster), mouse (Mus musculus) and human – we investigated the effect of 
evolutionary conservation on the ranking of the disease gene pairs, finding that evolutionary 
conservation of co-expression does indeed improve disease gene ranking. Therefore, exploiting 
evolutionary conservation could potentially improve the performance of co-expression data in 
existing disease candidate gene prioritization tools[2,6-8], which might in turn improve the 
prioritization of less well-studied genes. 
 
Results 
Evolutionary conservation of co-expression improves disease gene ranking performance  
We investigated how well disease genes tend to rank relative to non-causative candidate 
disease genes when ranked according to co-expression with other genes known to cause the 
same disease. We combined co-expression scores across species using orthology relationships 
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from the euKaryotic clusters of Orthologous Groups (KOG) database[18]. The co-expression 
scores are thus based on these KOGs rather than on individual genes (see methods section for 
further details). We used expression data from human, mouse, fruit fly (D. melanogaster), worm 
(C. elegans) and baker’s yeast (S. cerevisiae) assembled from the Gene Expression Omnibus 
database[19] and the Genomics Institute of the Novartis Foundation[20] Gene Atlas expression 
data. For this study we used artificial disease loci containing 100 genes per locus. Testing with 
50, 100 and 200 genes per locus does not make much difference though smaller loci tend to 
perform slightly better than larger loci (data not shown). Only disease gene pairs with co-
expression scores unlikely to occur randomly in the corresponding dataset (i.e. more than 2 
standard deviations from the dataset randomization mean) were included in the final rankings. 
This process implicitly weighs the scores according to the number of species involved, as the 
random score distributions are narrower for datasets combining more species. The standard 
deviations of these randomized distributions range from 0.051 for the five-species combined 
dataset to between 0.057 (yeast) and 0.094 (mouse) for the individual single-species datasets. 
Therefore, a given correlation score is more likely to be considered significant in a multi-species 
dataset than in a single-species dataset. 
Genes whose co-expression is conserved through evolution have been shown to have stronger 
functional ties than genes whose co-expression is not[17]. Therefore, conserved co-expression 
between species should improve disease gene ranking over co-expression in one species 
alone. Such a trend is indeed apparent (Figure 1). Both for human and for multi-species KOG-
based co-expression sets, disease gene pairs generally score in the upper half of the co-
expression rankings for the KOG-mappable genes in the disease loci and are significantly better 
than random expectation (medians 0.64 and 0.69 for human-only and conserved co-expression 
sets respectively; p << 10-16 for both sets, Wilcoxon signed rank test). Therefore, the causative 
disease gene in a candidate locus will generally rank higher than the other locus candidate 
genes. Furthermore, the multi-species combined co-expression set performs significantly better 
than the human-only co-expression set (medians 0.64 and 0.69 respectively, p < 10-6, Wilcoxon 
rank sum test), indicating that the use of evolutionary conservation can significantly improve co-
expression-based candidate disease gene ranking. 
Given that co-expression-based disease gene ranking is only sensible if there is a non-random 
co-expression relationship between the disease genes, we further narrowed down the analysis 
to only those disease gene pairs that are likely to be genuinely co-expressed, having scores that 
are unlikely to occur randomly in their datasets. This substantially improves the rankings (Figure 
2), at the expense of reduced coverage (695 versus 3286 disease gene rankings). Both the 
human-only and the conserved co-expression datasets now rank the disease genes very high 
(medians of 0.87 and 0.93 respectively), with the conserved co-expression still significantly 
outperforming the human-only co-expresssion (p < 10-11, Wilcoxon rank sum test). A much 
higher proportion of disease genes is now ranked in the top 10% of the candidate gene lists, 
and the use of evolutionary conservation increases this proportion by almost half, from 31% to 
44% of the ranked disease genes. 
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Figure 1. Evolutionary conservation of co-expression improves disease candidate gene prioritization 
performance over human-only co-expression. The disease gene rank histogram shows the relative 
proportions of disease genes scoring in different rank bins based on co-expression with known disease 
genes causing the same disease. Disease gene rank indicates its degree of co-expression with known 
disease genes, relative to those of the other locus candidate genes. Evolutionary conservation results in a 
much higher proportion of disease genes ranking in the top 10% of the locus candidate genes and fewer 
in the mid-regions of the lists. A) Disease gene rank histogram. B) Cumulative proportion of disease 
genes detected as the co-expression rank threshold is decreased from 1 to 0. 
 
Disease gene ranking improved by co-expression conservation at different evolutionary 
distances 
Evolutionary conservation across multiple species clearly improves the disease gene ranking 
performance of gene co-expression. However, what influence might different evolutionary 
distances have on this improvement? Is the evolutionary distance between human and mouse 
sufficient to improve co-expression performance, and is yeast biology so divergent that it would 
reduce rather than improve performance? To examine the role of evolutionary distance on the 
disease gene ranking performance of gene co-expression, we conducted pairwise comparisons 
in which we compared the ranking performance human co-expression with co-expression 
conserved between human and each of the other species. For all pairwise comparisons except 
the human-yeast comparison, evolutionary conservation significantly improves co-expression-
based disease gene ranking compared to using only data for human genes (Figure 3, Table 1). 
Surprisingly, even human-mouse conservation improves disease gene ranking despite the 
relatively short evolutionary distance between these two species. 
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Figure 2. Filtering out insignificant co-expression improves performance. When disease gene pairs with 
co-expression scores that do not differ significantly from those of randomized datasets are filtered out, the 
disease gene ranking performance improves substantially. However, the coverage drops from 3286 to 
695 pairs. A) Disease gene rank histogram. B) Cumulative proportion of disease genes detected as the 
co-expression rank threshold is decreased from 1 to 0. 
 
In contrast to the other species, co-expression conservation with yeast does not significantly 
improve disease gene ranking (Table 1). For this species pair yeast-only co-expression 
performs best, outperforming even the combined human-yeast set at ranking human disease 
genes (albeit not significantly; p = 0.26). This is primarily due to specific disease types involving 
housekeeping processes such as metabolism (congenital disorder of glycosylation, glycogen 
storage disease) and DNA repair (xeroderma pigmentosum) which consistently score well 
particularly in the yeast set. As yeast co-expression already performs very well, the combination 
with human co-expression may not yield much extra information. However, this performance 
comes at the expense of much reduced coverage of disease genes relative to the other sets, 
which all have a similar coverage (550 disease gene rankings for the human-yeast set, versus 
~3000 for human-mouse, human-fly and human-worm sets). It is thus evident that despite the 
large evolutionary distance between these two species, yeast co-expression is still effective at 
ranking human disease genes for those genes that have orthologs in both species. 
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Figure 3. Co-expression-based disease gene rankings are improved by conservation at various 
evolutionary distances. Pairwise cross-species co-expression improves disease gene ranking over single-
species datasets for comparisons between human and mouse (A), fruit fly (B), and nematode worm (C) 
co-expression. However, co-expression in yeast alone performs as well as co-expression conserved 
between human and yeast (D), and significantly better than human-only co-expression (p = 0.01). 
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Table 1. Pairwise species comparisons for co-expression-based disease gene ranking. 
Individual 
species 
# Disease 
gene pairs 
Median 
rank 
Pairwise 
combined sets 
# Disease 
gene pairs 
Median 
rank 
P-value 
(Combined 
better than 
single species) 
Human 3286 0.64 6.7x10-4 * 
Mouse 3188 0.63 
Human-Mouse 3114 0.67 
1.3x10-5 * 
Human 3286 0.64 0.007 * 
Fly 3534 0.62 
Human-Fly 3176 0.66 
1.8x10-5  * 
Human 3286 0.64 2.1x10-4 * 
Worm 3264 0.63 
Human-Worm 2954 0.67 
9.1x10-6 * 
Human 3286 0.64 0.12 
Yeast 674 0.69 
Human-Yeast 550 0.67 
0.74 
Footnote: * statistically significant at p = 0.05 level 
 
Disease gene ranking performance is dependent on co-expression data used 
We initially used the multi-species co-expression dataset from Stuart and colleagues[21], but 
this resulted in limited disease gene ranking performance. We suspected that the extensive 
pooling of expression data from different platforms might have a negative impact on 
performance. Therefore, we created our own custom multi-species co-expression dataset, in 
which we restricted ourselves to a single microarray platform per species. Consistent with the 
findings of others[22,23], this single platform approach resulted in significantly better 
performance, even when using only the four species included in the Stuart et al. dataset (Figure 
4). Though both datasets tend to rank disease genes highly, the new (GEO/GNF) dataset 
performs significantly better than the larger and more inclusive dataset from Stuart and 
colleagues (p < 10-10, Wilcoxon rank sum test) without loss of coverage (3286 and 3212 disease 
gene rankings for the GEO/GNF and the Stuart et al. datasets respectively). 
In addition to restricting expression data to a single platform per species, normalizing the 
microarray expression data according to total expression level also improves the ranking of 
disease genes relative to non-disease genes from the candidate loci. As we were mainly 
interested in relative expression levels of genes across conditions and not in total gene 
expression levels, we normalized all expression values according to the total expression level of 
the microarray sample (see methods section for further details). This reduces systematic biases 
between samples due to differences in total expression levels and highlights the expression 
relationships between genes per sample, resulting in up to 5% improvement in candidate 
disease gene ranking (data not shown). 
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Figure 4. Single platform co-expression dataset outperforms multiple platform co-expression dataset. The 
more cohesive GEO/GNF set containing a single microarray platform per species outperforms the more 
inclusive multi-platform Stuart et al. set (p < 10-10). Both sets have similar coverage, with 3212 and 3286 
disease gene pairs for the Stuart et al. and GEO/GNF sets respectively. These results are based on co-
expression data from human, fly, worm and yeast, with co-expression scores are averaged across 
species wherever possible. A) Disease gene rank histogram. B) Cumulative proportion of disease genes 
detected as the co-expression rank threshold is decreased from 1 to 0. 
 
All disease gene ranking and conserved co-expression correlation data presented here are 
freely available online from the following URL: http://www.cmbi.ru.nl/~moti/coexpression/ 
 
Discussion 
In this study, we show that we can increase the predictive value of co-expression for disease 
gene prioritization by exploiting evolutionary conservation, despite the variations in the biology 
of the species compared. Given a genuine co-expression relationship between the disease 
genes, using conserved co-expression to prioritize candidate disease genes can reduce the 
number of genes to be tested over sevenfold compared to using a random ranking of the 
candidate disease genes, as the correct gene will be found on average after testing 7% of the 
candidates (the median disease gene rank is 0.93) instead of 50% (Figure 2). Encouragingly, 
even human-mouse conservation can lead to a substantial improvement in disease gene 
ranking performance, despite the relatively short evolutionary distance between these two 
species (Figure 3). This means that improvements in specificity can be gained without large 
losses in sensitivity, as most human genes have mouse orthologs. 
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An interesting finding is that large pooled datasets which combine as many expression data as 
possible from various experiments and platforms can actually result in reduced co-expression 
performance relative to smaller but more coherent expression datasets (Figure 4). Microarray 
data are notoriously variable between independently generated datasets while they are 
somewhat more consistent between experiments using the same platform[22,23]. In order to 
minimize dilution of the co-expression signal when combining data from many different sources 
a weighting scheme is required, such as using the co-expression overlap between different sets 
to weigh the relevance of the co-expression value[24]. Our results are consistent with these 
previously reported findings, as our single-platform-per-species dataset ranks disease genes 
significantly better than the more inclusive pooling approach adopted earlier by Stuart and 
colleagues[21]. An alternative explanation would be that their expression sets are of lower 
quality or are less representative of the relationships between disease genes, but there is no 
reason to assume that either of these is the case. This underscores the fact that combining as 
many data as possible does not necessarily lead to an improved performance of co-expression 
data for disease gene prioritization, so it is therefore not a trivial finding that combining data 
from different species does. 
Another reason why the larger sets do not perform as well as the smaller sets could lie in the 
use of correlation coefficients to determine genetic relatedness. Correlation coefficients estimate 
expression coherence across all conditions surveyed, but even functionally related genes may 
not have coherent expression patterns across all tissues and conditions. The larger the 
datasets, the greater the potential for irrelevant conditions to mask the co-expression 
relationship that a group of genes has under a limited set of conditions. Therefore, a 
biclustering-based approach[25,26] may yield more refined co-expression relationships between 
genes, and is a potential avenue for future improvement of co-expression-based disease 
candidate gene prioritization. 
 
Conclusions 
We analyze here the predictive power of gene co-expression for disease gene prioritization and 
identify factors that affect it, such as evolutionary conservation. We show that co-expression 
data from other species have predictive power for human disease gene prioritization, and that 
evolutionarily conserved gene co-expression can improve disease gene prioritization over 
human-only gene co-expression. In addition, we show that platform consistency is important 
and that smaller but more cohesive datasets can outperform larger pooled datasets. Though we 
only examined disease gene ranking, these findings have broader relevance for the use of 
microarray co-expression data in functional genomics. We provide these conserved co-
expression data as a new resource that can be used in disease gene prioritization programs, 
particularly those that integrate several different data types. 
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Methods 
Disease data 
We used the Online Mendelian Inheritance in Man (OMIM)[27] Morbid Map as a source of 
genetic diseases and known disease genes. We restricted our analysis to those diseases with 
two or more known disease genes. There were 890 known disease genes (727 distinct genes) 
for 177 diseases in our dataset. Artificial disease loci were constructed around these known 
disease genes based on localization information from the Ensembl database [28], by taking the 
required number of neighboring genes centered on the disease gene. These genes were then 
translated to HGNC gene IDs[29] or KOG IDs[18] depending on the analysis. This means that 
the locus genes used in the analyses are a subset of the Ensembl genes in the locus, 
depending on how many could be mapped to their relevant IDs. We used artificial loci of 100 
genes, which is representative for the average candidate disease locus, as the OMIM 
heterogeneous disease loci have a median of 88 genes per locus. In addition, we investigated 
the use of 50- and 200-gene artificial loci, as well as actual associated loci from OMIM Morbid 
Map, but do not consider them further as their results did not differ substantially from those of 
the 100-gene artificial loci. 
Expression data processing 
Initially we used the multi-species expression data used by Stuart and colleagues in their 
functional analysis of conserved co-expression[21]. This dataset contains expression data for 
human, fruit fly (Drosophila melanogaster), nematode worm (Caenorhabditis elegans) and 
baker’s yeast (Saccharomyces cerevisiae) genes. These expression data had already been 
normalized and were therefore not further processed prior to their use in the co-expression 
calculations. 
However, due to limited performance of this dataset in ranking disease genes we created a new 
multi-species co-expression dataset involving expression data from these four species and 
mouse (Mus musculus). For human and mouse expression data we used the gcRMA-
normalized Gene Atlas expression sets generated by the Genomics Institute of the Novartis 
Foundation[20], as this is an often-used and well-constructed expression dataset. The 
expression values were log2-transformed to increase robustness and emphasize the variation 
between the lower expressed genes relative to the more highly expressed ones. Lacking similar 
standard expression datasets for the other species, the expression data for fruit fly (Drosophila 
melanogaster), nematode worm (Caenorhabditis elegans) and baker’s yeast (Saccharomyces 
cerevisiae) were collected from the Gene Expression Omnibus (GEO) database[19] of the 
National Center for Biotechnology Information (NCBI). In order to maximize consistency of the 
expression data, only one expression platform was used per species. As these expression data 
are normalized in different ways in different experiments, we used the raw signal intensity data 
(Affymetrix CEL files) rather than the normalized expression data. This further restricted the 
data available to us, as these raw data are not required for submission of expression data to the 
GEO database and are not included with all datasets. Only experiments with at least 10 
microarray samples were considered. We ended up with 357 samples in 12 experiments for 
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yeast, 242 samples in 8 experiments for fly and 123 samples in a single experiment for worm 
(Table 2). For within-array normalization we used the Robust Multi-array Averaging (RMA) 
algorithm[30] as implemented in the R statistical software bioconductor library[31]. However, our 
between-array normalization was done by normalizing for total sample expression (see below), 
as we found this to yield better results than RMA-normalizing per experiment (data not shown). 
Total expression normalization prevents spurious correlation due to differences in total 
expression level between samples. For the yeast and fly datasets, data were pooled across all 
experiments before total expression normalization and calculation of the co-expression 
correlation coefficients. 
 
Table 2. GEO expression datasets used. 
Species GEO series ID Number of samples Reference 
GSE6515 78 [35] 
GSE1690 10 [36] 
GSE2780 10 [37] 
GSE2828 12 [38] 
GSE3069 18 [39] 
GSE3842 72 [40] 
GSE4714 30 [41] 
Fly 
GSE4235 12 [42] 
Worm GSE2180 123 [43] 
GSE4807 30 [44] 
GSE6073 12 [45] 
GSE1311, GSE1312, 
GSE1313 66 [46] 
GSE1639 18 [47] 
GSE1693 26 [48] 
GSE1934 24 [49] 
GSE1938 15 [50] 
GSE1975 28 [51] 
GSE2343 12 [52] 
GSE3076 96 [53] 
GSE3821 16 [54] 
Yeast 
GSE4135 14 [55] 
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The Affymetrix probe set expression levels were translated to gene expression levels, and for 
genes that were represented by multiple probe sets the median was taken. These genes were 
further filtered according to gene sets used (Table 3). Both GEO and GNF datasets were further 
normalized according to total sample expression level by dividing each gene expression value 
by the mean expression value of all considered genes in the microarray sample. This further 
minimizes spurious correlations due to differences in total expression level between 
experimental conditions or across tissues. 
 
Table 3. Genes included in the co-expression calculations. 
Species Genes included in co-
expression data Number of genes 
Human 
Those with gene names also 
present in Affymetrix HG-U133A 
microarray platform 
13955 (11410 genes in all 
disease loci combined) 
Mouse 
Those with mouse gene names 
(unknown transcripts, RIKEN 
transcripts and predicted genes 
excluded) 
14000 
Fly Those with FlyBase IDs 13282 
Worm WormBase-annotated genes 17948 
Yeast Those with systematic names (Y… IDs) 6563 
 
 
No artificial cut-off was used to filter out noisy low expression values, or to define presence or 
absence of gene expression in a sample. This is not necessary, as we are using correlation 
between expression profiles rather than absolute expression levels. The inclusion of non-
biologically significant noise should not result in spurious correlations between genes, and if 
there is a correlation between low expression values then they are probably not merely noise 
and should not be filtered out. 
It should be noted that while we used log2-transformed signal intensity values in a multi-species 
study involving different microarray platforms, and not relative abundances as Liao & Zhang 
did[16], our analysis does not suffer from the same problems that led them to use relative 
abundances. We do not directly compare expression values between different microarray 
platforms. Instead, these expression values are converted to co-expression values for each 
platform separately. This process involves only within-platform signal intensity comparisons. 
The between-species – and therefore between-platform – comparisons are done at the co-
expression level and involve comparisons of Spearman rank correlation coefficients. 
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Co-expression score calculations 
We used Spearman rank correlation coefficients as the microarray signal intensity values were 
not normally distributed. For the GEO datasets comprising several experiments (the fly and 
yeast sets), these data were pooled before gene pair co-expression correlation coefficients were 
calculated. 
In order to be able to compare co-expression relationships between species, we used the gene 
orthology relationships as defined by the euKaryotic clusters of Orthologous Groups (KOG) 
database[18]. We chose to use KOGs instead of a metagenes-based approach such as was 
used by Stuart and colleagues[21] in order to maximize coverage, as KOGs not only contain 
bidirectional best hits but also closely related paralogs. The gene to KOG mapping was done 
using the STRING database version 6.1[32]. Mapping of the protein IDs used in STRING to the 
gene IDs used on the microarrays was done using Ensembl BioMart[33]. Of the 13955 human 
genes with expression data used in this study 8186 could be mapped to KOGs. 
A single pair of KOGs can have multiple co-expression values if one or both of them contain 
multiple genes per species. In such a case these co-expression scores need to be combined 
into a single co-expression score representative of all pairwise combinations of genes in the two 
KOGs (Figure 5). We accomplished this by taking the mean of all such gene pair co-expression 
scores, resulting in a single KOG-based co-expression score (within-species averaging). 
In order to incorporate evolutionary conservation into the final co-expression scores, we took the 
mean of the species-specific KOG-based co-expression scores over all species considered 
(between-species averaging). For the comparison between human and multi-species conserved 
co-expression the union of all the sets was taken for maximal coverage – i.e. all KOG-based co-
expression scores were used regardless of which species were represented in the KOGs. 
Disease gene ranking analyses 
We investigated the co-expression ranking performance between candidate disease genes and 
known disease genes for each pair of disease genes causing the same disease (Figure 6). To 
this end we ordered all co-expression values between a known disease gene and the genes in a 
candidate disease locus, and scored the relative rank (0-1) of the actual causative gene in the 
resultant list. If the causative gene was at the top of the list it was assigned a relative rank of 
1.0, and if at the bottom it received a relative rank of 0.0. A score of 0.5 indicates an equal 
number of more highly co-expressed and less highly co-expressed non-disease genes in the 
candidate locus, and is equivalent to random expectation. For each disease each causative 
gene was sequentially treated as the known disease gene and tested against all the other loci. 
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Figure 5. Procedure for calculating conserved co-expression scores. The procedure is illustrated using 
an example involving KOGs KOG0011 and KOG3438 between human and fly. KOG0011 contains two 
genes in each species (RAD23A, RAD23B and FBgn0026777, FBgn0039147 in human and fly 
respectively) while KOG3438 contains one in human (CKS1B) and two in fly (FBgn0010314 and 
FBgn0037613). For each species a KOG0011-KOG3438 co-expression (thick purple and green arrows) 
correlation is calculated by taking the mean of all gene-gene combinations (thin black arrows) for the two 
KOGs. The mean of these species-specific KOG-pair correlations (thick vertical orange arrow) is taken to 
represent the final multispecies KOG0011-KOG3438 co-expression correlation. This co-expression value 
is used for all relevant gene-pairs as their KOG-based co-expression score. If co-expression is conserved 
in both species then this value will be high, if it is high in only one species it will be intermediate, and if it 
is low in both it will be low. 
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Figure 6. Disease gene ranking procedure. Co-expression Spearman correlation coefficients (SCC) are 
determined for all candidate disease genes from a disease locus with known causative gene (E) and 
another gene known to cause the same disease (A). The SCCs are ranked, and the ranks are 
subsequently normalized to the 0.0-1.0 range. The relative position of the causative gene in the locus (E) 
is determined. This procedure would subsequently be repeated with E as known disease gene and A as 
candidate disease gene. For each disease, each gene is treated as a candidate disease gene in turn and 
its co-expression is successively compared to all other genes known to cause the same disease, leading 
to a list of scores per disease. 
 
To avoid ranking candidate disease genes which do not have any co-expression relationship 
with each other at all, we randomly permuted the co-expression datasets used to determine the 
random distribution of co-expression scores for each dataset. We then excluded all disease 
gene pairs for which the co-expression score fell within 2 standard deviations of the 
randomization means. These distributions all had co-expression scores with a mean of 
approximately zero and standard deviations ranging between 0.05 and 0.09 depending on the 
dataset. Multiple randomizations always resulted in almost identical score distributions per 
dataset due to the large numbers involved. 
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To investigate the influence of evolutionary conservation on disease gene pair ranking 
performance, human-derived co-expression data were compared with co-expression data 
averaged across all five species included in the study. Additionally, pairwise species 
comparisons were performed comparing human-only co-expression data with pairwise 
conserved co-expression between human and mouse, fly, worm or yeast. 
In order to test for the effect of averaging gene-gene co-expression within KOGs, the 
performance of the GNF human expression set when using KOG-based co-expression was 
compared to its performance when using gene-based co-expression. 
 Tools 
The R statistical software package[34] was used for the microarray data processing and the 
Spearman rank correlation calculations, as well as for statistical tests and data plotting. For 
performance reasons, small custom-written C++ programs were used to average the gene-gene 
correlation coefficients into KOG-KOG correlation coefficients, and the per-species KOG-KOG 
correlations into cross-species KOG-KOG correlation values. Python scripts were written for the 
disease gene correlation coefficient ranking analyses. All scripts and source code are available 
on request. 
 
Acknowledgements 
We would like to thank Walter Hoolwerf and Mark Jans for implementing the initial version of the 
conserved co-expression database. This work was supported in part by the BioRange program 
of the Netherlands Bioinformatics Centre, and by the Horizon program, both of which are 
supported by a BSIK grant through the Netherlands Genomics Initiative. 
 
References 
1. Oti M, Brunner HG: The modular nature of genetic diseases. Clin Genet 2007, 71(1):1-11. 
2. Chen J, Xu H, Aronow BJ, Jegga AG: Improved human disease candidate gene prioritization 
using mouse phenotype. BMC Bioinformatics 2007, 8:392. 
3. George RA, Liu JY, Feng LL, Bryson-Richardson RJ, Fatkin D, Wouters MA: Analysis of protein 
sequence and interaction data for candidate disease gene prediction. Nucleic Acids Res 2006, 
34(19):e130. 
4. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, Rigina O, Hinsby AM, Tumer Z, 
Pociot F, Tommerup N et al: A human phenome-interactome network of protein complexes 
implicated in genetic disorders. Nat Biotechnol 2007, 25(3):309-316. 
5. Xu J, Li Y: Discovering disease-genes by topological features in human protein-protein interaction 
network. Bioinformatics 2006, 22(22):2800-2805. 
6. Adie EA, Adams RR, Evans KL, Porteous DJ, Pickard BS: SUSPECTS: enabling fast and 
effective prioritization of positional candidates. Bioinformatics 2006, 22(6):773-774. 
Chapter 4: Conserved co-expression for candidate disease gene prioritization 
78 
 
7. Aerts S, Lambrechts D, Maity S, Van Loo P, Coessens B, De Smet F, Tranchevent LC, De Moor 
B, Marynen P, Hassan B et al: Gene prioritization through genomic data fusion. Nat Biotechnol 
2006, 24(5):537-544. 
8. Franke L, Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, Wijmenga C: Reconstruction of 
a functional human gene network, with an application for prioritizing positional candidate genes. 
Am J Hum Genet 2006, 78(6):1011-1025. 
9. Brunner HG, van Driel MA: From syndrome families to functional genomics. Nat Rev Genet 2004, 
5(7):545-551. 
10. van Driel MA, Bruggeman J, Vriend G, Brunner HG, Leunissen JA: A text-mining analysis of the 
human phenome. Eur J Hum Genet 2006, 14(5):535-542. 
11. Perez-Iratxeta C, Wjst M, Bork P, Andrade MA: G2D: a tool for mining genes associated with 
disease. BMC Genet 2005, 6:45. 
12. Rossi S, Masotti D, Nardini C, Bonora E, Romeo G, Macii E, Benini L, Volinia S: TOM: a web-
based integrated approach for identification of candidate disease genes. Nucleic Acids Res 2006, 
34(Web Server issue):W285-292. 
13. Zhang W, Morris QD, Chang R, Shai O, Bakowski MA, Mitsakakis N, Mohammad N, Robinson 
MD, Zirngibl R, Somogyi E et al: The functional landscape of mouse gene expression. J Biol 
2004, 3(5):21. 
14. Bergmann S, Ihmels J, Barkai N: Similarities and differences in genome-wide expression data of 
six organisms. PLoS Biol 2004, 2(1):E9. 
15. Liao BY, Zhang J: Low rates of expression profile divergence in highly expressed genes and 
tissue-specific genes during mammalian evolution. Mol Biol Evol 2006, 23(6):1119-1128. 
16. Liao BY, Zhang J: Evolutionary conservation of expression profiles between human and mouse 
orthologous genes. Mol Biol Evol 2006, 23(3):530-540. 
17. van Noort V, Snel B, Huynen MA: Predicting gene function by conserved co-expression. Trends 
Genet 2003, 19(5):238-242. 
18. Koonin EV, Fedorova ND, Jackson JD, Jacobs AR, Krylov DM, Makarova KS, Mazumder R, 
Mekhedov SL, Nikolskaya AN, Rao BS et al: A comprehensive evolutionary classification of 
proteins encoded in complete eukaryotic genomes. Genome Biol 2004, 5(2):R7. 
19. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and 
hybridization array data repository. Nucleic Acids Res 2002, 30(1):207-210. 
20. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, 
Kreiman G et al: A gene atlas of the mouse and human protein-encoding transcriptomes. Proc 
Natl Acad Sci U S A 2004, 101(16):6062-6067. 
21. Stuart JM, Segal E, Koller D, Kim SK: A gene-coexpression network for global discovery of 
conserved genetic modules. Science 2003, 302(5643):249-255. 
22. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, Gabrielson E, Garcia JG, 
Geoghegan J, Germino G et al: Multiple-laboratory comparison of microarray platforms. Nat 
Methods 2005, 2(5):345-350. 
23. Kuo WP, Liu F, Trimarchi J, Punzo C, Lombardi M, Sarang J, Whipple ME, Maysuria M, Serikawa 
K, Lee SY et al: A sequence-oriented comparison of gene expression measurements across 
different hybridization-based technologies. Nat Biotechnol 2006, 24(7):832-840. 
24. Lee HK, Hsu AK, Sajdak J, Qin J, Pavlidis P: Coexpression analysis of human genes across 
many microarray data sets. Genome Res 2004, 14(6):1085-1094. 
25. Cheng Y, Church GM: Biclustering of expression data. Proc Int Conf Intell Syst Mol Biol 2000, 
8:93-103. 
26. Madeira SC, Oliveira AL: Biclustering algorithms for biological data analysis: a survey. IEEE/ACM 
Trans Comput Biol Bioinform 2004, 1(1):24-45. 
Chapter 4: Conserved co-expression for candidate disease gene prioritization 
79 
 
27. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA: Online Mendelian Inheritance in 
Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005, 
33(Database issue):D514-517. 
28. Hubbard T, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T, Cuff J, Curwen V, Down T 
et al: The Ensembl genome database project. Nucleic Acids Res 2002, 30(1):38-41. 
29. Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK, Povey S: Genew: the Human Gene 
Nomenclature Database, 2004 updates. Nucleic Acids Res 2004, 32(Database issue):D255-257. 
30. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: 
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. 
Biostatistics 2003, 4(2):249-264. 
31. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, 
Gentry J et al: Bioconductor: open software development for computational biology and 
bioinformatics. Genome Biol 2004, 5(10):R80. 
32. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, Jouffre N, Huynen MA, Bork 
P: STRING: known and predicted protein-protein associations, integrated and transferred across 
organisms. Nucleic Acids Res 2005, 33(Database issue):D433-437. 
33. Kasprzyk A, Keefe D, Smedley D, London D, Spooner W, Melsopp C, Hammond M, Rocca-Serra 
P, Cox T, Birney E: EnsMart: a generic system for fast and flexible access to biological data. 
Genome Res 2004, 14(1):160-169. 
34. R: A Language and Environment for Statistical Computing [http://www.R-project.org/] 
35. Transcriptional control in embryonic Drosophila midline guidance assessed through a whole 
genome approach: Magalhães TR, Palmer J, Tomancak P, Pollard KS: BMC Neurosci 2007, 
31;8:59. 
36. Wang J, Kean L, Yang J, Allan AK, Davies SA, Herzyk P, Dow JA: Function-informed 
transcriptome analysis of Drosophila renal tubule. Genome Biol 2004, 5(9):R69. 
37. Akdemir F, Christich A, Sogame N, Chapo J, Abrams JM: p53 directs focused genomic 
responses in Drosophila. Oncogene 2007, 26(36):5184-93. 
38. Dostert C, Jouanguy E, Irving P, Troxler L, Galiana-Arnoux D, Hetru C, Hoffmann JA, Imler JL: 
The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of 
drosophila. Nat Immunol 2005, 6(9):946-953. 
39. Beckstead RB, Lam G, Thummel CS: The genomic response to 20-hydroxyecdysone at the onset 
of Drosophila metamorphosis. Genome Biol 2005, 6(12):R99. 
40. Wijnen H, Naef F, Boothroyd C, Claridge-Chang A, Young MW: Control of daily transcript 
oscillations in Drosophila by light and the circadian clock. PLoS Genet 2006, 2(3):e39. 
41. Zimmerman JE, Rizzo W, Shockley KR, Raizen DM, Naidoo N, Mackiewicz M, Churchill GA, 
Pack AI: Multiple mechanisms limit the duration of wakefulness in Drosophila brain. Physiol 
Genomics 2006, 27(3):337-350. 
42. Wang X, Bo J, Bridges T, Dugan KD, Pan TC, Chodosh LA, Montell DJ: Analysis of cell migration 
using whole-genome expression profiling of migratory cells in the Drosophila ovary. Dev Cell 
2006, 10(4):483-495. 
43. Baugh LR, Hill AA, Claggett JM, Hill-Harfe K, Wen JC, Slonim DK, Brown EL, Hunter CP: The 
homeodomain protein PAL-1 specifies a lineage-specific regulatory network in the C. elegans 
embryo. Development 2005, 132(8):1843-1854. 
44. Tai SL, Boer VM, Daran-Lapujade P, Walsh MC, de Winde JH, Daran JM, Pronk JT: Two-
dimensional transcriptome analysis in chemostat cultures. Combinatorial effects of oxygen 
availability and macronutrient limitation in Saccharomyces cerevisiae. J Biol Chem 2005, 
280(1):437-447. 
Chapter 4: Conserved co-expression for candidate disease gene prioritization 
80 
 
45. Yarragudi A, Parfrey LW, Morse RH: Genome-wide analysis of transcriptional dependence and 
probable target sites for Abf1 and Rap1 in Saccharomyces cerevisiae. Nucleic Acids Res 2007, 
35(1):193-202. 
46. Singh J, Kumar D, Ramakrishnan N, Singhal V, Jervis J, Garst JF, Slaughter SM, DeSantis AM, 
Potts M, Helm RF: Transcriptional response of Saccharomyces cerevisiae to desiccation and 
rehydration. Appl Environ Microbiol 2005, 71(12):8752-8763. 
47. Sabet N, Volo S, Yu C, Madigan JP, Morse RH: Genome-wide analysis of the relationship 
between transcriptional regulation by Rpd3p and the histone H3 and H4 amino termini in budding 
yeast. Mol Cell Biol 2004, 24(20):8823-8833. 
48. Hochwagen A, Wrobel G, Cartron M, Demougin P, Niederhauser-Wiederkehr C, Boselli MG, 
Primig M, Amon A: Novel response to microtubule perturbation in meiosis. Mol Cell Biol 2005, 
25(11):4767-4781. 
49. Schawalder SB, Kabani M, Howald I, Choudhury U, Werner M, Shore D: Growth-regulated 
recruitment of the essential yeast ribosomal protein gene activator Ifh1. Nature 2004, 
432(7020):1058-1061. 
50. Pitkanen JP, Torma A, Alff S, Huopaniemi L, Mattila P, Renkonen R: Excess mannose limits the 
growth of phosphomannose isomerase PMI40 deletion strain of Saccharomyces cerevisiae. J Biol 
Chem 2004, 279(53):55737-55743. 
51. Ronald J, Akey JM, Whittle J, Smith EN, Yvert G, Kruglyak L: Simultaneous genotyping, gene-
expression measurement, and detection of allele-specific expression with oligonucleotide arrays. 
Genome Res 2005, 15(2):284-291. 
52. Takagi Y, Masuda CA, Chang WH, Komori H, Wang D, Hunter T, Joazeiro CA, Kornberg RD: 
Ubiquitin ligase activity of TFIIH and the transcriptional response to DNA damage. Mol Cell 2005, 
18(2):237-243. 
53. Guan Q, Zheng W, Tang S, Liu X, Zinkel RA, Tsui KW, Yandell BS, Culbertson MR: Impact of 
nonsense-mediated mRNA decay on the global expression profile of budding yeast. PLoS Genet 
2006, 2(11):e203. 
54. Kresnowati MT, van Winden WA, Almering MJ, ten Pierick A, Ras C, Knijnenburg TA, Daran-
Lapujade P, Pronk JT, Heijnen JJ, Daran JM: When transcriptome meets metabolome: fast 
cellular responses of yeast to sudden relief of glucose limitation. Mol Syst Biol 2006, 2:49. 
55. Yu C, Palumbo MJ, Lawrence CE, Morse RH: Contribution of the histone H3 and H4 amino 
termini to Gcn4p- and Gcn5p-mediated transcription in yeast. J Biol Chem 2006, 281(14):9755-
9764. 
 
 81 
 
 
 
 
 
 
 
Chapter 5: The biological coherence of human phenome 
databases 
 
 
Martin Oti, Martijn Huynen, Han G. Brunner 
 
 
Submitted 
 
Chapter 5: The biological coherence of human phenome databases 
82 
 
Abstract 
Disease networks are increasingly explored as a complement to networks centred around 
interactions between genes and proteins. The quality of disease networks is heavily dependent 
on the amount and quality of phenotype information in phenotype databases of human genetic 
diseases. We explored which aspects of phenotype database architecture and content best 
reflect the underlying biology of disease. We used the OMIM, Orphanet and POSSUM 
phenotype databases for this purpose, and devised a biological coherence score based on the 
sharing of gene ontology annotation to investigate the degree to which phenotype similarity in 
these databases reflects related pathobiology. Our analyses support the notion that a fine-
grained phenotype ontology enhances the accuracy of  phenome representation. In addition, we 
find that the OMIM database that is most used by the human genetics community is heavily 
under-annotated. We show that this problem can easily be overcome by simply adding data 
available in the POSSUM database to improve phenotype representations in OMIM. Also, we 
find that the use of feature frequency estimates – currently only implemented in the Orphanet 
database – significantly improves the quality of the phenome representation. Our data suggest 
that there is much to be gained by improving human phenome databases, and that some of the 
measures needed to achieve this are relatively easy to implement.  More generally, we propose 
that curation and more systematic annotation of human phenome databases can greatly 
improve  the power of the phenotype for genetic disease analysis. 
 
Introduction 
The human genome is defined by the complete DNA sequence and by the functional 
relationships between all human genes. Similarly, the human phenome can be viewed as the 
sum total of all human phenotypes, and the relationships that exist between the various 
diseases and traits. By correlating networks of genes and phenotypes[1,2], we can investigate 
disease pathobiology at the whole phenome scale[1-13]. Such analyses build on the premise 
that phenotypic overlap is a good predictor of genetic relationships, and their success relies on 
the quality and amount of the phenotype data[5,8,11-13]. 
The importance of using adequate phenotype information is obvious both for clinical diagnosis 
and for proper disease classification for research studies. The concept of disease families that 
can be organized into phenotype networks has spurred new interest into more precise and more 
comprehensive phenotype annotation[14-17]. For example,  mutations in proteins involved in 
ciliary functioning result in overlapping phenotypes, collectively referred to as ciliopathies[18]. 
The realization that features such as retinopathy and kidney cysts are indicative of disturbed 
cilium function has enabled the identification of ciliary diseases based only on their 
phenotype[16,19,20], as well as the identification of novel ciliopathy genes[21]. This and other 
examples suggest that much can be learned from disease comparisons on a phenome-wide 
scale. Such phenotype comparisons will need to become more sophisticated as correlations are 
sought between genetic variants and phenotypic features in ever greater detail, up to the level 
of individual genotype-phenotype mappings across the genome and across populations[22]. 
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Here we analyzed three human phenotype data sets to investigate which characteristics of the 
disease phenotype descriptions in the available databases would maximize their utility. We 
examined  OMIM (Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/Omim/)[23] 
using phenotype descriptions based on a recently developed phenotype ontology called 
HPO[24] (Human Phenotype Ontology; http://www.human-phenotype-ontology.org/). In addition 
we performed analyses on the diagnosis-oriented Orphanet[25] (http://www.orpha.net/) and 
POSSUM (Pictures Of Standard Syndromes and Undiagnosed Malformations)[26] 
(http://www.possum.net.au/) databases. Using the sharing of gene ontology annotation as a 
measure of biological coherence between diseases, we investigated the degree to which 
phenotype similarity in these databases reflects shared pathobiology for different treatments of 
the phenotype data. It is important to note that differences in information content and structure 
of the OMIM, POSSUM, and Orphanet databases preclude comparing them directly with each 
other, so comparisons were always between different treatments of data from a single 
database. To remove biases that remain even when comparing treatments within one database, 
all results were expressed relative to random permutations of the phenotypes in that database. 
We find that a fine-grained phenotype ontology improves phenome representation, as does 
inclusion of feature frequency estimates. In addition, we find that the OMIM database that is 
most used by the community is heavily under-annotated, at least for the purpose of systematic 
phenotype comparisons. We show that this problem can easily be overcome by simply adding 
data available in the POSSUM database to improve phenotype representations in OMIM. Our 
data suggest that there is much to be gained by improving human phenome databases, and that 
some of the measures needed to achieve this are relatively easy to implement.  While manual 
curation and systematic annotation of disease phenotypes may require substantial investment, 
we feel that this is justified and necessary to realize the full potential of systematic genotype-
phenotype correlations and phenomics. 
 
Methods 
Data sets 
In order to compare databases for the relationships between their phenotype content and the 
underlying genetic architecture, we first needed to formalize phenotype descriptions. Several 
current disease phenotype databases already define their own standardized feature terms. The 
diagnosis-oriented LDDB (London Dysmorphology Database)[27], Orphanet[25] 
(http://www.orpha.net/) and POSSUM (Pictures Of Standard Syndromes and Undiagnosed 
Malformations)[26] (http://www.possum.net.au/) databases all use a controlled vocabulary to 
systematically annotate disease phenotypes with features, an approach that facilitates 
differential diagnosis. We used Orphanet and POSSUM in our analyses as examples of such 
structured human phenome databases. However, the largest phenotype database available, the 
OMIM (Online Mendelian Inheritance in Man; http://www.ncbi.nlm.nih.gov/Omim/)[23], is 
intended to serve more as an information repository than as a diagnostic tool. As such it does 
not use a controlled vocabulary. To enable phenotype comparisons to be conducted for this 
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database, previous efforts have employed text mining to convert the free text records into 
feature lists, using terms defined in external vocabularies[8,11]. In this study, we used another 
recent conversion of OMIM phenotype data, which uses a manually curated systematic 
hierarchical vocabulary (or ontology) to describe OMIM phenotypes[24]. This ontology, known 
as the Human Phenotype Ontology or HPO (http://www.human-phenotype-ontology.org/), was 
used to annotate OMIM phenotypes with feature lists based on annotation taken from the OMIM 
database itself. The HPO is comprehensive, with over 8000 terms organized into a deep 
hierarchical structure (Table 1).  
 
Table 1. Overview of the considered syndrome databases. 
OMIM 
 Orphaneta POSSUM 
HPO b MimMiner c 
Num. syndromes 2070 3167 4779 5948 
Num. features in 
ontology 864 1115 8275 1368
 d
 
Feature ontology 
depth: 
max. / median 
4 / 2 2 / 2 13 / 6 15 / 5 
Median num. 
features per 
syndrome: original / 
expanded e 
13 / 25 22 / 34 7 / 20 8 / 22 
Num. syndromes 
mapped to disease 
genes 
668 924 2053 2055 
Num. disease genes 1038f 986 2019 1937 
Reference [25] [26] [24] [11] 
a
 Only the feature-annotated syndromes were included in this analysis; there were 7435 Orphanet 
syndromes in the full Orphanet syndrome database. 
b
 The Human Phenotype Ontology contains phenotype annotation for a subset of OMIM diseases. 
c
 The MimMiner text-mining conversion of the OMIM database is listed for comparison, but was not used 
in this study. 
d
 The “Anatomy” (A) and “Pathological Conditions, Signs and Symptoms” (C23) parts of the MeSH 
ontology were used in the MimMiner approach. 
e
 The number in parentheses refers to the median number of features per syndrome after the syndrome 
feature vectors are expanded to include the feature’s ontological ancestors in the feature vector. 
f The Orphanet database used originally contained 569 disease genes, but this number was expanded to 
1935 using syndrome-to-gene mappings from the OMIM database. 1038 of these were associated with 
feature-annotated syndromes. 
 
The Pictures Of Standard Syndromes and Undiagnosed Malformations (POSSUM) and 
Orphanet phenotype data were received upon request from the Murdoch Children’s Research 
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Institute in Melbourne, Australia and the INSERM in Paris, France, respectively. The POSSUM 
data were received in August 2007 while the Orphanet data were received in July 2008. The 
Human Phenotype Ontology (HPO) and Online Mendelian Inheritance in Man (OMIM) data were 
downloaded on December 18, 2008. 
Cluster biological coherence score calculation procedure 
We used a cluster-based approach as we are interested in the degree to which phenotypically 
similar diseases share pathogenetic mechanisms, as proposed by the syndrome family 
concept[3]. We calculated phenotypic distances between syndromes based on their feature 
vectors. This approach is described in detail in Van Driel et al. 2006[11]. Briefly, we first used 
the hierarchical relationships between features in the relevant feature ontology to supplement 
the feature vectors with their more general ancestor features, and subsequently calculated the 
phenotypic distances between all syndrome pairs using the cosine similarity metric, which uses 
the angle between the two feature vectors as distance measure. 
After calculating the phenotypic distances between syndromes, we hierarchically clustered the 
phenotypes using average linkage. We then partitioned the resulting dendrogram into clusters 
using the “Dynamic Tree Cut” algorithm[28], which creates comparable cluster sizes across 
different dendrograms (data not shown). This algorithm requires a minimum cluster size as 
parameter, which we set to five syndromes. 
Upon partitioning the syndromes into clusters, we then calculated the average biological 
coherence of the clusters using the “Gene Ontology” (GO) gene functional annotation[29] as 
genetic relatedness measure (downloaded from the Ensembl database[30] on August 28, 
2007). We used GO annotation as it reflects many different kinds of functional relatedness and 
has a large coverage of genes (>16,000 genes). 
Cluster biological coherence was calculated as follows: First, we retrieved the GO terms 
associated with the disease genes underlying cluster syndromes. These GO terms were then 
pooled across all genes causing the same syndrome, resulting in a set of GO terms annotated 
to the syndrome. For each syndrome pair, we determined the GO term overlap between the two 
syndromes (Equation 1):  
     Sp(i,j) = n(Gi∩Gj)/n(GiUGj)    (1) 
where Sp(i,j) is the pairwise GO term overlap score for diseases i and j, n is the number of GO 
terms meeting the specified criteria and Gi and Gj are the sets of GO terms associated with 
diseases i and j respectively. We did not incorporate ontological relationships between GO 
terms into the comparison. For each cluster, the mean pairwise overlap was used as the 
biological coherence score for that cluster (Equation 2): 
     Sc = ∑ni,jSp(i,j)/n     (2) 
where Sc is the genetic cohesiveness score for cluster c, Sp(i,j) is the GO overlap score for 
diseases i and j, and n is the number of disease pairs in the cluster. The mean biological 
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coherence score across all clusters was used as the overall cluster biological coherence score 
for the database (Equation 3): 
     S = ∑ncSc/n      (3) 
where S is the overall genetic cohesiveness score for the phenotype data set, Sc is the genetic 
cohesiveness score for cluster c, and n is the number of clusters in the phenotype data set. 
Randomizations 
We did not compare the cluster biological coherence scores between data sets directly because 
the many differences between the databases would make it hard to determine which aspects of 
the database did cause the variation in the biological coherence score. Instead we compared 
the scores of the actual data sets to those of randomly permuted data sets. Randomization was 
done by reshuffling the features over the  diseases, while maintaining the phenotypic structure 
of the data sets. Thus, feature frequencies in the data sets and feature distributions across 
diseases  were maintained, and only the feature assignment to diseases was randomized. In 
this randomization approach disease  to gene mappings are maintained, correcting for biases 
due to the sharing of genes between diseases, variation in number of genes per disease , and 
function annotation bias of genes, as these remain identical across both actual and randomized 
data sets. As final biological coherence measure, we used the ratios of the cluster biological 
coherence scores of the actual data sets to those of 30 randomized variants. These ratios were 
used as performance metric for evaluating effect of weighting schemes or other database 
properties. All ratio comparisons were done using the non-parametric two-sided Wilcoxon rank 
sum test with continuity correction as implemented in the R statistical software package 
(http://www.r-project.org/). 
OMIM supplementation analyses 
The OMIM diseases  were supplemented with feature annotation from the POSSUM database. 
We excluded the more detailed skeletal features–those with feature IDs above 746–which were 
added later to the POSSUM database in order to better describe the skeletal abnormalities that 
this database is oriented towards. This supplementation resulted in the increase in median 
number of features per OMIM disease  from 14 to 38 for those diseases  that could be 
supplemented. We performed the comparisons between the original and the supplemented 
OMIM data sets using only the 1950 OMIM syndromes that could be supplemented with at least 
one POSSUM feature. The supplemented feature vectors were further processed analogously 
to the original feature vectors. 
HPO feature ontology truncation procedure 
The HPO feature ontology contains over 8,000 features organized into a deep hierarchical 
structure with a median feature depth of six and a maximum depth of thirteen. We mapped all 
features located at a depth level of five or higher (i.e. four or more steps from the root of the 
HPO ontology) to their more general ancestor features at the fourth level, resulting in a set of 
1,833 more broadly defined features. Where a deep feature had multiple ancestors at this level, 
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it was mapped to all of them. Syndrome feature vectors were modified using this feature 
mapping, with deeper features being replaced with their appropriate fourth-level ancestor 
features. All features were only registered once per feature vector, regardless of how many 
deeper features they replaced. These modified feature vectors were further processed 
analogously to the full ontology-based feature vectors. 
Orphanet feature occurrence frequency weighting scheme 
Orphanet features are annotated with occurrence frequency estimates. These frequency 
estimates are divided into three classes, “Very Frequent”, “Frequent’ and “Occasional”. To 
investigate the effect of incorporating feature frequency estimates on syndrome clustering, we 
weighted these three frequency classes with the weights 1.0, 0.1 and 0.01 respectively. We 
contrasted this scheme with one in which the assignment order was reversed, assigning a 
weight of 1.0 to the “Occasional” frequency class and 0.01 to the “Very Frequent” class. These 
weighted feature vectors were further processed analogously to the unweighted feature vectors. 
Inverse Document Frequency weighting scheme 
Features in feature vectors were weighted using the Inverse Document Frequency algorithm 
(Equation 4), which assigns higher weights to features occurring in fewer syndromes: 
Fidf = log2(n/nf)F     (4) 
where Fidf is the IDF-weighted feature score, n is the total number of phenotypes, nf is the 
number of phenotypes with the feature, and F is the original feature score. In this scheme, 
weights increase logarithmically with rarity. All weights were subsequently rescaled to the 0–1 
range. These weighted feature vectors were further processed analogously to the unweighted 
feature vectors. 
Statistical analysis 
Biological coherence scores were compared between data sets using the Wilcoxon signed rank 
test with continuity correction as implemented in the R statistical software package 
(http://www.r-project.org/). This test does not assume normally distributed data. 
 
Results 
Incomplete phenotype descriptions impair phenome coherence 
The number of phenotype features per disease in OMIM (7) is much less than it is for the 
POSSUM and Orphanet databases (22 and 13 respectively) (Table 1). We reasoned that 
increasing phenotype annotation in OMIM might aid the discovery of biological relationships 
between diseases in that database. We investigated this by supplementing OMIM disease 
annotation with features from the POSSUM database, thus increasing the OMIM disease 
annotation almost threefold from 14 features per disease to 38 features per disease. We then 
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hierarchically clustered all OMIM phenotypes based on their HPO feature similarities, creating a 
disease network that we could link to the biological function of disease genes. The biological 
coherence of resulting OMIM phenotypic clusters was measured by the degree to which disease 
genes shared Gene Ontology (GO) function annotation. Briefly, GO terms were pooled across 
genes per disease, and the mean degree of GO annotation overlap between all disease pairs in 
a cluster was used as the cluster biological coherence score. The mean score over all clusters 
was used as the final biological coherence score for the dataset (see methods section for more 
detailed description of procedure). 
Enriching OMIM with POSSUM annotation does indeed lead to improved phenotypic clustering 
of known syndrome families (Figure 1). The 12 annotated subtypes of Ehlers Danlos syndrome, 
and of Charcot-Marie-Tooth disease segregate better (Figure 1A) and the detection of similarity 
between the phenotypically more diverse ciliopathies is also increased (Figure 1B).  Using 
enriched phenotype descriptions, the OMIM disease similarity matrix reflects underlying genetic 
relationships to a much greater degree (Figure 2A; p<10-16, two-sided Wilcoxon signed rank 
test). We conclude that the OMIM database is currently greatly under-annotated and that this 
affects its performance on detecting biological relationships between disease phenotypes. 
We further demonstrated this point by artificially under-annotating the well-annotated POSSUM 
and Orphanet syndromes, through the random elimination of half the annotated features per 
syndrome. As expected, the performance of POSSUM and Orphanet is much reduced when 
half of the annotated features are randomly removed (Figure 2B; p<10-16 in both cases, two-
sided Wilcoxon signed rank test). These results underline the importance of complete 
phenotype descriptions for phenotype-based disease analysis and highlight the limitations of 
using the OMIM database for such analyses. 
Detailed feature ontologies improve phenome coherence 
We then asked whether one would require a highly detailed feature ontology as recently 
developed in HPO in order to accurately reflect the biology that underlies inherited diseases. 
Such feature ontologies organize disease features into a hierarchical structure, with deeper 
features becoming progressively more specific. The HPO has a comprehensive feature ontology 
containing over 8000 features, in contrast to the POSSUM and Orphanet ontologies which both 
contain about a thousand features each (Table 1). It also has the deepest ontology, with a 
median feature depth of 6 (as opposed to 2 for the POSSUM and Orphanet ontologies) and a 
maximum depth of 13 (as opposed to 2 and 4 for POSSUM and Orphanet respectively).  
To investigate the benefits of such a highly detailed ontology, we first hierarchically clustered all 
OMIM phenotypes based on their HPO feature similarities. This created a disease network that 
we could link to the biological function of disease genes. We then repeated the analysis using a 
simplified version of HPO truncating the feature tree at three steps from the root of the ontology. 
This procedure reduced the HPO feature set from a total of 8,275 to just 1,833 features. 
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Figure 1. Comprehensively annotated syndromes cluster better than sparsely annotated syndromes. (A) 
The Ehlers-Danlos and Charcot-Marie-Tooth syndrome families overlap in the phenome landscape of the 
OMIM data set, but separate when the phenotype descriptions are supplemented with POSSUM 
annotation. The phenome landscapes were created using multi-dimensional scaling of the HPO feature-
based OMIM distance matrices (left), supplemented with POSSUM annotation (right). The more similar 
the annotations of two syndromes are, the closer they are on the landscape. The background colors 
indicate the density of syndromes in that region of the landscape. Lighter colors represent higher 
densities. (B) Mean phenotypic similarity is consistently greater for the POSSUM supplemented OMIM 
data set (red dashed lines) than for the original OMIM data set (blue dashed lines). Besides Ehlers-
Danlos (n=12) and Charcot-Marie-Tooth (n=12), the more phenotypically diverse family of ciliopathies is 
also shown (n=59; Supplementary Table 1). Continuous lines show the distributions of mean distances for 
randomly composed syndrome families of equivalent size (n=107) for the original  and supplemented 
OMIM data sets. 
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Surprisingly, an initial comparison indicated that the highly detailed feature ontology of HPO did 
not improve the degree to which phenotype clustering reflects biological relationships between 
disease genes (Figure 2A). In fact, the use of more detailed feature definitions had a slightly 
detrimental effect (p=0.003, two-sided Wilcoxon signed rank test). However, this is likely an 
artifact of the previously noted under-annotation of diseases in OMIM. To confirm this, we 
repeated the experiment using the OMIM disease annotation that had been supplemented with 
features from the POSSUM database (Figure 2A). As could be expected, the detailed 
phenotype ontology did indeed improve phenome representation. The HPO feature ontology 
performed better on biological coherence of phenotype clusters relative to the simplified 
ontology (p<10-10, two-sided Wilcoxon signed rank test). This result highlights two effects; firstly, 
detailed and comprehensive feature ontologies such as HPO enable improved phenotype 
description, and secondly, under-annotation of disease phenotypes severely limits the benefits 
of such detailed feature ontologies. 
Using feature occurrence frequency can improve phenome coherence 
We then asked whether all phenotypic features are of equal importance to the overall disease 
phenotype. We first restricted the phenotype descriptions to those features that occur very 
frequently in the respective diseases. Even though this leads to a considerable reduction of 
features per syndrome (median 57% of original features), the biological coherence scores 
remained high (Figure 2B). This result shows that the core phenotypic features that occur most 
commonly in a disease best reflect the underlying biological relationships. 
Consistent with this, we found that if we emphasized commonly occurring features and assigned 
lower weights to infrequent features, a more biologically relevant phenotype clustering was 
obtained (Figure 2C; p<10-5, two-sided Wilcoxon signed rank test). By contrast, emphasizing 
infrequent features by assigning them higher weights almost completely abolished any 
recognizable biological coherence of phenotype clusters (Figure 2C; p<10-16, two-sided 
Wilcoxon signed rank test). Thus, while the weighting of phenotypic features based on their 
frequency of occurrence improves disease classification, emphasizing features that are not part 
of the core phenotype may have a severe detrimental effect. This result clearly argues for the 
systematic curation of phenotype data. More specifically, the inclusion of  feature frequencies 
appears to be a requirement for optimal phenotype representation, a feature that is currently 
only available in Orphanet. 
Emphasizing rare features is detrimental to phenome coherence 
It has previously been suggested that those features which occur in many diseases will be too 
general to discriminate between diseases, and too common to aid in specifying the pattern of 
features that defines a  disease family. Rarer features might be more informative for the 
underlying biology[8,11]. We investigated this assumption for the systematically annotated 
POSSUM database. In contrast to previous studies[8,11], we find that a weighting scheme that 
uses the  standard “inverse document frequency” (or IDF) score is detrimental to the biological 
coherence of similar phenotypes (Figure 2D; p<10-7, two-sided Wilcoxon signed rank test). 
Chapter 5: The biological coherence of human phenome databases 
91 
 
 
Figure 2. Biological coherence of phenotypic clusters for different data sets and conditions. The box plots 
show relative enrichment of shared GO terms for genes associated with diseases within clusters 
compared to randomly permutated phenotype data sets (n=30). Box limits show the 25th and 75th 
percentiles, whiskers extend out up to 1.5x the box range, points outside this range are plotted 
individually. (A) The full HPO ontology results in biologically more coherent phenotype clusters than a 
simplified HPO ontology containing only more general features, but only when the OMIM phenotypes are 
supplemented with POSSUM annotation (purple boxes). (B) Artificial under-annotation of the POSSUM 
and Orphanet databases by randomly halving the syndrome feature lists (“sparse”) leads to strong 
reductions in cluster biological coherence. However, limiting the Orphanet syndrome descriptions to just 
the very frequent features has limited impact on cluster coherence, despite the strong reduction in the 
average number of features per syndrome to just 57% of the original. (C) Weighting Orphanet features 
according to their prevalence within affected patients improves the biological coherence of clustered 
phenotypes. Counter-weighting them by assigning higher weights to less frequently occurring features 
abolishes the biological coherence of the resulting phenotype clusters almost completely. (D) Weighting 
annotated features according to their specificity (number of syndromes they occur in) using the inverse 
document frequency (I.D.F.) weighting scheme diminishes cluster biological coherence for well annotated 
POSSUM syndromes, but improves it for under-annotated syndromes. 
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Interestingly, this only holds for fully annotated syndromes since under-annotated syndromes do 
benefit from emphasizing rarer features (Figure 2D; p<10-11, two-sided Wilcoxon signed rank 
test). This explains previous results, which were based on text-mining of less well-annotated 
phenotypes. We conclude that frequent phenotypic features are generally more indicative of 
underlying genetic relationships than the sharing of specific features that are observed in a few 
syndromes or diseases only. 
 
Discussion 
Here, we have used a biological coherence score based on the sharing of gene ontology 
annotation between diseases. We use this scoring system to identify database characteristics 
that enable a better clustering of related disease phenotypes. Our analysis of the OMIM, 
POSSUM, and Orphanet databases highlights three areas where improvements of phenotype 
annotation are required. First, the number of features per disease in OMIM can easily be 
increased and this will much improve its applicability for phenome scale analyses. Second, a 
simple score of the frequency of feature occurrence per disease as is implemented in Orphanet, 
refines the phenotype description and improves database performance. Third, emphasizing 
phenotype features that are rare in the databases does not allow one to cluster diseases more 
efficiently. These findings have implications for future and perhaps current database design. 
Clearly, current human phenotype databases were intended as repositories, as tools for 
accurate clinical diagnosis of syndromes, and to provide references to a selection of the 
pertinent literature for specific genetic diseases and syndromes. One could therefore argue that 
our plea for improvement is demanding something that lies outside the original scope for which 
these databases were designed. In contrast, we would argue that our ability to compare and 
group genes based on their sequence and function has proven to be of immense use for 
genome scientists. We therefore believe that the human phenome deserves a representation 
that allows scientists to be similarly inquisitive and creative in distilling biologically relevant 
patterns. 
Further down the line we need to improve the collection of phenotype data as well as their 
storage. While curators can standardize phenotype recording in databases, such efforts could 
be greatly assisted by the standardization of phenotype recording in the clinic[15,16]. Such 
standardized reporting would require controlled feature vocabularies, of which there are several 
in existence[24-27] or under development[31]. Given the difficulties of designing feature 
vocabularies and their importance in phenotype analysis, it might be beneficial to unify 
terminology across vocabularies. Ultimately, a complete human phenome description 
incorporating all human phenotypic variation[14] – including molecular phenotypes[32] – would 
be most desirable for correlating phenotype variation to genetic variation. Such analyses could 
even be performed at the level of individual genomes and phenotypes once sufficient data from 
initiatives such as the Personal Genome Project become available[22]. We believe that the time 
is ripe for the allocation of substantial resources to improve human phenome annotation on the 
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one hand, and to foster the more systematic storage of such data in human phenotype 
databases on the other. 
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6.1 Summary of findings 
In this thesis we set out to demonstrate that phenotypically similar diseases do tend to be 
caused by mutations in functionally related genes, and that this phenomenon can be used to 
identify potential novel disease genes (Chapters 1 & 2 and refs. [1,2]). We did this by 
investigating the degree to which genes causing the same disease are functionally related at the 
molecular level, using two measures of functional relationships – physical protein-protein 
interactions and correlated expression profiles (co-expression). As many gene functional data 
are acquired from model organisms rather than human material, we also investigated the utility 
of such data from other species for elucidating human disease pathobiology. Finally, we also 
investigated the relationship between disease phenotypes and disease genetics from the 
phenotypic angle to find out if the relationship extends beyond individual diseases to 
phenotypically overlapping but distinct diseases. In the process we identified phenotype 
database properties that maximize their utility for disease investigation. 
We began our investigations using genetically heterogeneous diseases, which are diseases that 
can be caused by mutations in one of several alternative genes. We chose to start with them as 
they represent disease mutations with maximal phenotypic overlap, i.e. clinically 
indistinguishable phenotypes. If there are functional relationships between genes causing 
similar phenotypes, they should be strongest for those genes that lead to virtually identical 
disease phenotypes when mutated. 
In addition to choosing disease mutations with the strongest possible phenotype similarity, we 
also chose to begin with one of the strongest possible measures of gene functional 
relationships, namely physical protein-protein interactions (PPIs). If two proteins interact 
physically and specifically with each other, then they can be expected to be involved in the 
same process. This is especially the case for proteins that interact with each other in protein 
complexes. We investigated whether genes underlying genetically heterogeneous phenotypes 
are more likely to interact with each other physically at the protein level using protein-protein 
interaction data from several sources (Chapter 3). We used primarily PPIs based on high-
throughput experimental assays, but also included literature-derived PPIs in the analysis. We 
also investigated whether PPIs can be used to identify novel disease genes in positional 
candidate disease genes in genomic loci known to be associated with particular diseases, but 
for which the causative gene had not yet been identified. As the amount of PPI data from human 
sources is limited, we also included PPI data from other species. We used both binary 
interaction data from yeast two-hybrid protein interaction assays as well as protein interactions 
within complexes identified through mass spectrometry. 
We showed that proteins of genes causing the same disease have a tendency to interact with 
each other physically. This tendency is tenfold greater than their tendency to interact with non-
disease-related genes. We show that this information can be use to improve positional 
candidate disease gene prioritization, as PPI partners of known heterogeneous disease genes 
that lie in another genomic locus associated with the same disease are more likely candidates 
than neighboring genes in the locus. Based on this premise we make several predictions of 
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novel disease genes, some of which have been confirmed. Importantly, we found that even 
protein-protein interactions detected in other species can be predictive for human diseases. We 
found that high-throughput PPIs taken from organisms as evolutionarily distant as baker’s yeast 
(Saccharomyces cerevisiae) are still capable of predicting heterogeneous disease genes as well 
as those based on human material. This is partly due to the increased predictive power of 
proteins involved in the same complexes relative to those shown to interact using the binary 
yeast two-hybrid approach, as was later demonstrated by others[3]. However, we also found 
that literature-based PPIs are strongly biased toward known disease genes, and are probably 
not representative for the identification of novel disease genes. Our findings suggest that those 
disease genes that could be detected using literature-based PPIs have unsurprisingly already 
been identified by the research community. Our PPI findings support the notion that similar 
disease phenotypes are caused by mutations in genes that are functionally related.  
In Chapter 4 we investigated whether a different kind of functional genomic data, namely 
correlated mRNA expression patterns, can also lead to similar results. In contrast to the 
previously used protein-protein interaction data, mRNA expression patterns can be determined 
efficiently and cost-effectively on a genome-wide scale meaning that these data are far more 
abundant and comprehensive. If genes causing similar disease phenotypes are likely to be 
functionally related, then genes involved in genetically heterogeneous diseases should have a 
relatively higher tendency to be coordinately expressed (co-expressed) across tissues and 
conditions. However, mRNA expression levels are but one level of gene regulation; gene 
expression can be coordinated at several different levels including transcription, translation and 
protein stability[4]. mRNA levels can therefore be expected to be a noisy proxy for gene 
expression, and this is indeed the case[5,6]. This led us to further investigate how these mRNA 
expression data can be best exploited to maximally reflect functional relationships between 
genes and their ability to rank genuine disease genes amongst unrelated positional candidate 
disease genes. To this end we investigated different expression data sets and normalization 
procedures, but we primarily investigated the use of evolutionary conservation of co-expression 
to strengthen the reliability of these co-expression ties between genes. This evolutionary angle 
and the deeper investigation of expression data pre-processing together set this study apart 
from others that use co-expression data for candidate disease gene prioritization, such as 
Prioritizer[7], ENDEAVOUR[8] and G2D[9]. 
We showed that genes causing the same disease do indeed have a higher tendency to be 
coordinately expressed across tissues and conditions. There is a clear tendency for 
heterogeneous disease genes to have a higher co-expression with fellow disease genes in 
other genomic loci than with other neighboring genes in those loci, despite the tendency for 
genes located close to each other on the genome to have similar expression levels[10]. We 
further showed that conserved co-expression is a stronger indicator of shared pathology than 
co-expression in human tissues alone. The requirement for genes to be coordinately expressed 
in different species filters out less consistent and therefore less reliable relationships between 
genes. We also demonstrated that mRNA expression data choice and pre-processing can have 
a substantial impact on their performance in co-expression-based ranking of positional 
candidate disease genes. We found that pooling microarray expression datasets from different 
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sources is detrimental to their performance, introducing extra noise. We also show that relative 
expression levels perform better than absolute expression levels. In summary, we found that 
when it comes to identifying common involvement of genes in diseases using mRNA co-
expression data, quality is better than quantity. While the predictive value of (conserved) co-
expression by itself is more limited than those of other kinds of gene functional data such as 
protein-protein interactions, it should nevertheless be a useful data source for integrative 
candidate disease gene prioritization tools such as Prioritizer[7] and ENDEAVOUR[8] that blend 
several different kinds of gene functional data together. 
The utility of these protein-protein interactions and (conserved) mRNA co-expression for 
candidate disease gene prioritization is consistent with those of other studies (many of which 
are described in Chapter 2), and confirms the notion that similar disease phenotypes are 
caused by functionally related genes. However, while there are large and growing amounts of 
gene functional data to use in such prioritization tools, disease phenotypes have so far not been 
given the same level of consideration. Nevertheless, the phenotype is critical to disease 
definition upon which further molecular analyses are based, and is also a rich source of readily 
available information about the disease. It is therefore of great importance to investigate how 
best to describe disease phenotypes for research purposes. It is clear that phenotypically very 
similar diseases tend to be caused by functionally related genes, but can this relationship be 
extended further to diseases that have overlapping but non-identical phenotypes? To what 
extent could such a relationship be exploited in disease analysis using existing disease 
phenotype databases? And how can these disease phenotype descriptions be improved? What 
kinds of phenotype information are important from a pathobiological point of view? We 
investigated this using systematically annotated disease phenotypes from several existing 
disease databases (Chapter 5). Given our focus on the phenotype, we took a broad view of 
gene functional relationships in this study, using gene ontology (GO) functional annotation to 
identify functional links between genes instead of restricting ourselves to a single kind of 
functional data as we had done in the previous studies. 
We showed that the tendency of functionally related genes to lead to phenotypically similar 
diseases extends beyond genetically heterogeneous diseases. Even when more broadly 
defined disease phenotype clusters are used, causative genes tend to be functionally related. 
We further identified several properties of phenotype databases that improve their utility for 
phenotype-based disease analyses. We found that both deep trait hierarchies and the use of 
trait frequency estimates can improve the biological coherence of phenotypic disease clusters. 
Somewhat contrary to previous expectations we found that overall disease phenotypic similarity 
is more important than the sharing of specific rare traits. This is reflected in the fact that the 
frequently used Inverse Document Frequency weighting scheme is actually harmful when 
applied to well-annotated phenotypes, only benefiting under-annotated phenotype comparisons. 
Above all, we highlighted the importance of complete and systematic disease phenotype 
annotation, and emphasize the need to pay more attention to this aspect of disease research in 
the future. 
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Together, these results demonstrate the genetic relatedness of similar disease phenotypes and 
underscore the validity of using gene functional information to prioritize disease candidate 
genes for both genetically heterogeneous diseases and syndrome families. Such phenotype-
based bioinformatic analysis of candidate disease genes will become even more important in 
the near future with the advent of widespread individual whole-genome re-sequencing, due to 
the vast quantities of data that will need to be interpreted. In the rest of this discussion, we take 
a look at these expected future developments and the important role phenotype-based 
functional genetic analyses can be expected to play in them. 
 
6.2 Moving from locus-based to genome-wide approaches 
6.2.1 Locus-based candidate disease gene prioritization is becoming less relevant 
In the past, the focus of genetic disease research has been on identifying genes in which 
mutation leads to the disease under investigation. Purely candidate gene-based approaches 
were previously hampered by limited functional biological knowledge, so linkage mapping has 
historically been the major source of disease gene localization information—particularly since 
the use of large numbers of naturally occurring DNA polymorphisms as molecular markers 
became practical[11]. This has resulted in the identification of large numbers of disease-
associated genomic loci[12], from which disease genes can and have been cloned. However, as 
this process is laborious and costly, it was important to prioritize these positional candidate 
genes for cloning in order to minimize the number of genes that need to be tested before the 
disease mutation is found. This prioritization of positional candidate disease genes was a 
primary focus of this thesis, in which different kinds of functional genomic data were shown to 
improve positional candidate disease gene ranking. At the present day, even though disease 
genes have been cloned from an ever-increasing number of these loci, there still remain many 
disease loci that are yet to divulge their mutant genes 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=OMIM). 
The situation is set to change in the near future, as the current rise in the application of deep 
sequencing to genetics research will eventually eliminate the need to prioritize positional 
candidate genes for sequencing. This will be brought about by the ability to sequence whole 
disease-associated loci in parallel and without the need for primer design, and at relatively low 
cost. However, such deep genomic sequencing will bring with it challenges of its own due to the 
plethora of rare genomic variants (alleles) that are bound to be uncovered by deep-sequencing 
disease loci. Such rare variants can resemble disease mutations but are not necessarily related 
to the disease in question. Given the fact that each individual’s genome contains more than 3 
million SNPs and hundreds of thousands of structural variations[13-16], many of which are rare, 
every sequenced locus can be expected to contain several of these disease-irrelevant rare 
genomic variants that resemble mutations. Indeed, a recent survey of all the exons on the X-
chromosome in over 200 families found that up to 1% of X-chromosome genes can contain rare 
truncating mutations that are nevertheless non-pathogenic [17,18]. When an entire disease 
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locus is sequenced including introns and intergenic regions, even more rare genomic variants 
will be found that may or may not be involved in gene regulation. These rare non-coding 
variants will be even more difficult to interpret than coding variants. 
Despite these problems, identifying which gene in the locus is causative for the disease should 
remain tractable as long as the region is sequenced in multiple patients from unrelated families. 
The disease genes should always be affected, while the disease-unrelated rare genomic 
variants are, by virtue of their rarity in the population, not likely to recur in different unrelated 
families. Even if different mutations are involved in different families, it should be possible to get 
an idea about which genes in the locus are likely to be involved in the disease due to the fact 
that they are consistently mutated in patients. As a result, bioinformatic candidate disease gene 
prioritization will probably play a more limited role in future locus-based genetic analyses than it 
currently does, although it may still play an important role in cases where few unrelated patients 
are available. Therefore, existing positional candidate disease gene ranking approaches – such 
as those described in this thesis – will need to be retooled and repurposed in order to remain 
relevant and useful to disease research. 
6.2.2 Genome-wide candidate disease gene prioritization is becoming more relevant 
These locus-based deep sequencing approaches are mainly suited to the identification of a 
subset of disease genes, namely those that those that cause diseases which are amenable to 
linkage mapping. This technique is most suited to identifying rare disease genes with a strong 
impact on disease phenotype[11], which facilitates the interpretation of the genomic variants 
detected by deep sequencing as described in the previous section. If mutations involved in 
complex diseases or modifier genes that have a more limited impact on Mendelian disease 
phenotype are to be identified, it will be necessary to expand the search space to the whole 
genome as it will be difficult to find specific loci harboring major causative genes to which the 
search can be restricted. Such analyses were beyond the scope of this thesis, but they will 
become more and more important in the near future as complex disease genetics is tackled and 
Mendelian diseases are elucidated in ever more detail. 
While expanding the search space to the whole genome is necessary to get a more complete 
picture of disease genetics, it will also bring with it its own challenges that will need to be 
resolved before the correct disease genes can be identified. It will uncover large numbers of 
potential disease mutations which will need to be prioritized in order to minimize the time and 
cost required for follow-up experimental investigation. Prioritization will thus remain essential, it 
will just be applied to genome-wide candidate disease mutations for follow-up analysis rather 
than to positional candidate disease genes for sequencing. When taking a genome-wide view of 
disease genetics like this, it will be essential to have precise disease phenotyping, as subtle 
differences between phenotypes of the same disease can reflect differences in underlying 
biology, while subtle similarities between the phenotypes of apparently unrelated diseases could 
point to commonalities in their underlying biology. This issue of proper disease phenotyping will 
be discussed in more detail later, after we first take a look at the role of bioinformatic analysis in 
genome-wide candidate disease gene prioritization. 
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6.2.2.1 Bioinformatic analysis is important for genome-wide association studies 
To a certain degree, this expansion of the search space to the whole genome is already being 
used in genome-wide association studies (GWASs), which are used to investigate the 
contribution of genomic loci to complex diseases on a genome-wide scale. This genome-wide 
scale, combined with larger study sizes that have more power to detect modest genetic effects, 
has had a substantial impact on the field of complex disease genetics which until recently had 
met with very limited success[11]. Earlier association studies were centered on specific 
candidate genes for practical reasons, but detected associations that were usually difficult to 
reproduce. However, recent advances in genotyping technology combined with results from the 
HAPMAP project[19] have led to a sharp rise in the number of GWAS loci reproducibly  
implicated in complex diseases, from  tens of loci to hundreds of loci[11]. 
Despite this increase in detected loci, such GWASs are still limited in the amount of genetic risk 
that they can explain. In contrast to linkage mapping which is best suited to identifying rare 
variants with strong phenotypic effects, GWASs are most suited to identifying common genetic 
variants, which generally contribute only modestly to the disease phenotype[11]. They are much 
less suited to detecting rare variants, even those that have larger effects on the phenotype. 
Additionally, their ability to detect a variant’s contribution to the phenotype depends on both the 
size of its effect and the study size. The large numbers of SNPs tested in such studies also 
require the use of stringent cut-offs for determining the statistical significance of associations in 
order to correct for multiple testing. This can lead to bona-fide associations being overlooked 
because they do not meet such stringent statistical requirements. Apart from the new difficulties 
introduced by testing larger numbers of genetic markers, the larger population sizes needed to 
improve statistical power increase the risk of including structured sub-populations in analyses 
which can lead to false associations – although the large numbers of SNPs tested in GWASs at 
least enable such sub-structuring to be detected[11]. These statistical issues are compounded 
yet further when gene-by-gene or gene-by-environment effects are taken into account[20]. 
Given the limitations of such purely statistical approaches, extra information will be required to 
identify which genes are involved in these complex diseases. Existing knowledge about gene 
function will need to be exploited, reinvigorating the candidate gene approach which has met 
with more limited success in the past. The current fast pace of discovery in the biological 
sciences and the vast amounts of new data that are being generated are making such an 
approach more and more feasible. Indeed gene functional information is already being exploited 
in current GWASs to make sense of the associations[21-23]. 
One way in which it is applied is to find common denominators between different candidate 
regions, analogously to some existing approaches to Mendelian candidate disease gene 
prioritization (Chapters  1 & 2). GWASs identify SNPs  that may not themselves contribute to the 
phenotype, but simply in linkage disequilibrium with the actual causative variation, within a 
region that generally spans tens of kilobases[11]. Additionally, the majority of associations 
detected by GWASs lie in introns or intergenic regions[24]. These complications mean that the 
number of potential disease genes within a disease-associated locus can range from several 
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down to none at all. However, as multiple loci are generally detected for the same disease 
common biological denominators can be sought between genes in different disease-associated 
loci. This approach has successfully led to the identification of novel pathways involved in 
different complex traits, such as hypothalamic function in obesity[25,26] and a few pathways 
that are shared between several immune-related diseases[27]. Once such functional 
commonalities are identified, they can guide the further search for candidate disease genes, 
even in loci that may not meet the statistical criteria used in such association studies[21-23]. 
This bioinformatic approach also overcomes a second limitation of purely statistical approaches, 
in that it automatically identifies interactions between disease genes. Though interactions 
between disease loci can be detected statistically with GWASs, the vast number of potential 
gene-by-gene as well as gene-by-environment interactions impose insurmountable numerical 
limits on their use in practice[20]. In contrast, the experimental detection of biological 
relationships between genes is ever increasing and does not suffer from any such limitations. 
These known interactions between disease genes highlight the nature of the biological 
relationships between them directly, in contrast to the GWAS statistical associations that still 
need to be interpreted in a biological framework. Functional approaches should therefore 
provide a more productive avenue for finding such interactions amongst disease genes or 
between them and environmental conditions than purely statistical approaches. Current 
bioinformatic approaches to disease gene prioritization such as those described in this thesis 
should be applicable to these problems once they are updated for genome-wide application[21]. 
6.2.2.2 Bioinformatic analysis is important for the interpretation of  rare genomic variants 
 Ultimately, genome re-sequencing must eventually replace SNP genotyping if the full spectrum 
of mutations contributing to complex disease is to be elucidated. Re-sequencing enables the 
detection of all genomic variants within individuals rather than just a pre-determined set of SNPs 
which occur relatively frequently in the population. Such an approach can enable one of the 
main limitations of GWASs to be overcome—the inability of association studies to detect rare 
genomic variants. It is now clear that rare variants play a major role in complex traits, as even 
the largest  GWASs fail to account for more than a few percent of the genetic component of 
complex traits[11]. This is perhaps unsurprising as, from an evolutionary perspective, common 
genetic variants are not likely to have a strong detrimental effect on the organism’s fitness. 
Therefore, disease-causing variants can generally be expected to be rare in the population[28].  
The extreme case of this inverse relationship between mutation severity and frequency is 
embodied by monogenic diseases, which constitute very rare mutations with very strong 
detrimental effects on the phenotype. 
There are also arguments for the persistence of detrimental genetic variants in the population, 
such as late onset of disease, antagonistic pleiotropy, and changing environments[29]. 
Nevertheless it appears that rare missense SNPs are indeed under negative selection which 
provides further support for this model of complex disease[29,30]. There is also empirical 
evidence for this phenomenon, as obese individuals have been found to have an 
overrepresentation of rare SNPs in obesity-related genes[31]. A consequence of this genetic 
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architecture is that different patients may have different combinations of rare alleles contributing 
to the complex disease phenotype, complicating genetic analysis. This is somewhat analogous 
to genetically heterogeneous diseases, in which different genes are mutated in different patients 
but all result in the same phenotype. Therefore, as with genetically heterogeneous diseases, 
bioinformatic analysis can be used to prioritize rare genetic variants that might contribute to 
complex disease. For instance, pathways can be sought whose genes are overrepresented 
amongst rare genomic variants in patients relative to controls, even if the mutated genes differ 
between subsets of patients. 
6.2.2.3 Bioinformatic analysis can help identify modifier genes for monogenic diseases 
Not only complex diseases benefit from a genome-wide approach to disease mutation analysis, 
even monogenic or oligogenic diseases can benefit from such a broad search space. These 
diseases are more amenable to linkage analysis, for which functional candidate gene 
prioritization will become less important with the widespread adoption of deep sequencing. 
However, they usually have phenotypes that are quite variable between patients, and which can 
be influenced by genetic variation in modifier genes located elsewhere on the genome. These 
modifier genes can be difficult to detect, and though suspected to be common, relatively few 
have been identified to date[32]. Bioinformatic gene function analyses can be used to prioritize 
candidate modifier genomic variants that may affect the associated disease phenotype by 
evaluating their functional relationships with primary disease genes. 
Given the large amount of phenotypic variation present in most syndromes, it is likely that 
modifier genes are common both in terms of number of genes in the genome and, for at least 
some genetic variants of modifier genes, also in terms of allele frequency in the population. For 
example, a relatively common allele of the RPGRIP1L gene has been found to function as a 
retinal phenotype modifier in several disparate ciliopathies for which retinal involvement is 
variable[33]. Other rare mutations in the same gene are also likely to function as determinants 
of retinal involvement. Interestingly, not only does this gene function as a retinal modifier in 
ciliopathies that are caused by other genes, it can itself also be a primary disease-causing gene 
for one of the ciliopathies – Joubert syndrome[34,35]. This further emphasizes the blurry 
distinction between primary disease genes and disease modifier genes[36], and strengthens the 
case for using biological relationships between genes to identify candidate disease genes 
regardless of the nature of their involvement with the disease. Once again, the genome-wide 
scope of such analyses will  necessitate the use of automated bioinformatic approaches to their 
investigation. 
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6.3 The importance of detailed phenotype characterization for genome-
wide approaches 
6.3.1 Interpreting genome-scale variation data requires detailed phenotype descriptions 
We are currently moving into an era of genetic analyses at the level of entire individual 
genomes. At this scale, we have an overview of all the genetic variation within the individual that 
can influence his or her phenotype. However, not all aspects of a patient’s phenotype will be 
involved in the disease pathology, and conversely, subtle aspects of the patient’s phenotype 
that are involved in the pathology may be overlooked. As a result, it will be necessary to 
generate as complete a view of the phenotype as possible in order to be able to interpret the 
significance of genetic variants across the entire genome. Moreover, as the phenotype is 
influenced by environment as well as genetics, it will also be highly desirable to chart the living 
environment, lifestyle and life history of patients. Only with a complete view of the phenotype 
can all the genomic variants potentially be elucidated. The main problem with such 
comprehensive data gathering is that such data will inevitably contain large amounts of 
irrelevant information in addition to the information that is pertinent to understanding the 
patient’s condition. To complicate matters further, interactions between genes and environment 
and between allelic variants of genes at different loci will further obscure the relationship 
between genotype and phenotype. For these reasons, it is currently unfeasible to map the full 
spectrum of genomic variants to their phenotypic effects in any one patient, let alone the entire 
disease phenome. Nevertheless, with sufficiently detailed phenotype descriptions, substantial 
progress can be made in this direction. 
Detailed phenotype descriptions can increase the resolution at which genetic analyses can be 
performed, which is essential as these analyses expand to encompass entire genomes. As 
previously mentioned, there are statistical limits to the ability of GWASs to identify contributory 
complex disease loci, especially when interactions are taken into account. Similar limitations will 
also apply to large-scale individual genome re-sequencing. It will therefore be of great 
importance to use phenotype descriptions that are as detailed as possible for such genome-
wide analyses, in order to minimize the conflation of different but related disease processes in 
these studies. Additionally, given the large number of genes involved in complex diseases, it is 
likely that different genes could be involved in different patients or populations. For such cases, 
subtle but consistent phenotypic differences between disease populations could reflect 
differences in their underlying disease gene complements. 
There are several ways in which phenotype descriptions that are too coarse-grained could 
obscure the underlying disease genetics of a particular disease. Firstly, broadly defined 
phenotypes may fail to distinguish between different but related phenotypes and secondly, they 
may fail to reflect phenotypic substructure. Finally, in addition to obscuring subtle differences 
between phenotypes, coarse-grained phenotyping could also obscure subtle similarities 
between phenotypes that are globally quite different from each other. 
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6.3.2 Detailed phenotype descriptions help discriminate between similar phenotypes 
With phenotype descriptions that are too broadly defined, different but related phenotypes may 
be classified as a single phenotype. In other words, different phenotypes may be lumped 
together, potentially obscuring details that could reflect important differences in their underlying 
pathobiology. This phenomenon can be illustrated by taking a closer look at some of the genetic 
underpinnings of type 2 diabetes and obesity. For instance, genetic variants associated with 
type 2 diabetes (T2D) risk can differ between obese and non-obese patients, with gene variants 
involved in insulin action being more important in obese patients while those involved in insulin 
secretion are more important in lean patients[37]. It is therefore important to distinguish between 
the two groups when phenotyping T2D patients for studies. 
Even obesity itself is a broad phenotype. Association studies on obesity have generally used 
body mass index (BMI) as a measure for obesity due to its ease of measurement. However, this 
measure (weight/height2) does not directly measure body fat content (adiposity), and it 
completely ignores fat distribution. Fat is not the only tissue type that contributes to BMI, and 
excess adipose tissue could be primarily subcutaneous or concentrated in the visceral 
region[38]. These obesity-related phenotype variants could vary in their underlying genetics. An 
example of this is provided by the familial partial lipodystrophies, genetic disorders that are 
associated with abnormal distribution of adipose tissue across the body[39,40]. Mutations in the 
peroxisome proliferator-activated receptor-γ (PPARG), a gene which has been associated with 
obesity[41], can cause familial partial lipodystrophy type 2[42,43]. PPARG is involved in 
adipocyte differentiation[44]. This is a biological function that differs from others which have also 
been associated with obesity, such as for instance hypothalamic function[45]. Therefore, 
refining the obesity phenotype description with information about fat distribution as well as fat 
content and BMI can enable more detailed bioinformatic analysis of the different aspects of 
obesity pathobiology. 
6.3.3 Detailed phenotype descriptions facilitate identification of phenome substructure 
Not only does coarse-grained phenotype definition obscure similar but distinct phenotypes, it 
can also gloss over phenotypic substructure in the disease phenome. Disease phenotypes 
frequently consist of a constellation of features or sub-phenotypes which could exist 
independently of the overall phenotype and might reflect different biological processes that are 
involved in the associated disease. For instance, Senior-Loken syndrome, which affects retina 
and kidneys, can be considered a sub-phenotype of Joubert syndrome which reproduces those 
symptoms and additionally affects the cerebellum[2]. Orofacial clefting can occur as an isolated 
feature or can co-occur with other features in more than 350 Mendelian syndromes[46]. Such 
phenome substructure can assist in disease genetic analysis (Chapter 2 and ref. [2], but 
requires modular phenotype descriptions at sufficient resolution to detect the substructure. 
There are also several syndromes which co-occur more often than expected by chance, 
suggesting related genetic processes[47]. Such co-occurring diseases can also be viewed as 
combinations of sub-phenotypes. The best known example of modular sub-phenotypes is 
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probably the endophenotype concept from neuropsychiatry[48-51]. These are subclinical traits 
of a neuropsychiatric disorder that can occur independently of it. Autism, for instance, can be 
viewed as a combination of language and communication deficits, repetitive behavior, and 
social unresponsiveness [52]. These endophenotypes are only modestly correlated (r = 0.1-
0.4)[53,54], and can segregate independently in unaffected family members[55,56]. They may 
therefore reflect underlying molecular processes more directly than the full autism 
phenotype[53,57]. Describing phenotypes such as these at lower levels of granularity enables 
these phenotypic overlaps between syndromes to be analyzed more systematically, and 
provides better starting points for the genetic analysis of these diseases. 
6.3.4 Detailed phenotype descriptions improve comparisons between diseases 
Coarse-grained phenotype descriptions not only obscure differences between similar 
phenotypes, they can also obscure similarities between different phenotypes. They can lead to 
subtle phenotypic links between apparently unrelated diseases being overlooked, which might 
obscure subtle biological relationships between the diseases. Indeed, even if the diseases are 
already known to share other features with each other, such hidden links can further expand the 
set of affected biological functions that can be ascribed to common pathological processes, 
giving further clues as to what these might be. An example of such a subtle phenotypic link 
between related diseases is anosmia, which is a common feature in ciliopathies[58]. Cilia are 
important in the functioning of sensory neurons[59], amongst which photoreceptors, inner ear 
hair cells and olfactory neurons. Therefore, impairment of these senses can potentially indicate 
cilia dysfunction. However, while vision and hearing impairment are readily identifiable 
symptoms due to the importance of these senses in normal human functioning, anosmia is a 
more subtle feature that is more easily overlooked[60]. Nevertheless, given the large number of 
genes that can cause vision or hearing impairment (http:// http://www.ncbi.nlm.nih.gov/omim/), 
the presence of anosmia as an additional symptom can be important in indicating what manner 
of molecular dysfunction underlies a disease. 
Another example is the “molar tooth sign”[61], a cerebellar and brain stem malformation 
characteristic of several ciliopathies related to Joubert syndrome[62]. Some of these ciliopathies 
– such as Nephronophthisis – have not generally been associated with such neurological 
dysfunction[63], but the presence of this feature in patients with these syndromes highlights 
their etiological links to Joubert syndrome[64]. There are undoubtedly many other subtle 
phenotypic links to be observed between diseases, but detecting commonalities such as these 
will require particularly fine-grained and comprehensive phenotype descriptions. 
6.3.5 Detailed phenotype descriptions should also include environmental information 
In addition to genetics and phenotypes, a third axis in disease analysis is environmental 
influence. It will play a more important role in diseases where genetic contribution is more 
subtle, such as in complex diseases, but could in principle be relevant for any disease. 
Therefore, though it is not really a part of the patient phenotype,  it would nevertheless be 
desirable to include as much environmental information as possible during the collection of 
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patient phenotype descriptions. However, it will be very difficult to obtain truly comprehensive 
environmental data that are on a par with the genomic or even phenotypic data, as patient life 
histories cannot be directly observed in the clinic. Nevertheless, there are still many forms of 
environmental and life history information that can be gathered using simple questionnaires or 
taken from medical records, as is being done for instance in the Personal Genome Project[65]. 
Furthermore, as with genetic and phenotypic data, some environmental information will be more 
important than others and the most prominent factors – such as lifestyle and diet – should also 
be amongst the most readily available. 
Analyzing such environmental data could be just as challenging as acquiring them. Due to the 
diversity of possible gene-to-phenotype interactions, it will probably be necessary to conduct 
such studies on specific subpopulations as different populations with different genetic 
backgrounds might respond differently to the same environmental conditions. An example of 
this are the Pima Indians from Arizona, who have a higher incidence of type 2 diabetes than 
people of European descent living under the same conditions[66]. This is not just a genetic 
effect as exemplified by the fact that Pima Indians living under different dietary and exercise 
conditions in Mexico do not have an equivalently high incidence of type 2 diabetes[66,67]. As 
different genetic backgrounds complicate the gene-environment interactions, the best approach 
to the elucidation of environmental effects is probably the investigation of phenotypically 
discordant monozygotic twins, though even they are not necessarily (epi)genetically 
identical[68,69]. Regardless of the approach taken, it is clear that genetic information alone is 
not sufficient to fully understand most disease processes, and it will be important to record as 
much environmental information as possible when phenotyping patients for disease analysis 
purposes. 
6.3.6 Formalized phenotype descriptions are necessary to exploit increasing detail 
It is clear that more detailed phenotype descriptions are going to be needed if disease genetics 
are to be investigated at the whole genome level. However, in order to fully exploit such 
phenotypic information, it will be necessary to formalize and standardize its collection and 
encoding[70-73]. This issue is discussed in more detail in Chapters 2 & 5 and will not be treated 
comprehensively here. Importantly, we show in Chapter 5 that for the purpose of bioinformatic 
phenotype analysis, systematically described disease phenotypes based on feature ontologies 
are far superior to those taken from a database that was not designed to use ontology-based 
phenotype descriptions. For bioinformatic analyses to be maximally effective, disease 
phenotypes should be comprehensively recorded in the clinic using standardized 
approaches[70,71], and stored in structured databases that use feature ontologies to describe 
disease phenotypes[74-77]. While current ontologies are generally oriented towards 
morphological features, it will be important for them to be expanded to include as much 
information as possible about the phenotypic effects of disease mutations, including the less 
obvious molecular phenotypes[78]. 
Properly designed feature ontologies, coupled with comprehensive phenotype annotation, can 
enable disease phenotypes to be systematically described at the level of detail required to 
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capture the nuances both within and between diseases. For monogenic diseases in which 
individual rare mutations exert a large effect on the phenotype, it is easier to identify the set of 
phenotypic features that are affected by the mutation. Nevertheless, even such monogenic 
diseases are rarely uniform in their phenotype, frequently due to the effects of modifier allelic 
variants at other loci[32]. For complex diseases this situation is compounded even further, as 
the disease process is probably primarily due to this genetic background of modifier genes. All 
this genetic variation can be expected to influence the phenotype in different and potentially 
subtle ways, necessitating such detailed descriptions. The formalization of disease phenotype 
data collection and recording will therefore be required to describe them in sufficient detail to 
fully interpret genome-wide genetic data. 
 
6.4 The Future: Comprehensive elucidation of disease processes 
The role of bioinformatics in disease research is set to grow even larger in the future, as more 
and more data become available that need to be correlated with each other. Although the nature 
of the analyses will change to adapt to the new circumstances, the general approaches to 
disease bioinformatics outlined in Chapter 2 should remain broadly valid. The search for 
functional relationships between candidate and known disease genes for phenotypically related 
diseases – based on the premise that diseases are genetically coherent – should remain a 
fruitful avenue of research. However, the scale and scope of these analyses will need to be 
increased if disease pathobiology is to be understood in its entirety. 
6.4.1 Diseases are genetically coherent 
Genetic diseases are caused by disruptions in biological processes, either developmental or 
homeostatic, in which multiple genes can partake. Such processes could potentially be 
disrupted by mutations in a single critical gene, but could also be disrupted by milder mutations 
in multiple less critical genes, whose functioning could in turn potentially be affected by 
environmental influences. This biological process-oriented view of genetic diseases is further 
strengthened by the phenomenon of genetically heterogeneous diseases, that can be caused 
by mutations in any one of several different genes. Such sets of genes frequently constitute 
proteins in the same complex, such as Fanconi Anemia[79], Hermansky-Pudlak syndrome[80] 
and Usher syndrome[81]. Alternatively they could be genes involved in the same metabolic 
pathway, such as Congenital Disorders of Glycosylation[82]. They could also be genes involved 
in the functioning of the same subcellular organelle, such as the cilia in Bardet-Biedel 
syndrome[83]. 
The fact that even complex diseases can be caused by mutations in single genes[84-86], and 
the identification of common pathways uniting complex trait candidate genes[25,27,38], indicate 
that even complex diseases are genetically coherent. This means that bioinformatic analysis of 
gene functional relationships should also be a productive approach to their investigation. It also 
argues for the continued investigation of rare Mendelian diseases despite the current interest in 
complex diseases, as they are more suitable for investigating the underlying biology due to their 
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genetic simplicity[84-87]. Given the ever-increasing quantities of genome-wide genetic data and 
the rising interest in more sophisticated phenotypic descriptions, it should eventually become 
feasible to fully elucidate disease pathobiology, identifying all the biological processes involved. 
6.4.2 Our current knowledge of human biology is limited 
However, our current knowledge of human functional biology is limited and much more needs to 
be learned before we will be capable of elucidating all disease processes. There are still a large 
number of uncharacterized protein-coding genes (only 11234 proteins with manually curated 
Gene Ontology annotation as of GOA release 73.0, April 2009; 
http://www.ebi.ac.uk/GOA/human_release.html), some of which are undoubtedly involved in as 
yet unidentified molecular processes. The last few years have witnessed the discovery of 
previously unrecognized biological processes such as RNA interference[88] and the diversity of 
histone modifications[89]. They have also led to the realization that gene regulation plays an 
unexpectedly large role in human biology. The majority of evolutionarily conserved human DNA 
base pairs do not code for proteins[90], and recent genome-wide association studies have 
identified disease-associated variants primarily in non-coding intronic and intergenic regions[24]. 
Chromatin immuno-precipitation (ChIP) studies of transcription factors have similarly identified 
vast numbers of intronic and intergenic binding sites[91], which may correspond to long-range 
transcription regulatory elements such as enhancers and insulators[92], and could be involved 
in disease[93]. It is now realized that the majority of the genome is transcribed[94], and several 
new classes of non-coding RNA species have been identified[95]. These novel non-coding 
RNAs are generally involved in the regulation of transcription through epigenetic means[96] or 
the regulation of translation[97], and can be involved in disease[98,99]. Repetitive DNA 
elements such as transposons, previously thought to be purely parasitic DNA, are now 
recognized to also have roles in gene regulation[100-102]. Additionally, disease phenotypes can 
be caused by non-coding tandem repeat expansions[103] or repeat contractions[104], 
mechanisms which probably also affect local chromatin organization. It is a safe bet that yet 
more unexpected biological phenomena remain to be discovered which may be involved in 
disease processes. 
6.4.3 New data types and approaches are becoming available to help remedy this 
Given these biological complexities, the vast number of non-coding genomic variants that will be 
uncovered[13-16] will be difficult to interpret. Happily there are also novel types of functional 
genomic data being produced that can aid in this process (Table 1), in addition to ever 
increasing quantities of the more traditional kinds (Chapter 2). 
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Table 1: Emerging data types for bioinformatic candidate disease gene analyses. 
Data type 
class Data type Description Comments 
Population 
genetic 
sequence 
data 
Population genetics can help distinguish common 
from rare variants in patient DNA. 
Population genetic variation data such 
as Single Nucleotide Polymorphisms 
(SNPs) and Copy Number 
Polymorphisms (CNPs) have been 
available for some time, but increasing 
quantities will help build more 
complete pictures of population 
variation. 
Evolutionary 
sequence 
conservation 
Can be used to identify functionally important but 
unannotated regions in the genome. The phylogenetic 
extent of conservation can give further clues about the 
possible functions of the regions. 
Interpreting evolutionarily conserved 
but unannotated genomic regions 
remains challenging. Additionally, not 
all functionally important elements are 
necessarily evolutionarily conserved. 
Evolutionary 
history 
Evolutionary 
mutant 
models 
Some organisms have evolved features which 
correspond to disease states in humans, such as 
reduced eyes (microphthalmia) in cave-dwelling fish. 
Comparing their genomes with those of closely related 
species without those features can give insights into 
the processes involved, which can in turn aid in the 
investigation of human diseases[105,106]. 
The mechanisms by which these 
phenotypes are generated in these 
other species might differ from how 
they occur in patients. However, they 
could still give insights into the 
processes involved. 
Genetical 
genomics 
Similar to Quantitative Trait Loci (QTLs), using 
molecular phenotypes instead of anatomical 
phenotypes[107]. Used to identify genomic variants 
that correlate with the magnitude of the molecular trait. 
Particularly popular for investigating 
transcriptional regulatory relationships 
by using gene expression levels as 
the quantitative traits. 
Chromatin 
Immuno-
Precipitation 
(ChIP) data 
Chromatin Immuno-Precipitation can be followed by 
either hybridization to tiling arrays (ChIP-chip) or high 
throughput sequencing (ChIP-seq) to identify DNA 
sequences bound to target proteins. Can be used for 
genome-wide identification of transcription factor 
binding sites and histone modifications. 
The newer ChIP-seq technology is 
more sensitive and specific than ChIP-
chip[108]. Consequently it is currently 
replacing the older technology. 
Functional 
Genomics 
High 
throughput 
RNA 
sequencing 
(RNA-seq) 
Used to determine cellular RNA expression levels. In 
contrast to microarrays, it does not depend on  pre-
selected probes, so it can also detect novel 
unsuspected RNAs. It also does not suffer from a 
background signal and has a larger dynamic range 
than microarrays, enabling it to detect lower 
abundance transcripts than microarrays[109,110]. 
A disadvantage of current high 
throughput sequencing technologies is 
that the individual sequence reads are 
short which can cause problems when 
mapping them to the genome. 
Gene Types 
Non-coding 
RNAs 
(ncRNAs) 
Non-coding RNAs play a larger role than previously 
expected in gene regulation[95]. Databases exist that 
catalog ncRNAs[111-115]. 
There are several different classes of 
ncRNAs, with several different 
functions[95]. 
Phenotype Phenotype 
There are several ongoing projects to systematically 
catalog human disease phenotypes using structured 
feature vocabularies[76,116]. These will enable 
systematic and comprehensive analyses of 
phenotypic relationships between diseases. 
Detailed phenotype descriptions are 
important to guide the interpretation of 
all previously mentioned functional 
data types. Coarse-grained phenotype 
classification could lead to the 
conflation of different biological 
processes which actually have distinct 
phenotypic effects[38]. 
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More and more genomic data are becoming available for more and more individuals, increasing 
the viability of population genetics-based approaches to disease analysis. SNP frequencies can 
be analyzed for evidence of either purifying or positive selection[29,30,117-119]. Such analyses 
are facilitated by the recent HAPMAP project, which mapped the haplotype structure of different 
populations at a genome-wide scale and identifying common genetic variants[19] . They will be 
further facilitated by the international 1000 genomes project[120], which will enable rarer alleles 
to be characterized down to a frequency of about 1% (http://www.1000genomes.org/). Given 
their population-based nature, these analyses will be more suited to the identification of genetic 
variants involved in complex diseases or functioning as penetrance or expressivity modifiers of 
Mendelian diseases, rather than the identification of primary Mendelian disease genes. 
Nevertheless, such insights will be crucial if disease processes are to be understood in their 
entirety. 
Expanding beyond the human species, the ever-increasing number of species whose genomes 
have been sequenced enables far more extensive use of evolutionary information than 
employed in this thesis. Evolutionary sequence conservation of genomic regions enables the 
identification of functional non-protein coding elements[121]. The larger numbers of sequenced 
vertebrate genomes enables better detection of the extent to which such elements are 
evolutionarily conserved[122], which might in turn give insights into the functioning of the 
elements. For instance, enhancers involved in the regulation of mammary gland development 
can be expected to be restricted to the mammalian lineage. Another potential application of 
evolutionary analysis to disease elucidation is the use of evolutionary mutant models. These are 
species that have evolved traits that mimic human genetic disorders[105,106]. For instance, 
there are species of Antarctic ice fish which lack hemoglobin and red blood cells. Comparing 
their genomes with those of related species that do have red blood cells could give further 
insights into red blood cell biology and anemic diseases[105]. There are many other examples 
of evolutionary mutant models involving different species[105,106], and the approach is also 
applicable to breeds of domestic animals such as dogs[123,124]. Unfortunately, the lack of 
genome sequences for most such species and breeds is a current limitation to this 
approach[106]. 
Apart from new evolutionary approaches, new functional approaches are becoming increasingly 
viable. One approach that has seen a recent rise in interest is genetical genomics, in which 
genetic mapping and functional genomics are combined to identify genomic variants that are 
associated with variation in functional genomics data[107]. The approach is analogous to 
quantitative trait mapping, except that the traits analyzed are molecular rather than physical. For 
instance, the expression levels of genes or the concentrations of metabolites could be used as 
phenotypic traits and correlated with specific genomic variants. The use of gene expression 
levels as quantitative traits is particularly popular, and this sub-field of genetical genomics 
(expression genetics) is used to investigate gene expression regulatory relationships between 
and within genomic loci at a genome-wide scale[125]. 
In addition to novel analytical approaches,  disease analysis can also look forward to ever-
increasing amounts of novel kinds of data. Given the recent insights into the role of epigenetics 
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and non-coding RNA in human biology, chromatin immune-precipitation and non-coding RNA 
data are logical data types to include in future analyses. Chromatin immuno-precipitation 
followed by sequencing (ChIP-seq)[126] can be used to identify  the locations of various 
chromatin modifications[127], as well as transcription factor binding sites, across the whole 
genome in a given cell type. This technology succeeds a similar approach in which microarrays 
were used instead of sequencing to identify the relevant DNA sequences[128]. Datasets such 
as these are collected in expression databases such as the Gene Expression 
Omnibus(http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (http://www.ebi.ac.uk/microarray-
as/ae/). Non-coding RNA data are also available from several databases[111-115]. 
There are currently several existing candidate disease gene prioritization tools, as discussed in 
Chapter 2. Future disease gene prioritization will equally require help from computational tools, 
which will need to be take advantage of these novel data sources. The general approaches 
outlined in Chapters 1 & 2 – identifying functional links between candidate disease genes and 
known ones, identifying common functional themes between various disease-associated 
genomic loci , and identifying candidate genes with functional links to specific aspects of the 
disease phenotype – will still remain relevant in the future. However, they will need to be 
modified to accommodate novel data and their focus will need to shift from disease loci to the 
whole genome. Some recent candidate disease gene prioritization approaches already prioritize 
candidate disease genes for complex diseases at a genome-wide scale[22,23,129,130]. 
Existing tools such as the Prioritizer[7] and ENDEAVOUR[8] computer programs can also be 
applied to genome-scale candidate disease gene prioritization[131-133]. Prioritizer is a 
computer program that uses functional links between genes at different disease-associated loci 
to prioritize candidate disease genes, and this tool has also already been adapted for use in 
complex disease loci from genome-wide association studies (GWASs) [21]. It uses a gene 
network which connects genes to each other based on various kinds of functional relationships. 
The links in this network could be expanded using novel kinds of functional genomics data. 
Similarly, ENDEAVOUR already uses several different kinds of functional genomics data to 
identify relationships between known disease genes and candidate disease genes. It is currently 
used primarily for prioritizing positional candidate disease genes, but integrating yet more kinds 
of data into this approach should further increase both its sensitivity and its specificity, 
increasing its performance when applied to the whole genome. The same applies for other 
existing candidate disease gene prioritization tools, such as GenTrepid[134] for instance. 
However, while these existing tools exploit gene functional data extensively, further 
developments in the application of phenotype data will still be required if their value is to be 
maximized. 
6.4.4 From disease genes to disease pathobiology and the elucidation of the disease 
phenome 
The past two decades have seen an explosion in the number of identified disease genes from 
about 100 to over 2000[11], particularly with the advent of the post-genomic era. This trend is 
set to continue in the near future as deep sequencing becomes more widespread. These 
developments will change the nature of disease genetics as more and more disease mutations 
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are identified. In particular, the focus will eventually shift from the identification of disease genes 
to the elucidation of disease pathobiology. This is not going to be as simple as creating a 
catalog of genes linked to cognate diseases, as disease pathobiology is far more complicated 
than this (Figure 1). The concept of disease genes is relatively simplistic as diseases are 
affected by genetic mutation at scales ranging from the sub-gene level to the whole 
chromosome level. Similarly, the concept of disease is relatively simplistic as there is much 
variation within, and overlap between, disease phenotypes. 
It is already clear that one gene can underlie disparate diseases, and that one disease can be 
caused by mutations in several different genes (Chapter 2 and [1,135]). However, even this bi-
partite network-based view of disease genetics is a rather over-simplified representation of 
reality. Diseases are not uniform entities, and neither are genes. Diseases share features with 
each other, to various degrees. Even diseases caused by the same mutation can be 
phenotypically disparate[136]. At the same, different mutations in the same gene  can affect 
different aspects of its functioning[1]. Mutations affecting a gene’s functioning need not even lie 
within the gene’s transcripts, or even within its genomic region[93]. 
Mutations in protein-coding disease genes can disrupt their function, but they could also disrupt 
only part of the genes’ function (e.g. mutations in the DNA-binding domain or trans-activation 
domain of p63 causing EEC and AEC syndromes respectively[137]), or disrupt their function in 
only a subset of cell types or developmental history (such as mutations in a SHH enhancer 
disrupting its expression exclusively in the developing limb bud and causing isolated preaxial 
polydactyly[138]). They could disrupt function by either reducing it or increasing it 
inappropriately, with potentially different phenotypic consequences. This is illustrated by 
mutations in the RET gene, which cause Hirschsprung disease when they are inactivating and 
Multiple Endocrine Neoplasia 2 (MEN2) when they are activating[139]. Function modulation 
could be the result of transcriptional or translational dosage modification, or of the modulation of 
molecular functions such as enzymatic activity or protein responsiveness to regulation – e.g. the 
constitutive activation of signal transducing receptors[140]. Protein dosage modulation could be 
realized by mutations in regulatory regions[93], splice sites[141] (which can also result in 
modified proteins) or by copy number variation[142]. In addition to modulating native function, 
mutations could even lead to unusual protein behavior that is disruptive of other cellular 
processes (toxic gain of function mutations), as in several neuronal and muscular diseases 
[143-145]. 
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Figure 1: The complexity of the disease process, viewed as a set of interacting networks (this figure only 
illustrates the overall concept and is far from exhaustive). Individual genomes contain large sets of DNA 
variants that overlap between individuals and can influence biological processes. These biological 
processes can be seen as networks of linked components in which both the components and the links 
can be of many different types, such as transcription or translation regulation, protein-protein interactions, 
metabolic fluxes, etc. These networks can also vary according to tissue or cell type, and can occur within 
or between them (not illustrated). These interacting biological processes give rise to the final phenotype, 
which can be viewed as a combination of phenotypic features. Such features can be used to link different 
phenotypes into a phenotype network. Environmental influences, which can be correlated to each other, 
can modulate biological processes or affect the underlying DNA itself through for instance mutagenesis or 
epigenetic reprogramming. Conversely the phenotype, which includes behavior, can influence 
environmental factors—such as dieting in order to lose weight, increasing exposure to UV radiation for 
cosmetic reasons, or increasing exposure to toxins such as alcohol or nicotine. An individual’s phenotype 
can also influence the environment of their offspring, such as for instance the intra-uterine environment. 
 
Different mutations in the same gene could have completely different effects on organismal 
biology depending on which aspects of which (sub)functions are disrupted, and on the nature of 
the disruption, such as in laminopathies[146]. They could lead to a dominant or recessive 
pattern of inheritance depending on the mutation; for instance, GJB2 (OMIM: 121011) has both 
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recessively and dominantly inheriting mutations that cause hearing loss[147]. Disease mutations 
need not affect the functioning of just one gene, either. Chromosomal deletions and duplications 
could affect multiple genes[148-151], as could disorders of imprinting[136,152]. Mutations 
affecting gene function need not even be genetic; they can also be epigenetic, such as the 
heritable MLH1 epimutation in Hereditary Non-Polyposis Colorectal Cancer[153]. Finally, 
diseases can probably even be caused, or at least influenced, by mismatches between 
epigenetic programming and environmental conditions as is postulated by the thrifty phenotype 
hypothesis for Type 2 Diabetes[154,155]. 
Given the myriad ways in which mutations can affect gene functions, the vast numbers of genes 
whose functioning can be altered indirectly by the malfunctioning of other genes, and the vast 
amount of genetic variation in the population, disease elucidation is going to require more 
sophisticated views of the relationships between genotypes and phenotypes. Such increased 
sophistication will need to be applied not just to disease genetics, but also to disease 
phenotypes. As already discussed previously, phenotypic similarities and differences between 
diseases can reflect similarities and differences in their underlying molecular genetics, and 
these phenotypic features can be subtle and non-obvious. Every patient’s phenotype would 
ideally be described as an individual collection of features rather than being assigned a disease 
label. Given the ongoing transition from a single canonical genome sequence to the sequencing 
of individual genomes, it is important that disease phenotype descriptions keep pace and 
undergo a similar transition, from single canonical descriptions of the disease phenotype to the 
separate descriptions of individual patient phenotypes. 
If patient genomes are also sequenced, individual mappings of genotypes to phenotypes can be 
created. If this is done for many patients with disparate diseases, a large collection of genotype-
to-phenotype mappings can be assembled. Each phenotype can be seen as a node in a 
network linked through shared features. Each gene can be linked to other genes through a vast 
selection of different functional interaction types. From such a data set, phenotypic links can be 
correlated with various kinds and combinations of genetic links in order to identify biological 
processes that lead to specific feature sets when disrupted (Figure 1). Mapping such shared 
features to genomic variants could also lead to the identification of novel links between different 
biological processes. A glimpse of this is given by the recent identification of the importance of 
hypothalamic function in obesity etiology[25,38], but can be extended much further by 
combining phenome-wide feature-based phenotype analyses with genome-wide variation 
analyses. Environmental parameters can be included in such analyses, either by using them to 
categorize gene-phenotype relationships according to different environments or by correlating 
them directly with genetic and phenotypic variation. 
As the genetic variation in the human variome[156-158] is charted in ever more detail, the 
recording of associated phenotypic variation in the human phenome[159] will need to keep 
pace. Otherwise, in contrast to historical disease research where incomplete genetic 
understanding has been the limiting factor, in the future it will be incomplete phenotypic 
understanding that risks becoming the limiting factor in disease investigation. 
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Summary 
 
Genetic diseases are caused by mutations that disrupt the functioning of genes. These genes 
do not function independently of each other, they work together to carry out various tasks in the 
body and its cells. Therefore, it is not surprising that mutations in different genes can cause the 
same disease, or different diseases that resemble each other in their signs and symptoms. This 
knowledge is used in genetic research to guide the search for genes which might be involved in 
various genetic diseases. In the past, it has been applied individually to specific diseases by 
medical genetic researchers working on those diseases. Recently however, technological 
advances in both laboratory technology and computers have enabled large scale analyses to be 
conducted on the whole set of known diseases – the human disease phenome – at once. 
These new laboratory techniques enable large quantities of data to be generated for large 
numbers of genes, and much of these data are stored in electronic form in large databases. 
Microarrays can be used to measure the levels of gene expression for all genes at once in the 
same biological sample. Mass spectrometry enables the levels of proteins and cellular 
chemicals to be measured on a large scale, and can also be used to identify which proteins 
interact with each other. These data are not only being generated for human samples, but also 
for many other species that are widely used in laboratories for medical and biological research 
such as mice, rats, fruit flies, worms and yeast. Whole genome sequences are also available for 
these species, and more and more are becoming available each year. More and more data 
about the genetic variation between people in the human population are being generated, such 
as for example between people who have a certain disease and people who don’t. These large 
data sets are a treasure trove of information, but their sheer size makes them difficult or 
impossible to analyze by hand. Instead, computer programs need to be used to automatically 
sift through these data sets to extract as much useful information as possible. This is where 
Bioinformatics comes in. Bioinformatics is the application of computational processing 
techniques to biological data. It enables such large data sets to be effectively exploited, and can 
be used to assist in disease genetics research. It has become particularly relevant for this 
purpose in the last decade or so, since the advent of microarray and other high-throughput 
techniques, as well as the completion of several whole genome sequences, enabled the 
widespread generation of large biological data sets. 
There are several different techniques that can be used in the search for disease genes, which 
fall into two general categories – genetic mapping and functional candidate gene approaches. In 
genetic mapping, genetic markers are used to correlate the occurrence of particular diseases 
with genetic variants in particular regions of the genome. This can be done by tracing the 
disease through family trees and looking for specific genetic variants that occur only those 
members of the family with the disease, a technique called linkage mapping. This approach is 
effective for finding genomic regions associated with rare disease mutations that have a strong 
impact on the disease phenotype, such as in Mendelian diseases (these are diseases that are 
inherited according to Mendelian principles, and include most rare genetic diseases). 
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Alternatively, large numbers of patients and non-patients can be taken from the population at 
large, and genomic regions sought which have variants that occur more frequently in patients 
than in non-patients. This approach, called association mapping, is more suited to finding 
common genomic variants that are involved in common diseases such as type 2 diabetes or 
coronary heart disease. Both approaches result in disease-associated genomic regions that 
could contain multiple genes.  After localizing a disease gene to a particular genomic region, the 
genes within that locus can be sequenced to identify the disease mutations, an approach 
termed positional cloning. This is primarily effective in combination with linkage mapping, as 
association study population sizes are large and complex disease mutations usually only occur 
in subsets of patients. Historically, most disease genes have been identified in Mendelian 
diseases using linkage mapping followed by positional cloning. A major limitation of this 
approach has been the expensive and time consuming sequencing of the positional candidate 
disease genes within the linkage-mapped genomic loci, particularly since this approach can 
result in loci with hundreds of genes. 
In contrast to genetic mapping which only looks at DNA variants, candidate gene approaches try 
to identify potential disease genes based on their biology. Given a certain amount of knowledge 
about the biological nature of the disease process, genes are sought that are involved in those 
disease-associated biological processes. They are then sequenced for mutations. Candidate 
gene approaches are based on the premise that genes causing the same or similar disease are 
functionally related to each other. This approach has historically been much less successful 
than genetic mapping, primarily due to the limitations in our knowledge of human biology, and 
until recently even which genes are present in the human genome. However, the completion of 
the human genome along with the recent deluge of gene functional data has reinvigorated this 
approach and made it vastly more productive. It has also introduced the need for Bioinformatics 
to process these large amounts of data. In response, several Bioinformatic tools have been 
developed to aid in disease gene investigation. They are generally used to prioritize positional 
candidate disease genes lying in genomic loci that have been identified using linkage mapping. 
They do this by attempting to find gene functional data that links them to other genes associated 
with the same disease, or more directly to the disease itself. In the future, as DNA sequencing 
becomes much cheaper and quicker, it will be necessary for such prioritization tools to prioritize 
candidate disease genes at the genome-wide level. 
In this thesis we investigate the basic premise underlying all these present and future candidate 
disease gene prioritization tools, namely that similar or identical diseases are caused by 
mutations in functionally related genes. Instead of building a specific tool, we investigate the 
degree to which different kinds of gene functional relationships reflect shared disease 
pathology. We also investigate the degree to which similar disease phenotypes reflect the 
disruption of shared disease processes. These findings can help guide the development of both 
candidate disease gene prioritization tools and disease phenotype databases, to increase their 
utility to future genetic disease research. 
We start by giving an overview of the relationships between disease genes and disease 
phenotypes in chapters 1 & 2. Chapter 1 gives a general overview of the process of disease 
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gene identification and the role of Bioinformatics in it. Chapter 2 expands on this, emphasizing 
the modular nature of genetic diseases. Using empirical knowledge, we explain that genetic 
diseases are modular at both the genetic and the phenotypic level. Such modularity enhances 
the degree to which phenotypic similarity can be used to infer genetic similarity by highlighting 
gene functional modules. In this chapter we additionally give an overview of existing 
Bioinformatic approaches to candidate disease gene prioritization. 
In chapter 3 we begin the investigation of the degree to which diseases with the same or similar 
phenotypes are caused by mutations in functionally related genes. In this chapter we use 
protein-protein interactions as our measure of gene functional relationships, as it is one of the 
strongest indicators of functional relatedness between two proteins. We also investigate 
positional candidate disease genes for genetically heterogeneous diseases, as these represent 
disease-causing mutations with very similar, clinically indistinguishable phenotypes. We show 
that protein-protein interactions are indeed enriched between disease genes, and positional 
candidate disease genes interacting at the protein level with known disease genes are ten times 
more likely to be involved in the same disease than their neighboring positional candidates. 
Interestingly, this holds true for protein-protein interaction data from other species as well, which 
greatly increases the amount of data that can be used for this purpose. However, we also find 
that literature-derived human protein-protein interactions are strongly biased toward known 
disease genes and should therefore be used with caution when prioritizing novel candidate 
disease genes. 
In chapter 4 we investigate positional candidate disease gene prioritization using another kind of 
functional relationship between genes, namely coordinated expression (co-expression). In 
contrast to the protein-protein interaction data investigated in chapter 3, co-expression data are 
far more abundant and comprehensive. However, they are also less powerful at identifying 
functional relationships between genes than protein-protein interactions. Therefore, we 
investigate whether utilizing evolutionary conservation can increase the value of co-expression 
data for candidate disease gene prioritization. Once again we use genetically heterogeneous 
diseases to get sets of disease genes that lead to virtually identical phenotypes when mutated. 
We show that co-expression is higher between genes causing the same disease than for other 
genes, and that this effect is strengthened by exploiting evolutionary conservation of co-
expression. We further show that such evolutionarily conserved gene co-expression can be 
used to improve candidate disease gene prioritization. 
In chapter 5 we turn our attention from disease genes to disease phenotypes. Having shown 
that genes causing virtually identical disease phenotypes tend to be functionally related, we 
investigate whether this phenomenon extends beyond identical phenotypes to overlapping but 
non-identical phenotypes. In order to do this, disease phenotypes need to be described in a 
systematic manner that can enable quantitative phenotypic overlap estimation. This has 
historically been done using text mining of free text phenotype descriptions, but this approach 
does not result in systematic phenotype descriptions due to the limitations of text mining. There 
are several databases that systematically annotate disease phenotypes with phenotypic 
features, but is not clear how useful they will be for such disease phenome analyses. In this 
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chapter we confirm that the relationship between similar phenotypes and similar molecular 
genetics does indeed extend to separate but overlapping disease phenotypes. We additionally 
identify several database properties that influence the genetic coherence of systematically 
determined phenotype clusters. We find that both deep trait hierarchies and the use of trait 
frequency estimates can improve the biological coherence of phenotypic disease clusters. 
Contrary to previous studies we find that overall disease phenotypic similarity is more important 
for identifying genetic relationships between diseases than is the sharing of specific rare traits. 
The contrary findings of previous studies were due to the fact that they were based on 
incompletely described disease phenotypes generated using text mining. Above all, we highlight 
the importance of complete and systematic disease phenotype annotation, and emphasize the 
need to pay more attention to this aspect of disease research in the future. 
We conclude in chapter 6 with a look into the future of the field, and the importance of 
phenotype-guided bioinformatic analyses therein. Due to the advent of new sequencing 
technologies, this field is going to change rapidly over the coming years. Positional candidate 
disease gene prioritization is becoming less relevant due to the ability to sequence entire 
candidate loci and later even whole genomes relatively cheaply and quickly. However, there will 
also be new challenges, such as making sense of the large number of mutations and genetic 
variants such high throughput approaches uncover, and identifying what their contributions are 
to the disease process. In short, the role of Bioinformatics in genetic disease research is going 
to remain large in the future, probably even larger than it is today. As we have shown, its utility 
will depend on good phenotype databases as well as more gene functional data. Most 
importantly however, the fundamental premise behind these Bioinformatic candidate gene 
approaches – namely that phenotypically similar diseases are related at the genetic level as well 
– is a sound one, as we have explicitly demonstrated in this thesis. 
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Genetische ziektes worden veroorzaakt door mutaties die de werking van genen verstoren. 
Genen werken niet onafhankelijk van elkaar, maar werken eerder samen met elkaar om de 
verscheidene biologische functies van het lichaam te bewerkstelligen. Het moet dus als geen 
verassing komen dat mutaties in verschillende genen toch tot dezelfde ziektes kunnen leiden, of 
tot ziektes die uiterlijk sterk op elkaar lijken. Deze kennis wordt gebruikt in onderzoek naar 
genetische ziektes om de zoektocht naar de onderliggende genen te informeren. In het verleden 
werd dit afzonderlijk toegepast op individule ziektes. Sinds kort hebben technologische 
ontwikkelingen daar echter verandering in gebracht, want tegenwoordig is het mogelijk om zulke 
analyses op de totale set van ziektes – het menselijk ziektephenoom – in één keer toe te 
passen. 
Deze nieuwe laboratorium technieken leveren grote hoeveelheden data op over grote aantallen 
genen, waarvan veel in grote electronische databanken opgeslagen ligt. Microarrays kuunen 
gebruikt worden om genexpressie te meten voor alle genen in een biologisch monster in één 
keer te meten. Massa spectrometrie stelt ons in staat de niveau’s van eiwitten of chemische 
stoffen op grote schaal te meten, en kan bovendien ook gebruikt worden om physieke 
interacties tussen eiwitten te detecteren. Deze data worden niet alleen vergaard voor menselijk 
materiaal, mmar ook voor andere veelgebruikte laboratorium dieren zoals muizen, ratten, 
fruitvliegjes, wormen en gist. De genoomsequenties van al deze soorten zijn nu beschikbaar, en 
elk jaar komen er steeds meer genoomsequenties uit. Ook worden er meer data gegenereerd 
over de genetische variatie in menselijke populaties, waaronder bijvoorbeeld de verschillen 
tussen mensen met of zonder een bepaalde ziekte. Zulke grote datasets zijn moeilijk met de 
hand te analyseren, en vereisen de hulp van computerprogramma’s. Hiertoe dient de 
bioinformatica. Bioinformatica omvat het toepassen van computationele algoritmes om 
biologische data te analyseren. Het maakt het mogelijk om zulke grote datasets te verwerken, 
en is vooral de laatste tijd – met de opkomst van de eerdergenoemde grootschalige technieken 
– erg waardevol gebleken voor medisch onderzoek. 
Er zijn meerdere manieren om naar ziektegenen te speuren, maar ze vallen in het algemeen 
onder twee noemers – genetische mapping en kandidaatgen aanpakken. Bij genetische 
mapping worden specifieke genetische varianten op specifieke genomische gebieden 
gecorreleerd met het voorkomen van bepaalde ziektes. Dit kan gedaan worden door ziektes in 
families door de generaties te traceren, om genetische varianten te zoeken die alleen 
voorkomen in patiënten en niet in gezonde familieleden. Deze techniek heet “linkage mapping” 
en is vooral geschikt om zeldzame ziektemutaties op te sporen die een grote effect hebben op 
het ziektephenotype, zoals bij Mendeliaanse ziektes (dit zijn ziektes die overerven volgens de 
Mendeliaanse overervingswetten). Een alternatieve genetische mapping aanpak zijn de 
zogeheten associatiestudies. In deze aanpak worden genetische varianten gezocht die vaker in 
patiënten voorkomen dan in mensen zonder de relevante ziekte. Voor deze aanpak zijn grote 
aantallen mensen nodig om statistisch significante resultaten te krijgen. Vanwege deze vereiste 
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zijn associatiestudies vooral geschikt om veel voorkomende genetische varianten te zoeken die 
betrokken zijn bij veel voorkomende ziektes, zoals bijvoorbeeld type 2 diabetes of gevoeligheid 
voor hartinfarcten. Allebei deze aanpakken resulteren in het identificeren van ziekte-
gerelateerde genomische gebieden (of loci) die mmerdere genen kunnen bevatten. Deze 
gebieden moeten vervolgens ge-sequenced worden om de ziektemutatie te vinden, een aanpak 
die “positional cloning” heet. In het verleden zijn de meeste ziektegenen gevonden voor 
Mendelaanse ziektes door middel van linkage mapping gevolgd door positional cloning. Echter, 
een nadeel van deze aanpak is dat het sequencen van genen in die loci duur en tijdrovend kan 
zijn, vooraal als er honderden genen in liggen. 
In tegenstelling tot genetische mapping waarbij alleen naar DNA varianten gekeken wordt, 
proberen kandidaatgen aanpakken mogelijke ziektegenen te identificeren aand de hand van 
hun biologie. Als er wat bekend is over de biologie van het ziekteproces kan deze kennis 
gebruikt worden om genen te zoeken die ermee te maken hebben. Deze worden dan 
gecontroleerd op mutaties in patiënten. Kandidaatgen aanpakken zijn wel gebaseerd op de 
aanname dat genen die bij eenzelfde ziekte betrokken zijn ook iets met elkaar te maken 
hebben. In het verleden kende deze aanpak weinig succes, grotendeels door gebrek aan 
biologische kennis over menselijke genen. Echter, door de recente technologische 
ontwikkelingen en bijkomende grote hoeveelheden data wordt deze aanpak steeds 
interessanter en productiever, al heeft het ook een noodzaak voor bioinformatica met zich 
meegebracht. Als antwoord hierop zijn er de laatste tijd een aantal bioinformatische tools 
ontwikkeld om kandidaat ziektegen prioritering op grote schaal mogelijk te maken, veelal in 
genomische gebieden die door linkage mapping bepaald zijn. Ze werken door functionele 
verbanden tussen kandidaat ziektegenen onderling te identificeren, of door ze direct aan de 
ziekte te koppelen. Zulke tools zullen in de toekomst ook op genoom-schaal moeten kunnen 
werken, aangezien vooruitgangen in de techniek het mogelijk zullen maken de volledige 
genomen van patiënten te sequencen. 
In dit proefschrift onderzochten wij de grondvesten waarop al deze huidige en toekomstige 
kandidaat ziektegen prioritieringstools gebaseerd zijn, namelijk dat ziektes die op elkaar lijken 
veroorzaakt worden door mutaties in genen die met elkaar te maken hebben. In plaats van zelf 
een tool te bouwen hebben wij onderzocht in hoeverre verschillende typen functionele 
verbanden tussen ziektegenen hun betrokkenheid bij dezelfde ziekteprocessen weerspiegelen. 
We zochten ook uit in welke mate op elkaar lijkende phenotypen een gezamenlijke 
onderliggende ziekteproces weerspiegelen. Deze bevindingen kunnen gebruikt worden om 
zowel kandidaatgen prioritieringstools als ziektephenotype databases te verbeteren. 
In hoofdstukken 1 & 2 beginnen we met een overzicht van de relaties tussen genen en 
ziektephenotypen. Hoofdstuk 1 geeft een algemeen overzicht van het proces van ziektegen 
identificatie en de rol van bioinformatica daarin. Hoofdstuk 2 gaat hier verder op in, en legt de 
nadruk op de modulariteit van genetische ziektes. Aan de hand van empirische kennis laten we 
zien hoe genetische ziektes zowel op genetisch als op phenotypisch niveau modulair zijn. Zulke 
modulariteit vergroot de mate waarin phenotypische similariteit gebruikt kan worden om 
genetische verbanden te identificeren door gezamenlijke functioneel genetische modules aan te 
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duiden. In dit hoofdstuk geven we bovendien een overzicht van bestaande bioinformatica 
aanpakken voor kandidaatgen prioritering. 
In hoofdstuk 3 beginnen we met het onderzoek naar de mate waarin genetische ziektes met 
gelijke of op elkaar lijkende phenotypen veroorzaakt worden door mutaties in functioneel 
gerelateerde genen. In dit hoofdstuk gebruiken we fysieke eiwit-eiwit interacties als maat voor 
functioneel verwantschap aangezien het één van de sterkste indicaties is dat ze iets met elkaar 
te maken hebben. We gebruiken ook ziektegenen van genetisch heterogene ziektes aangezien 
ze phenotypen veroorzaken die klinisch identiek zijn – en die dus heel sterk op elkaar lijken. We 
tonen aan dat eiwit-eiwit interacties inderdaad verrijkt zijn tussen ziektegenen, en dat 
positionele kandidaargenen wiens eiwitten met ziektegenen interacteren een tien keer zo grote 
kans hebben om bij dezelfde ziekte betrokken te zijn dan kandidaatgenen zonder interacties 
met ziektegenen. Interessant genoeg gaat dit ook op voor eiwit-eiwit interacties die uit andere 
soorten afkomstig zijn, wat de hoeveelheid bruikbare eiwit-eiwit interactie data sterk vergroot. 
We vinden echer ook dat interacties die uit literatuurbronnen gehaald zijn een sterke bias 
vertonen voor bekende ziektegenen en dus met zorg gebruikt moeten worden voor het 
prioriteren van kandidaatgenen die nog nooit met een ziekte in verband zijn gebracht. 
In hoofdstuk 4 kijken we of een andere vorm van gen functioneel verwantschap, namelijk 
gecorreleerde gen expressie (co-expressie). In tegenstelling tot de in hoofdstuk 3 gebruikte 
eiwit-eiwit interactie data zijn co-expressie data veel omvangrijker. Ze zijn echter ook een 
minder sterke indicatie van functionele relaties tussen genen dan eiwit-eiwit interacties. Om 
deze reden onderzoeken we of het gebruik van evolutionaire conservering deze data nuttiger 
kunnen maken voor kandidaat ziektegen prioritiering. Wederom gebruiken we heterogene 
ziektegenen vanwege hun sterk op elkaar lijkende ziektephenotypen. We laten zien dat co-
expressie inderdaad hoger is tussen genen die dezelfde ziekte veroorzaken dan voor andere 
genen, en dat dit effect versterkt wordt door evolutionaire conservering van co-expressie te 
gebruiken. We laten ook zien dat dit gebruikt kan worden om de prioritiering van positionele 
kandidaat ziektegenen te verbeteren. 
In hoofdstuk 5 verzetten we onze aandacht van ziektegenen naar ziektephenotypen. Na 
aangetoond te hebben dat genen wiens mutatie tot eenzelfde phenotype leiden de neiging 
hebben functioneel gerelateerd te zijn, kijken we nu of dit patroon ook doorgetrokken kan 
worden naar op elkaar lijkende, maar toch verschillende ziektephenotypen. Om dit te doen is 
het nodig de ziektephenotypen op een systematische manier te beschrijven, om kwantitatieve 
overlappen te kunnen bepalen. In het verleden werd dit gedaan door tekst-mining van tekstuele 
ziektebeschrijvingen, maar deze aanpak hheft zijn beperkingen en resulteert niet in erg 
systematische beschrijvingen van ziektephenotypen. Er zijn verschillende databanken die 
ziektephenotypen wel systematisch beschrijven, maar het is nog niet duidelijk hoe bruikbaar 
deze zijn voor dit soort ziektephenoom analyses. In dit hoofdstuk bevestigen wij dat de relatie 
tussen verwante genen en verwante phenotypen inderdaad doorgetrokken kan worden buiten 
de grenzen van individuele ziektes. Daarnaast identificeren wij een aantal databank 
eigenschappen die de genetische coherentie van systematisch bepaalde phenotype clusters 
vergroot. We vinden dat zowel diepe ziektekenmerk hierarchieën als het gebruik van frequentie 
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inschattingen ziektekenmerken de genetische coherentie van phenotype clusters vergroot. In 
tegenstelling tot eerdere studies vinden we dat de algehele phenotypische similariteit 
belangrijker is voor het identificeren van genetische verwantschap tussen ziektes dan het delen 
van specifieke zeldzame kenmerken. De tegenstrijdige bevindingen van eerdere studies zijn te 
wijten aan het feit dat deze gebruik maakten van onvolledige ziektebeschrijvingen die verkregen 
werden door tekst-mining. Onze belangrijkste bevinding is echter dat complete en 
systematische phenotypebeschrijvingen heel belangrijk zijn voor ziektephenotype onderzoek, 
en dat het meer aandacht nodig heeft voor toekomstig onderzoek. 
We eindigen in hoofdstuk 6 met een blik naar de toekomst van dit veld, en het belang van het 
door ziektephenotypen geïnformeerde bioinformatica daarin. Door de opkomst van nieuwe 
sequentie-technologieën zal dit veld sterk veranderen over de komende jaren. Positionele 
kandidaatgen prioritering wordt minder relevant aangezien het hele genomisch gebied – en 
eventueel zelfs hele patiëntengenomen – in één keer gesequenced zal kunnen worden. Toch 
zullen er ook nieuwe uitdagingen ontstaan, zoals het interpreteren van de grote aantallen 
mutaties en genetische varianten die deze technologieën zullen opleveren, en het in kaart 
brengen van hoe ze aan het ziekteproces bijdragen. Hierdoor zal de rol van de bioinformatica in 
het onderzoek naar genetische ziektes groot blijven ook in de toekomst, waarschijnlijk zelfs nog 
groter dan het tegenwoordig al is. Zoals wij hebben laten zien zal de toepasbaarheid van de 
bioinformatica afhangen van zowel goede ziektephenotype databanken als van meer 
functioneel genetische data. Het allerbelangrijkste is echter dat het grondbeginsel waarop deze 
bioinformatische kandidaatgen aanpakken gebaseerd zijn – namelijk dat phenotypisch op elkaar 
lijkende ziektes ook genetisch met elkaar te maken hebben – ook daadwerkelijk klopt, zoals wij 
in dit proefschrift duidelijk hebben laten zien. 
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Chapter 2, Figure 1: Possible relationships between genes and phenotypes. The similar phenotypes of 
Stickler, Marshall and OSMED syndromes are caused by mutations in the functionally closely related 
genes COL2A1, COL11A1 and COL11A2. The phenotypically distinct Pallister-Hall syndrome is caused 
by mutations in the functionally unrelated or only weakly related GLI3 gene. Several genes can underlie 
one phenotype, as in the case of Stickler syndrome which can be caused by mutations in each of the 
three collagen genes. Conversely, one gene can lead to different phenotypes as in the case of COL11A1 
(Stickler and Marshall phenotypes) and COL11A2 (Stickler and OSMED phenotypes). Thickness of black 
lines linking genes indicates (hypothetical) degree of functional relatedness between them. 
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Chapter 2, Figure 3: Mapping phenotype networks to gene networks for candidate disease gene 
prediction. In this hypothetical example, diseases 1, 2 and 3 have known causative genes (genes A, C 
and E respectively), and are all phenotypically related to disease 4 which lacks an identified causative 
gene. If the known causative genes are functionally closely related, as in this case, then candidate genes 
(genes B and D) can be hypothesized for disease 4 due to their close functional relationships to the 
known genes of the phenotypically related diseases. This kind of analysis could potentially also identify 
higher level links between functional genetic modules and syndrome families. Green lines connect 
(green) known disease genes with their (green) diseases, while red lines indicate potential causative links 
between (red) candidate genes and the (red) disease of unknown etiology. Black lines of varying 
thickness indicate the degree of phenotypic and functional similarity between diseases and genes 
respectively. 
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Chapter 4, Figure 5: Procedure for calculating conserved co-expression scores. The procedure is 
illustrated using an example involving KOGs KOG0011 and KOG3438 between human and fly. KOG0011 
contains two genes in each species (RAD23A, RAD23B and FBgn0026777, FBgn0039147 in human and 
fly respectively) while KOG3438 contains one in human (CKS1B) and two in fly (FBgn0010314 and 
FBgn0037613). For each species a KOG0011-KOG3438 co-expression (thick purple and green arrows) 
correlation is calculated by taking the mean of all gene-gene combinations (thin black arrows) for the two 
KOGs. The mean of these species-specific KOG-pair correlations (thick vertical orange arrow) is taken to 
represent the final multispecies KOG0011-KOG3438 co-expression correlation. This co-expression value 
is used for all relevant gene-pairs as their KOG-based co-expression score. If co-expression is conserved 
in both species then this value will be high, if it is high in only one species it will be intermediate, and if it 
is low in both it will be low. 
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Chapter 4, Figure 6: Disease gene ranking procedure. Co-expression Spearman correlation coefficients 
(SCC) are determined for all candidate disease genes from a disease locus with known causative gene 
(E) and another gene known to cause the same disease (A). The SCCs are ranked, and the ranks are 
subsequently normalized to the 0.0-1.0 range. The relative position of the causative gene in the locus (E) 
is determined. This procedure would subsequently be repeated with E as known disease gene and A as 
candidate disease gene. For each disease, each gene is treated as a candidate disease gene in turn and 
its co-expression is successively compared to all other genes known to cause the same disease, leading 
to a list of scores per disease. 
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Chapter 5, Figure 1. Comprehensively annotated syndromes cluster better than sparsely annotated 
syndromes. (A) The Ehlers-Danlos and Charcot-Marie-Tooth syndrome families overlap in the phenome 
landscape of the OMIM data set, but separate when the phenotype descriptions are supplemented with 
POSSUM annotation. The phenome landscapes were created using multi-dimensional scaling of the HPO 
feature-based OMIM distance matrices (left), supplemented with POSSUM annotation (right). The more 
similar the annotations of two syndromes are, the closer they are on the landscape. The background 
colors indicate the density of syndromes in that region of the landscape. Lighter colors represent higher 
densities. (B) Mean phenotypic similarity is consistently greater for the POSSUM supplemented OMIM 
data set (red dashed lines) than for the original OMIM data set (blue dashed lines). Besides Ehlers-
Danlos (n=12) and Charcot-Marie-Tooth (n=12), the more phenotypically diverse family of ciliopathies is 
also shown (n=59; Supplementary Table 1). Continuous lines show the distributions of mean distances for 
randomly composed syndrome families of equivalent size (n=107) for the original  and supplemented 
OMIM data sets. 
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Chapter 5, Figure 2. Biological coherence of phenotypic clusters for different data sets and conditions. The box 
plots show relative enrichment of shared GO terms for genes associated with diseases within clusters compared to 
randomly permutated phenotype data sets (n=30). Box limits show the 25th and 75th percentiles, whiskers extend out 
up to 1.5x the box range, points outside this range are plotted individually. (A) The full HPO ontology results in 
biologically more coherent phenotype clusters than a simplified HPO ontology containing only more general features, 
but only when the OMIM phenotypes are supplemented with POSSUM annotation (purple boxes). (B) Artificial under-
annotation of the POSSUM and Orphanet databases by randomly halving the syndrome feature lists (“sparse”) leads 
to strong reductions in cluster biological coherence. However, limiting the Orphanet syndrome descriptions to just the 
very frequent features has limited impact on cluster coherence, despite the strong reduction in the average number of 
features per syndrome to just 57% of the original. (C) Weighting Orphanet features according to their prevalence 
within affected patients improves the biological coherence of clustered phenotypes. Counter-weighting them by 
assigning higher weights to less frequently occurring features abolishes the biological coherence of the resulting 
phenotype clusters almost completely. (D) Weighting annotated features according to their specificity (number of 
syndromes they occur in) using the inverse document frequency (I.D.F.) weighting scheme diminishes cluster 
biological coherence for well annotated POSSUM syndromes, but improves it for under-annotated syndromes. 
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